

Interactions of Multiple Gas-Transducing Systems: Hallmarks and Uncertainties of CO, NO, and H₂S Gas Biology

Mayumi Kajimura,^{1,2} Ryo Fukuda,¹ Ryon M. Bateman,¹ Takehiro Yamamoto,¹ and Makoto Suematsu^{1,2}

Abstract

The diverse physiological actions of the “biologic gases,” O₂, CO, NO, and H₂S, have attracted much interest. Initially viewed as toxic substances, CO, NO, and H₂S play important roles as signaling molecules. The multiplicity of gas actions and gas targets and the difficulty in measuring local gas concentrations obscures detailed mechanisms whereby gases exert their actions, and many questions remain unanswered. It is now readily apparent, however, that heme-based proteins play central roles in gas-generation/reception mechanisms and provide a point where multiple gases can interact. In this review, we consider a number of key issues related to “gas biology,” including the effective tissue concentrations of these gases and the importance and significance of the physical proximity of gas-producing and gas-receptor/sensors. We also take an integrated approach to the interaction of gases by considering the physiological significance of CO, NO, and H₂S on mitochondrial cytochrome *c* oxidase, a key target and central mediator of mitochondrial respiration. Additionally, we consider the effects of biologic gases on mitochondrial biogenesis and “suspended animation.” By evaluating gas-mediated control functions from both *in vitro* and *in vivo* perspectives, we hope to elaborate on the complex multiple interactions of O₂, NO, CO, and H₂S. *Antioxid. Redox Signal.* 13, 157–192.

I. Introduction	158
II. Overview: Heme Proteins as the Key to the Generation, Signal Transduction, and Interaction of Gases	159
III. Gas Metabolism	160
A. O ₂	160
B. CO	160
C. NO	161
D. H ₂ S	161
IV. Determinants of the Effective Gas Concentrations at the Target	162
A. General considerations	162
B. Membrane permeability of gases	163
V. Mechanisms of Gas Sensing and Gas Actions	163
A. Heme-protein sensors	163
1. General aspects of heme-protein sensors: biochemical characteristics and structural–functional relations	163
2. Specific heme-protein sensors	166
a. NO sensor	166
b. CO sensor	166

Reviewing Editors: Nader Abraham, Vittorio Calabrese, Enrico Calzia, Carlos Gutierrez-Merino, Hideo Kimura, Giovanni Li Volti, Stefan Rytter, Gregg Semenza, Rui Wang, George Webb, and Matthew Whiteman

¹Department of Biochemistry and Integrative Medical Biology, School of Medicine, Keio University, Tokyo, Japan.

²ERATO Gas Biology Project, Japan Science and Technology Agency, Tokyo, Japan.

VI. Interactions of Multiple Gas-Transducing Systems	167
A. Multiplicity of actions: a hallmark of gas behavior	167
1. Does CO inhibit NOS and does NO inhibit HO?	168
2. Does CO autoinhibit HO and does NO autoinhibit NOS?	168
3. CO attenuation of NO-mediated sGC activation	168
B. Quantitative arguments	168
1. Tissue concentrations of CO	169
2. Tissue concentrations of NO	169
3. Tissue concentrations of H ₂ S	170
C. Functional arguments	171
1. Anatomical proximity of gas-producing and gas-reception sites	171
2. Is CO vasodilatory or vasoconstrictive?	172
3. CBS as a CO sensor <i>in vivo</i>	173
4. HO-2 as an O ₂ sensor: a possible role in hypoxia-induced vasodilation	173
5. Cross-talk between H ₂ S and NO	173
D. Non-heme protein O ₂ sensors/HIF/PHD	174
VII. Physiological Significance of CO, NO, and H ₂ S on Mitochondrial Signaling and Their Relation to O ₂ Metabolism	174
A. Mitochondrial redox signaling	174
B. Relations between CO, NO, H ₂ S, COX, and hypoxia	174
C. Interactions of CO and NO on COX	175
D. O ₂ sensing and hypoxic response: effects of CO, NO, and H ₂ S	175
E. Effects of CO and NO on mitochondrial biogenesis	176
F. Cytoprotective effects of CO, NO, and H ₂ S	177
G. The roles of H ₂ S, NO, and CO in “suspended animation”	177
VIII. Altered Gas Balance in CNS Diseases	178
A. CO in CNS diseases	178
B. NO in CNS diseases	179
C. H ₂ S in CNS diseases	179
IX. Challenges and Perspectives	180

I. Introduction

A GAS, BY DEFINITION, is a state of matter different from either the liquid or solid states. Gases possess the ability to diffuse readily in different materials and become uniformly distributed within a defined space. “Biologic gases” are assumed to diffuse freely across biologic membranes, acting in a variety of functional capacities in autocrine, paracrine, or juxtacrine fashions. Recently, the diverse physiologic actions of carbon monoxide (CO), nitric oxide (NO) and hydrogen sulfide (H₂S) and their role in diseases through regulation of gas-generating and -sensing mechanisms have attracted a great deal of interest. Figure 1 outlines the components of gas signaling transducing systems.

Molecular oxygen (O₂) is produced solely by plants and cyanobacteria and is a product of oxygenic photosynthesis, whereas CO, NO, and H₂S are enzymatically produced in mammals. O₂ is often viewed as a “physiological” ligand of the key heme proteins hemoglobin (Hb) and mitochondrial cytochrome *c* oxidase (COX). Conversely, the other three gases are often viewed as “toxic” ligands. This characterization has arisen because CO, NO, and H₂S are all capable of binding to either hemoglobin or mitochondrial cytochrome *c* oxidase, where they can either block O₂ transport to the tissue or inhibit energy production, respectively. [The result being that the tissue may experience either a hypoxic hypoxia or cytopathic hypoxia state (87)]. Alternatively, a growing body of evidence now indicates that these same gases also function in a regulatory capacity, controlling important physiologic

functions, including vascular tone, host defense against pathogens, neuromodulation, apoptosis, and energy metabolism. Many excellent reviews are available on signal transduction by various gases, and the reader is referred to a number of articles [*e.g.*, CO (140, 260, 373), NO (33, 128, 206), H₂S (144, 181, 187, 237, 304, 340), and interactions of CO, NO, and H₂S (67, 94, 147, 180, 225)].

A central question in the field of “gas biology” is how do these gases interact with one another when transducing signals and modulating cell function? There are several reasons why this is a difficult question to answer. In the first place, the effects of gaseous molecules are often not dependent on one specific receptor; accordingly, they can produce myriad effects virtually simultaneously. Additionally, gases exert biologic activity through interactions with macromolecules in ways that are fundamentally different from other signaling molecules, such as hormones or peptides.

This review focuses primarily on gaseous interactions involving coordinate bonding of gases to prosthetic heme complexes in gas sensors/receptor proteins. Additionally, key questions regarding the interactions of gases are considered for CO, NO, H₂S, and O₂. We focus on soluble guanylate cyclase as a primary gas target.

How do gases interact with one another to control cell and ultimately organ function? This question can be broken down into several related parts. First, where, when, and how are gases generated? Second, what and where are the molecular targets and sensors of these gases? Third, what effector systems are associated with these gases? And finally, how do




FIG. 1. Scheme to illustrate pathways of gas signal-transducing systems by the four gases, O₂, CO, NO, and H₂S. Valence electrons in each gas molecule are shown as dots and crosses. HO = heme oxygenase; NOS = nitric oxide synthase; CBS = cystathionine β -synthase; and CSE = cystathionine γ -lyase.

multiple gas-generating systems and gas-reception systems interact with one another?

In this review, we address these questions, discuss controversial areas, and review the physiological significance of CO, NO, and H₂S on mitochondrial signaling and their relation to O₂ metabolism.

II. Overview: Heme Proteins as the Key to the Generation, Signal Transduction, and Interaction of Gases

We begin this review by pointing out four main functions of heme proteins (see Table 1 for a list of main functions) because these metal-containing protein molecules are key molecular entities in gas transport, gas generation and gas sensing, as well as important sites of multiple gas interactions.

The first function of heme proteins to be considered is that of gas transport, typically recognized as O₂ transport by myoglobin and hemoglobin. These iron-containing heme proteins have a broad range of ligands, including CO (9), NO (364), and H₂S (86, 166, 242). The reversible nature of coordinate bonding between a gaseous ligand and the heme allows a gas to be bound and released and forms the basis for competition with another gas.

A second function of heme proteins is to transfer electrons, something typically recognized in mitochondrial cytochrome *c*. This heme protein mediates single-electron transfer between integral membrane complexes in the mitochondrial respiratory chain of eukaryotes. The transfer of an electron

TABLE 1. FOUR MAIN FUNCTIONS BY HEME PROTEINS

Classes	Proteins/enzymes	Reactions	Functions	
1 Storage and transport of gases	Myoglobin	$Fe^{2+} + O_2 \rightleftharpoons Fe^{2+}-O_2$ $Fe^{2+} + CO \rightleftharpoons Fe^{2+}-CO$ $Fe^{2+} + NO \rightleftharpoons Fe^{2+}-NO$	O ₂ storage	
	Hemoglobin	$Fe^{2+} + O_2 \rightleftharpoons Fe^{2+}-O_2$ $Fe^{2+} + CO \rightleftharpoons Fe^{2+}-CO$ $Fe^{2+} + NO \rightleftharpoons Fe^{2+}-NO$	O ₂ carrier	
	Neuroglobin (112)	$Fe^{2+} + O_2 \rightleftharpoons Fe^{2+}-O_2$	O ₂ carrier	
	Cytoglobin (112)	$Fe^{2+} + O_2 \rightleftharpoons Fe^{2+}-O_2$	O ₂ carrier	
	Nitrophorin (335)	$Fe^{3+} + NO \rightleftharpoons Fe^{3+}-NO$	NO carrier	
	Hemoglobin I (86, 242)	$Fe^{3+}-H_2O + H_2S \rightleftharpoons Fe^{3+}-H_2S + H_2O$	H ₂ S carrier	
	2 Electorn transfer 3 Reduction-oxidation	Cytochromes	$Fe^{3+} + e^- \rightleftharpoons Fe^{2+}$	
		Heme oxygenase	$heme + 3AH_2 + 3O_2 \rightarrow$ $biliverdin + Fe^{2+} + CO + 3A + 3H_2O$	Oxygenases
		Nitric oxide synthase	$L-arg + 1.5e^- + 1.5H^+ + 2O_2 \rightarrow$ $L-citrulline + NO + 2H_2O$	Oxygenases
		Prostaglandin endoperoxide H ₂ synthases	$arachidonic\ acid + 2O_2 \rightarrow PGG_2$	Oxygenases
Cytochrome <i>c</i> oxidase		$O_2 + 4e^- + 4H^+ \rightarrow 2H_2O$	Oxidoreductases	
Catalase		$2H_2O_2 \rightarrow 2H_2O + O_2$	Oxidoreductases	
Peroxidase		$H_2O_2 + AH_2 \rightarrow 2H_2O + A$	Cytochrome peroxidases	
Cytochrome p450		$O_2 + 2e^- + 2H^+ + A \rightarrow AO + H_2O$	Oxygenases	
4 Gas sensors		Soluble guanylate cyclase	$Fe^{2+} + NO \rightleftharpoons Fe^{2+}-NO$ $Fe^{2+} + CO \rightleftharpoons Fe^{2+}-CO$	Second messenger
		Cystathionine β -synthase	$Fe^{2+} + CO \rightleftharpoons Fe^{2+}-CO$	Allosteric inhibition
	CooA (10)	$Fe^{2+} + CO \rightleftharpoons Fe^{2+}-CO$	DNA binding	
	NPAS2 (78)	$Fe^{2+} + CO \rightleftharpoons Fe^{2+}-CO$	DNA binding	
	FixL (98)	$Fe^{2+} + O_2 \rightleftharpoons Fe^{2+}-O_2$	Histidine protein kinase	
	HemAT (123)	$Fe^{2+} + O_2 \rightleftharpoons Fe^{2+}-O_2$	Methyl carrier protein	
	PDEA1 (53)	$Fe^{2+} + O_2 \rightleftharpoons Fe^{2+}-O_2$	Second messenger	




FIG. 2. (A) The reaction catalyzed by heme oxygenase (HO). The HO reaction consists of three oxidation steps, where one molecule of O_2 is used in each reaction step. The reaction starts with the formation of the Fe^{3+} heme- HO complex. Then Fe^{3+} heme is reduced to the Fe^{2+} state by the first electron donated from NADPH-cytochrome P450 reductase. O_2 binds with the heme of the complex. The iron-bound O_2 converts to a peroxy intermediate ($\text{Fe}^{3+}\text{-OOH}$). Subsequently, the terminal O_2 of $\text{Fe}^{3+}\text{-OOH}$ attacks the α -meso-carbon of the porphyrin ring to form Fe^{3+} α -meso-hydroxylheme. A subsequent conversion of Fe^{3+} α -meso-hydroxylheme to verdoheme requires another O_2 , and this step produces CO by the regiospecific cleavage of the porphyrin ring of

the heme at the α -meso carbon atom. The rate-determining step is O_2 binding to verdoheme, which is much slower than O_2 binding to the heme complex (324). This step produces Fe^{2+} and biliverdin. Adapted by permission from Macmillan Publishers Ltd: Schuller *et al. Nat Struct Biol* 6: 860–867, 1999 (270). (B) The reaction catalyzed by nitric oxide synthase (NOS). NO is synthesized from the guanido nitrogen atom(s) of L-arginine by the action of NOS. The process involves the incorporation of an O_2 into the unstable intermediate N^ω-hydroxy-L-arginine and subsequently into L-citrulline (250, 257).

takes place at the iron of the prosthetic heme where the iron switches between two oxidation states: Fe^{2+} and Fe^{3+} (151).

A third function of heme proteins is to facilitate reduction-oxidation (redox) reactions that occur at catalytic sites of specific enzymes. In this case, enzyme reactions mediated by these heme proteins start with the reaction of O_2 and an electron or H_2O_2 at the iron of a prosthetic heme. During these reactions, the heme iron is activated by O_2 to form high-valence states (195, 257). Oxygenases are a subclass of enzymes that catalyze the addition of O_2 to a substrate. Heme oxygenase (HO), the CO-producing enzyme, and nitric oxide synthase (NOS) belong to this category.

A fourth function of heme proteins is that of gas sensor. Unlike the other three heme-protein functions, in which the heme is located at the *functional* site, in gas-sensing proteins, the prosthetic heme is not found at the *functional* site, but rather, it is located at a *regulatory* site. In this case, the heme group conveys a signal to the functional site of the protein. Cystathionine β -synthase (CBS, an H_2S -producing enzyme) and soluble guanylate cyclase (sGC) are examples of enzymes that belong to this category.

III. Gas Metabolism

A. O_2

Oxygenic photosynthesis is the biologic process occurring in plants and cyanobacteria that generates O_2 from water ($2\text{H}_2\text{O} \rightarrow 4\text{H}^+ + 4\text{e}^- + \text{O}_2$). Although O_2 is essential for mammals to generate energy (ATP) for cell survival and to break down larger substances into simpler components, our body cannot produce its own O_2 . Most of the O_2 entering the human body is consumed during oxidative phosphorylation by the terminal


enzyme of the electron-transport chain, COX, in a four-electron reduction of O_2 to yield H_2O ($4\text{Cytochromes } c^{2+} + 4\text{H}^+ + \text{O}_2 \rightarrow 4\text{Cytochromes } c^{3+} + 2\text{H}_2\text{O}$).

B. CO

In the human body, the predominant endogenous source of CO is from oxidative degradation of heme (iron protoporphyrin IX) by heme oxygenase (HO, EC 1.14.99.3). Although most heme is derived from senescing red blood cells and ineffective erythropoiesis, a small fraction comes from the degradation of other heme proteins, such as myoglobin, catalase, peroxidases, and cytochromes (23). Under pathophysiologic conditions, additional sources of non-heme CO are thought to be lipid peroxidation (331) and the metabolic activity of intestinal bacteria (82). CO is generated by HO, which catalyzes three successive monooxygenation steps to convert heme to biliverdin, Fe^{2+} , and CO in the presence of reducing equivalents (Fig. 2A) (270, 324).

HO is a unique heme protein, in that the heme serves as both a substrate and a catalytic center of this reaction. Reducing equivalents are supplied by cytochrome P450 reductase, which provides an electron, derived from NADPH, to the ferric heme. Overall, the reaction requires three O_2 molecules. CO is transported by the red blood cell, where it is bound to ferrous heme of hemoglobin (COHb). CO is subsequently eliminated through the lung, when it is displaced by O_2 as the red cell transits along a capillary in the alveolar membrane. Although the binding of CO to hemoglobin is strong (*i.e.*, high affinity), O_2 can outcompete CO (186) under the atmospheric O_2 conditions that exist in the lung. The reported values of COHb half-life in the circulation range from 22 to 360 min in humans (280, 287).

FIG. 3. Biosynthesis of H_2S . H_2S is synthesized mainly by three enzymes: cystathionine β -synthase (CBS), cystathionine γ -lyase (CSE), and mercaptopyruvate sulfurtransferase (MPST). Cysteine is converted by aspartate aminotransferase (AAT) to 3-mercaptopyruvate, which subsequently gives off H_2S by the action of MPST.



C. NO

NO is synthesized from L-arginine (L-arg), a readily available amino acid, by a family of nitric oxide synthase enzymes (NOS, EC1.14.13.39). Each NOS is a heme protein consisting of an oxygenase and a reductase domain. The reductase domain first provides an electron from NADPH to the ferric heme. Subsequently, the NOS hydroxylates the guanidine nitrogen of L-arg and oxidizes the N^{ω} -hydroxy-L-arginine intermediate (NOHA) to the free radical NO and L-citrulline (5, 250, 257, 295) (Fig. 2B). The reaction requires two O_2 molecules. In addition, NO is nonenzymatically generated by reduction of nitrite to NO, in which deoxyhemoglobin in the red blood cell acts as a nitrite reductase. In cells and blood, NO is oxidized by nonenzymatic reactions to nitrite and nitrate. Dinitrosyl iron complexes are reported as stable forms of NO storage in cells (228, 326). The half-life of NO in solution is short (< several seconds) (316). Nitrite and nitrate are excreted by the kidney.

D. H_2S

H_2S is a gas, which is very soluble in water. Although somewhat ambiguous, the term " H_2S " in this article refers mostly to combinations of the inorganic sulfides as undissociated hydrogen sulfide (H_2S), hydrosulfide anion (HS^-), and the sulfide anion (S^{2-}) in water, unless otherwise specified. Which of these species exerts biologic action(s) is not currently known (180, 352). The biochemical pathways and the mechanisms whereby endogenous H_2S are generated are not well understood and are currently the subject of active research. Readers are referred to excellent articles by Kamoun (144), Kimura (156), and Li *et al.* (180) for more-comprehensive reviews on this subject. In brief, as shown in Fig. 3, the multiple

reactions associated with three main enzymes, cystathionine β -synthase (CBS, EC 4.2.1.22) (57, 199, 283, 284), cystathionine γ -lyase (CSE, EC 4.4.1.1) (361), and 3-mercaptopyruvate sulfurtransferase (MPST, EC 2.8.1.2) (279) are responsible for its production in mammals (144, 156).

The first enzyme, CBS, uses pyridoxal phosphate (PLP) as a cofactor (152). CBS catalyzes the production of H_2S from cysteine by β -elimination (L-cysteine + L-homocysteine \rightarrow L-cystathionine + H_2S), β -replacement reactions (L-cysteine + 2-mercaptoethanol \rightarrow S-hydroxyl-L-cysteine + H_2S) (57, 200), and/or α , β -elimination reactions (L-cysteine + H_2O \rightarrow pyruvate + H_2S + NH_3) (57, 284). The second enzyme, CSE, is a PLP-dependent enzyme catalyzing the desulfhydration of cystine (144). Although CSE normally catalyzes γ -elimination reactions, it also catalyzes a β -disulfide elimination reaction, which results in the production of pyruvate, NH_4^+ , and thiocysteine (Fig. 3) (200). Thiocysteine can react with cysteine to form H_2S (289). Cysteine can be converted to 3-mercaptopyruvate by aspartate aminotransferase (AAT). The 3-mercaptopyruvate is then desulfurated by MPST, the third enzyme, to form H_2S and pyruvate (Fig. 3) (139). In rat liver and kidney (213, 222), unlike CBS and CSE, which are located in the cytosol (144), MPST is located in both mitochondria and cytosolic fractions. Among these three enzymes, we focus on CBS in the later discussion because this enzyme possesses a prosthetic heme that serves as a target for CO.

As seen in Fig. 4, in animal tissues, the sulfur atom exists in several oxidation states [*i.e.*, -2; H_2S and organic thiols such as cysteine, -1; polysulfide, 0; elemental sulfur such as protein-bound- S^0 , +2; thiosulfate, +4; sulfite, and +6; sulfate (185, 323)]. On generation, H_2S can be stored in three different forms: (a) stable, (b) acid-labile, and (c) bound-sulfane sulfur [the term "sulfane" designates a compound containing a




FIG. 4. Catabolism of H₂S and oxidation states of the sulfur atoms of various compounds. The sulfur atom of H₂S (reduced divalent) is oxidized in mitochondria to a fully oxidized state as a sulfate (hexavalent). The reduced sulfur atoms can be stored as labile sulfur species that can be released as H₂S in response to a signal. Dotted lines, Different catabolic pathways. *Sulfane sulfur. TST=thiosulfate: cyanide sulfurtransferase; SO=sulfite oxidase; TSMT=thiol S-methyltransferase. Adapted by permission from Elsevier Ltd: Lloyd, *Trends Microbiol* 14: 456–462, 2006 (185).

sulfur-bonded sulfur (144); e.g., polysulfides, polythionates, thiosulfate, thiosulfonates, and elemental sulfur. Compounds containing reduced divalent (–2) or oxidized hexavalent (+6) forms are defined as “stable” because the sulfur atoms are not liberated by simple chemical treatment with acid or dithiothreitol. The stable form includes organic sulfur present in the divalent state, including cysteine and methionine. By contrast, other forms of sulfur compounds are defined as “labile,” because H₂S is liberated by simple chemical treatment (323). The ion-sulfur (FeS) complex is an example of the acid-labile form, which releases H₂S under acidic conditions, whereas polysulfide (R-S_n-R where n ≥ 3) is an example of a bound-sulfane sulfur form, which releases H₂S under reducing conditions (156, 323).

The nonenzymatic production of H₂S from the organic polysulfides found in garlic has been suggested as a potential source in the circulation (22, 271), suggesting that stored forms of H₂S are physiologically significant. The existence of labile-sulfur fractions not only elaborates the biology of H₂S, but also complicates detection of endogenous levels of H₂S in the tissue. This issue is discussed later (Section IV.B.3).

What are the mechanisms of H₂S catabolism in the body? In a pioneering study, Haggard (110) reached the conclusion that sulfide is rapidly metabolized, based on his demonstration that a quick bolus injection of Na₂S in the dog was lethal, whereas a slow rate of injection caused no harm. However, the catabolic pathway(s) whereby endogenous H₂S is metabolized appear to be more ambiguous than those of CO or NO (181). Although several systems for breaking down, scavenging, and sequestering H₂S have been identified, most data were obtained by using exogenous H₂S (187).

The first pathway of H₂S catabolism is its oxidation. Studies using an organ-perfusion model indicated that H₂S was oxidized in mitochondria to thiosulfate (S₂O₃²⁻), sulfite (SO₃²⁻), and sulfate (SO₄²⁻) (20, 144, 181, 247), and then excreted in the urine (63). Sulfate (SO₄²⁻) is the major end product of H₂S (181). The initial oxidation to thiosulfate is most likely a nonenzymatic step. Conversions of thiosulfate to sulfite and sulfite to sulfate are catalyzed by thiosulfate:cyanide sulfurtransferase (TST) (241) and sulfite oxidase (SO), respectively. The second pathway of H₂S metabolism is the thiol S-methyltransferase (TSMT)-mediated methylation of H₂S to yield monomethylsulfide and dimethylsulfide (97). The third pathway involves the binding of H₂S to methemoglobin to form sulfhemoglobin. Additionally, H₂S can react with NO (350). It has also been reported that H₂S can diffuse across the alveolar membrane (83, 132, 209).

IV. Determinants of the Effective Gas Concentrations at the Target

A. General considerations

To understand how gases are functioning in physiological processes, it is important to know how much gas is actually being delivered to a given target. Three major determinants of the effective gas concentration are (a) the physicochemical properties of the gas itself (258); (b) the properties of the local environment, including the surrounding media through which a gas travels including viscosity, temperature, and tissue composition (117, 167); and (c) scavenging systems, including chemical reactions that consume the gas. Here we attempt to compare and contrast factors affecting gas-transport efficiency, while referring the reader to excellent books and reviews on the transport properties of O₂ (167, 346), CO (332), and NO (38, 39, 56). Although physical (203, 216), biochemical and physiological (144) properties of H₂S have been well studied, experimental and mathematical modeling of H₂S transport properties *in vivo* is limited.

TABLE 2. PHYSICO-CHEMICAL PROPERTIES OF O₂, CO, NO, AND H₂S

Property	O ₂	CO	NO	H ₂ S
Molar mass (g/mol)	32.00	28.01	30.01	34.08
Dipole moment (D, debye)	0 (367)	0.11 (367)	0.16 (367)	0.97 (183)
Solubility (g/100g H ₂ O/20°C)	0.0043 (183)	0.0028 (183)	0.0062 (183)	0.40 (183)
Solubility, Mole fraction (x10 ⁻⁵ H ₂ O/20°C)	2.29 (18)	1.77 (47)	3.47 (368)	185 (92)
Diffusion coefficient in H ₂ O (x10 ⁻⁵ cm ² s ⁻¹ 20°C)	2.30 (356)	2.03 (355)	2.07 (355)	1.75 (308)
1 st ionization energy (eV)	12.07 (367)	14.01 (367)	9.26 (367)	10.46 (183)
Affinity for metal ions	+(367)	++(367)	+++ (367)	N/A

Numbers in parentheses denote references.

Biologic membranes create a diffusion barrier. In general, gaseous molecules have a high solubility in nonpolar solvents, such as the lipid bilayer. The dipole moment indicates the polarity of the gas molecule. The larger this value, the more polar the gas (*i.e.*, the less permeable through hydrophobic membranes). As seen in Table 2, H₂S stands out among the four gases under consideration in this review. It has the largest dipole moment (H₂S >> NO > CO > O₂), suggesting that it has the lowest permeation through lipid bilayers, and it displays the greatest water solubility (H₂S >> NO > O₂ > CO). Unlike CO and NO, H₂S possesses an acidic proton with a pK_a of 6.8, making H₂S the anionic conjugate base, HS⁻, the predominant form at the physiologic pH 7.4 (202). Different fractions of H₂S species exist under different conditions. For example, in water at 25°C, pH 8.1, the following composition has been reported: H₂S (7.05%), HS⁻ (92.25%), and S²⁻ (2.9 × 10⁻⁵%) (203); whereas, in physiologic solution (160), a composition of H₂S (~30%) and HS⁻ (70%) has been reported. Because of its ionization, it can be speculated that H₂S may have a reduced ability to permeate the lipid bilayer compared with either O₂ or CO. NO (free radical) also changes its appearance; the ease of oxidation to the nitrosonium ion (NO⁺), the probability of reduction to the nitroxide ion (NO⁻), and the attack by O₂ leading to formation of NO₂ (197). It remains difficult, however, to determine the fractional contributions of each H₂S and NO species involved in physiologic processes.

From the diffusion coefficient (*D*), one can calculate how far a gas molecule travels in a given time and can estimate the time for a certain diffusion process. For O₂ to travel a 10-μm distance in water at 20°C, it takes 0.021 seconds; whereas, for H₂S that has a smaller *D*, it takes a slightly longer time, 0.028 s. It would be of great interest to compare the *D* of O₂, CO, NO, and H₂S in heme protein-containing solutions (the values listed in Table 2 were obtained in water). Although no such information can be found in the literature, Longmuir and Roughton (186) did compare the *D* of CO and molecular nitrogen (N₂), which have similar molecular weights (*i.e.*, 28.0) and physical properties. Measured values of *D*_{N₂} (2.8 × 10⁻⁶ cm/s) and *D*_{CO} (3.2 × 10⁻⁶ cm/s) at 20°C in 40% hemoglobin in water were similar. To our knowledge, no information exists on the diffusion of H₂S through biologic tissues, as has been done with O₂ (167).

Furthermore, the reported values of the redox potentials of NO are +0.71 volts in acidic solution (2NO + 2H⁺ + 2e⁻ → H₂N₂O₂) and +0.18 volts in basic solution (2NO + 2e⁻ → N₂O₂²⁻) (102). This indicates that NO is readily reducible or oxidizable, allowing it to function as either an oxidizing or a reducing agent (367). By contrast, H₂S tends to be regarded as solely a reducing agent (180, 185). However, the biologic chemistry of H₂S has not fully been investigated.

NO has a higher affinity than either O₂ or CO for metal ions (367). Because NO has an unpaired electron, it can readily accept or donate an electron to a metal ion, as described earlier. Although H₂S has been recognized to react with metals such as silver and zinc, no report exists comparing the interaction energy of NO and H₂S with a certain metal. The interaction with a metal depends on the first ionization energy of the lone pair electron in the gas ligand and the electron affinity of the metal (100). It can be speculated that H₂S exhibits a slightly weaker affinity to a metal as compared with that of NO (H₂S, 10.46 eV, *vs.* NO, 9.26 eV), but a stronger metal affinity than either O₂ or CO.

B. Membrane permeability of gases

An important question has recently been raised regarding the membrane permeability of gases. Do gases cross biologic membranes by simple diffusion alone, or might they be transported? Factors influencing the permeability of small neutral molecules such as gases are (a) how easily the gas dissolves into the membrane's hydrocarbon, and (b) the rate at which the gas diffuses through the hydrocarbon. Based on this "solubility-diffusion" model (88, 158), it is generally assumed that biologic membranes are no barrier to small gases, which can readily cross membranes without specific transporters. However, some experimental data do not support this model. For example, the apical membrane of gastric gland cells was found to have no demonstrable permeability to either H⁺, CO₂, HCO₃⁻, NH₃, or NH₄⁺ (333). Investigators suggest that the lipid bilayer can offer resistance to simple diffusion, based on data showing that changes in lipid composition alter gas permeability (119), whereas other investigators have challenged the solubility-diffusion model (69, 93), suggesting that gases are transported across biologic membranes by proteins.

Recently, NO membrane permeability was suggested to be facilitated by the aquaporin-1 (AQP1) protein (115). Additionally, when AQP1 was purified from human red blood cells and reconstituted into proteoliposomes, it was found to increase the permeability of both water and CO₂. As both effects were abolished with HgCl₂, the authors concluded that AQP1 served as a protein-mediated channel that increased CO₂ permeability (245). Although the notion that AQP-1 mediates gas permeability is supported by various studies (69, 81, 342), the experimental system has been criticized (204, 253) and the concept refuted. Moreover, in a study using transgenic mice lacking AQP1, CO₂ permeability in red blood cells was not reduced in the absence of AQP1 (84, 360). To date, no report suggests facilitated transport of either O₂, CO, or H₂S.

V. Mechanisms of Gas Sensing and Gas Actions

A. Heme-protein sensors

1. General aspects of heme-protein sensors: biochemical characteristics and structural-functional relations. Heme-based sensor proteins are key regulators of cellular responses to changes in O₂, CO, NO, and H₂S levels. These gas sensors act as signal transducers by coupling a "regulatory" heme-binding site to a "functional" signal-transmitter site. Four different types of heme-binding domains are known: (a) globin-coupled sensors, (b) heme-binding PAS domains, (c) CoxA, and (d) heme-NO-binding (HNOB). Coupled transmitter domain sites include cyclase, histidine protein kinases, and phosphodiesterases, as well as transcription factors with the basic helix-loop-helix motif.

What are the molecular mechanisms whereby heme-based gas-sensing molecules transduce signals? Understanding the structural-functional relations of the coordinated complex at the site of a prosthetic heme of these sensor proteins can help provide answers. Here we first describe key biochemical features of heme-protein sensors that should be taken into account when discussing the concept of gas sensing and signaling. This includes the relations between (a) oxidative states of the central iron of the prosthetic heme and the binding affinity of gases, (b) ligand binding and base affinity, (c) conformational changes




FIG. 5. Ligand discrimination by the oxidative state of the iron center of prosthetic heme. The oxidative state of the iron of heme in hemoglobin shifts between Fe²⁺ and Fe³⁺ states. The ferrous form (Fe²⁺) of hemoglobin prefers to bind ligands such as O₂, CO, and NO. Conversely, ferric heme (Fe³⁺) prefers to bind water, H₂S, and anions such as CN⁻, N³⁻, and OH⁻. L = ligands.

within the protein arising from ligand binding, and (d) structural changes and protein functions.

The oxidative state of the heme iron is an important determinant of ligand discrimination. The iron atom in the prosthetic heme can exist as either an Fe²⁺ (ferrous) or an Fe³⁺ (ferric) oxidation state that, as described earlier, has the ability to form six coordinate bonds. As shown in Fig. 5, each of the lone pairs on the nitrogen atom of the porphyrin ring in hemoglobin can form a coordinate bond with either an Fe²⁺ or an Fe³⁺ ion, holding it at the center of the porphyrin ring. This leaves two more coordinate positions, one above and one below the plane of the porphyrin ring. The globin attaches to one of these positions by using a lone pair of the nitrogen molecule of histidine known as proximal histidine. The other position is the point at which a gas forms the sixth coordinate bond.

The electronic structure of the iron atom in its ground state can be expressed by specifying the number of electrons in each orbital as follows: 1s²2s²2p⁶3s²3p⁶3d⁶4s². When iron is oxidized to Fe²⁺, it loses two electrons from its 4s orbital, changing its electronic state to 1s²2s²2p⁶3s²3p⁶3d⁶. When it is further oxidized to Fe³⁺, an additional electron is lost from the 3d orbital, resulting in a 1s²2s²2p⁶3s²3p⁶3d⁵ electronic configuration. In an octahedral complex with six ligands, the energy level of the iron 3d orbitals splits into two, giving low energy t_{2g} (d_{xy}, d_{xz}, d_{yz}) and high energy e_g (d_{x²-y²}, d_{z²}) orbitals. The former are essentially non-bonding, while the latter are weakly anti-bonding with respect to the coordination bonding with the ligands. The bonding molecular orbitals in the complex are close in energy to those of the atomic (or molecular) orbitals of the isolated ligands that compose a lone pair, although the iron 4s and 4p orbitals also contribute significantly to the stabilization of the coordination bonds (17, 194).

Electronic configurations of O₂, CO, NO, and H₂S are an important determinant for gas binding. All of O₂, CO, NO, and H₂S have lone pairs of electrons in their outer energy levels, making them active electron-lone-pair donors (Fig. 5). The ferrous oxidation state (Fe²⁺) of hemoglobin preferentially binds neutral ligands such as O₂ (the physiologic ligand), CO (a typical toxic ligand), and NO (9). Conversely, the ferric oxidation state (Fe³⁺) preferentially binds H₂S and water (138), and anions such as CN⁻, N³⁻, and OH⁻ (Fig. 5) (367).

Why does the Fe³⁺ of the prosthetic heme of myoglobin or hemoglobin prefer an anion to a neutral ligand? Under the condition of low electron density of the metal (M)-d-orbitals,




FIG. 6. Distinct positional changes at the distal histidine induced by different ligands: O₂, CO, and NO. Ligand geometry in the heme pocket of sperm whale myoglobin is shown. The heme iron is coordinated to a proximal histidine (His93), making the iron five-coordinate with a free binding site for O₂. The distal histidine (His64) located above the free binding site can form a hydrogen bond to the sixth iron ligand. The heme is ligated by O₂ (1MBO, blue), CO (1VXF, green), or NO (1HJT, red). Each structure was determined by x-ray crystallography, and each structure is superposed on another. Hydrogen bonds, interatomic distances <3.0 Å, are represented by lines. Adapted by permission from Wiley-Blackwell Ltd: from Brucker *et al. Proteins* 30: 352–356, 1998 (35).

donation of an electron from the ligand (L) to M (“π-donation”) tends to stabilize the complex by forming “π-bonding” (194). Because an Fe³⁺-heme possesses one less electron than an Fe²⁺-heme, the electron density of its d-orbitals is lower, making it more readily accepting of an electron from L. This is one explanation for why Fe³⁺ prefers more-electronegative ligands to neutral ones (194). Furthermore, the charge-transfer property from L to M depends on the ionization energy of the lone-pair electron in L and the electron affinity of M (100). In this regard, the first ionization energy among different lone-pair-donating ligands (the energy required to remove the first electron in the molecule) appears to become an important parameter. Here the smaller the ionization energy, the more readily the transfer of electronic charge occurs. As shown in Table 2, H₂S (10.46 eV) displays a smaller ionization energy compared with CO (14.01 eV), making H₂S a better ligand for an Fe³⁺-heme complex than CO (194).

Why then does the neutral ligand CO bind to Fe²⁺-heme, but not to Fe³⁺-heme? The bonding of CO to M is thought to have two steps. The first step is the donation of electron density from CO to M, “π-donation”, whereas the second step is the back donation from the dπ-orbital of M to an empty π* antibonding orbital of CO, called “π-back donation” (197). Such a “π-back donation” occurs more readily for the Fe²⁺-heme than that for the Fe³⁺-heme because the difference in energy between the d-orbital energy of an Fe²⁺ and the π*-orbital energy of CO is relatively small (194). Consequently, CO can interact with an Fe²⁺-heme, but not with an Fe³⁺-heme.

This description makes us realize the importance of the metal center redox state. The Fe²⁺ of hemoglobin can be rapidly oxidized to the Fe³⁺ of methemoglobin in the presence of O₂. However, in our body, the endogenous source of the re-




FIG. 7. Difference in transaxial effects of CO and NO ligation on the prosthetic heme of hemoglobin. Ligand affinities of the Fe^{2+} -heme-hemoglobin complex and the binding constants for proximal base are compared between CO and NO. For the gas-ligand affinity, NO binds better without the proximal base, which sets NO apart from CO. Correspondingly the binding constant for the proximal base is decreased by $\sim 10^3$ -fold; weakening the bonding of the heme iron to the imidazole base of the histidine residue. K_E , equilibrium constant in M^{-1} . Adapted from Yonetani *et al.*, *Journal of Biological Chemistry* 273: 20323–20333, 1998 (364).

ducing equivalent modulates the heme oxidative state. For hemoglobin, the electron donor is methemoglobin reductase, and for HO, it is cytochrome P450 reductase; however, the electron donor for CBS is unknown. Nitric oxide poses a more-complicated story because the relative distributions of the Fe oxidative states are not well understood (295).

Although myoglobin is not considered a gas sensor *per se*, it does bind O_2 , CO, and NO. Figure 6 shows the structures of native sperm-whale myoglobin whose ferrous heme has been ligated by O_2 , CO, or NO, respectively (35). Each structure was determined by x-ray crystallography and then superposed. As seen, ligand-binding by the different gases causes distinct positional changes of the distal histidine group. A change of this kind is considered to be the first step in the signal-transduction mechanism of heme-protein gas sensors.

How then is this first conformational change, induced by ligand binding, coupled to structural changes at distant sites within the heme-protein gas sensor? And furthermore, what is the mechanism whereby NO acts differently than CO? Hemoglobin can be used as a model to describe such a mechanism. Figure 7 shows a scheme comparing binding affinities (iron-to-gas bond) and base affinities (iron-to-imidazole) of CO and NO. Although both CO and NO are strong heme-ligands, NO has a much higher affinity for ferrous heme (nitrosylheme) than does CO. Conversely, the base affinity of nitrosylheme is lower than that for CO-heme.




FIG. 8. (A) Schematic presentation of structural changes in the immediate vicinity of the heme of α -NO hemoglobin. NO forms a five-coordinated nitrosyl-heme complex in which the α -heme Fe-His (F8) bond is weakened and cleaved, causing a shift in the quaternary structural equilibrium from the R-toward the extreme T-state. In this form, the O_2 affinity in the β -subunit is substantially reduced, making it an extreme low-affinity O_2 carrier. (B) Comparison of O_2 -delivery capacities of untreated RBCs (grey line) and α -NO RBCs (black line) at pH 7.4 and 15°C . Normal hemoglobin can carry four O_2 per tetramer, whereas α -NO hemoglobin can only carry two, because the α -subunits are ligated by NO. Under normal conditions, RBCs unload $\sim 11\%$ of total O_2 , whereas α -NO RBCs can deliver 29%. Adapted by permission from Taylor & Francis Ltd.: Tsuneshige *et al.*, *Artif Cells Blood Substit Immobil Biotechnol* 29: 347–357, 2001 (322).

CO binds preferentially to the six-coordinated structure with an equilibrium constant (K_E) of $4 \times 10^8 M^{-1}$, compared with $2 \times 10^4 M^{-1}$ for the five-coordinated structure, a 4 orders-of-magnitude difference. The opposite is true for the binding of NO, which prefers the five-coordinated structure to the 6-coordinated structure by a 3 orders-of-magnitude difference (255, 256, 266, 320). The consequence of this differential binding is that the binding of CO strengthens the Fe-axial bond to the imidazole base of proximal histidine; whereas that of NO markedly weakens the same bond (Fig. 7). Under some conditions, the proximal iron-histidine bond is severed, forming a 5-coordinated nitrosylheme complex. This has been observed in both α -NOHb in the presence of inositol




FIG. 9. Simplified drawing to show the proposed mechanism of NO sensing by sGC. NO binds and unbinds from the Fe^{2+} heme in the regulatory domain, which transduces the signal to the functional domain, where a conformational change is transduced to the functional unit, and the cyclase activity is turned on. For a more complete scheme, readers are referred to the articles by Marletta and his co-workers (73, 354). The equilibrium constants, K_{NO} , K_{CO} , are calculated based on rate constants from the literature.

hexaphosphate (364) and in the heme-regulatory subunit of sGC (101, 161).

Iron in the six-coordinated nitrosylheme is situated in the plane of the porphyrin ring; whereas, iron in the five-coordinated structure is displaced out of the plane, causing a shift of the iron toward the NO ligand. This shift is thought to induce further changes in protein structure (161, 364, 367). By using α -nitrosyl hemoglobin (α -NOHb) as a model, in which the two α -subunits are bound by NO, we relate a structural change induced by NO into a functional change of hemoglobin, namely the O_2 binding characteristics and O_2 -delivery performance of α -NOHb. Yonetani *et al.* (364) showed that α -NOHb modulates the quaternary structure of hemoglobin between the R (relaxed) and T (tense) forms. The T-state displays a dramatic decrease in affinity for O_2 in the β -subunits, attributable to the quaternary conformational change caused by NO-induced cleavage of the axial bond in the α -subunits. Conversely, O_2 binding to the β -subunits shifts the quaternary conformation toward the R-state, causing a decrease in the affinity of NO for the α -subunits (Fig. 8A). Indeed, the O_2 saturation curve of human erythrocytes containing α -NOHb (α -NO-RBC) is right-shifted compared with that of the NO-free erythrocytes (Fig. 8B) (298, 322). In this manner, α -NO-Hb is suggested to augment O_2 delivery in the peripheral tissues.

2. Specific heme-protein sensors

a. NO sensor. The soluble guanylate cyclase enzyme (sGC, EC 4.6.1.2), which catalyzes the conversion of GTP to the second-messenger cGMP, is a heme-based NO sensor and was the first definitive receptor of NO to be identified in mammals (73, 188, 243, 293, 319). sGC is a heterodimer consisting of α - and β -subunits (72). The N-terminal regulatory domain of each subunit has a heme-nitric oxide and oxygen binding domain (H-NOX), whereas the β -subunit has a prosthetic heme (136, 146). The ligand-binding characteristics of sGC are unusual, in that its heme group does not bind O_2 , even under atmospheric pressure.

The catalytic activity of sGC is controlled by both NO and CO (Fig. 9). NO binding can increase the catalytic activity of the enzyme by several hundred-fold (293); whereas, the

stimulatory effect of CO is far less potent, increasing enzyme activity by only three- to four-fold (142, 154, 161, 233, 292). However, in the presence of the allosteric activator YC-1 (3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole) (189), CO synergistically activates the enzyme to the same level as NO (294). For detailed kinetics, ligand-binding characteristics, and structure-function relations of this enzyme, readers are referred to excellent reviews by Marletta and his co-workers (49, 73) and others (211, 233, 243).

How are CO and NO different from each other with respect to their sGC-binding properties? Sharma and Magde (274) summarized important kinetic data for CO and NO binding to sGC, and the following values are taken from their table. CO rate constants for association and dissociation are $1.2 \times 10^5 M^{-1}s^{-1}$ and $28 s^{-1}$ at $23^\circ C$, respectively (154), whereas Stone and Marletta (291) reported values for CO on and off rates as $3.6 \times 10^4 M^{-1}s^{-1}$ and $3.5 s^{-1}$ at $10^\circ C$, respectively. By contrast, these values for NO are $1.4 \times 10^8 M^{-1}s^{-1}$ and $8 \times 10^{-4} s^{-1}$, respectively. This means that the association of NO to the heme is faster than that of CO, whereas dissociation of NO from the heme is slower than that of CO.

How is the binding of NO translated into an increase in the enzyme activity? Although no three-dimensional structural information of sGC is yet available, kinetics and equilibrium binding studies of NO to sGC have made it possible to propose a complicated multistep mechanism of sGC activation that involves at least two NO-binding sites (49). It was once thought that sGC followed a simple two-step activation process whereby NO bound to heme, forming a sGC-NO complex (six-coordinated histidine-Fe-NO), which subsequently changed to form a fully active five-coordinated histidine-Fe-NO complex. However, this model was revised by Zhao *et al.* (371), who showed that full activation required two NO-dependent kinetic processes. By monitoring NO binding and catalytic activity simultaneously, Russwurm *et al.* (259) showed that when 80% of heme is saturated, as in the Fe-NO complex, sGC displayed only 10% of maximal activity, supporting two NO-bound states of the sGC. Poulos (243) suggests in his review that sGC exists in a mixture of two species of five-coordinate Fe-NO complexes displaying identical spectra, in which one has low or no activity and the other has full activity. By contrast with NO, CO ligation results in the formation of a six-coordinated Fe^{2+} -CO complex (161). Stone and Marletta (291) suggest that the binding of CO to sGC is a simple one-step process, in which the off-rate of CO from the hexacoordinate complex is much faster than typically found in heme proteins. The differences in sGC ligand binding described earlier become important when the interactions of CO and NO are considered *in vivo*.

b. CO sensor. Are specific CO-specific sensors not affected by NO under physiologic conditions? The transcriptional activator CooA in the photosynthetic bacteria *Rhodospirillum rubrum* is the first example of a heme protein in which CO plays a physiological role. Here only the CO-bound form of CooA binds to its target DNA and acts as a transcriptional activator (11, 127, 275). In mammals, the heme protein neuronal PAS domain protein 2 (NPAS2) was reported to be a specific CO sensor (78, 251). It was identified as a member of the bHLH family of transcription factors expressed in the forebrain. The resonance Raman spectra indicated that CO coordinated to the heme iron histidine on the proximal side,




FIG. 10. Effects of CO and NO on the activity and structure of the prosthetic heme of rat recombinant full-length CBS. (A) Sodium sulfate polyacrylamide gel electrophoresis for purification of rat recombinant CBS. Lane 1, crude extract; lane 2, purified CBS. (B) Effects of CO and NO on the Fe^{2+} -CBS activity under optimal substrate conditions at pH 7.4. CO, but not NO ($100 \mu\text{M}$), significantly attenuated the activities of the ferrous enzyme. Data indicate mean \pm SEM of four experiments. The activities were measured by determining the conversion of homocysteine and serine to cystathionine. $*p < 0.05$ versus the group treated with vehicle (V). The concentration of CBS-heme was $10 \mu\text{M}$. (C) Stopped-flow visible spectrophotometry for Fe^{2+} -CBS to examine temporal transitional changes after mixing with CO. Data exhibited a decrease at 448 nm and a reciprocal elevation at 422 nm, demonstrating stabilization of the six-coordinated CO- Fe^{2+} -histidine complex. (D) Electron spin resonance spectroscopy indicating the five-coordinate NO- Fe^{2+} complex of the CBS-heme. Arrow, g value = 2.008. Adapted from Shintani *et al.*, *Hepatology* 49: 141–150, 2009. (E) Crystal structure of the human CBS (drawn from PDB 1JBQ). The heme and PLP are presented in a stick model.

whereas NO did not bind to the heme group (318). Here, CO is suggested to regulate the formation of a complex between NPAS2 and another bHLH transcription factor, BMAL1, in a process that regulates the circadian rhythms (78).

Cytochrome P450 enzymes were once considered putative CO-sensitive signal transducers (118, 312, 313). However, the ferrous heme of these enzymes has been found to be sensitive to both CO and NO, ruling them out as specific CO sensors. CBS, the “pseudo-cytochrome P450,” conversely, was found to be a *bona fide* CO-specific sensor. *In vitro* studies using recombinant CBS have shown that CO acts as an apparent competitive inhibitor of CBS, with the K_i value of $\sim 5 \mu\text{M}$, much smaller than that for NO ($200 \mu\text{M}$) (312). The result is striking because such a low K_i for CO suggests that CBS acts as a specific CO sensor *in vivo* under physiologic conditions. CO inhibits recombinant rat CBS by stabilizing the six-coordinated structure of the heme. By comparison, NO binds to heme, but stabilizes the five-coordinated structure.

CBS was first identified as H-450, in which the addition of CO to its reduced form produced a new spectral species that

resembled that of the reduced CO-complex of a denatured form of cytochrome P-450 (226). Among heme proteins, CBS is unique, in that it catalyzes a PLP-dependent reaction (152). The prosthetic heme of this enzyme is coordinated to histidine and cysteine as axial ligands in human and rodents. Because a distance of $\sim 20 \text{Å}$ exists between the heme and the PLP cofactor, a direct catalytic role of the heme is excluded (Fig. 10) (199). Although the crystallographic structure of CO-ligated forms has yet to be determined, perturbation of the heme environment by CO, but not by NO, is believed to be communicated to the active site with concomitant inhibition of enzyme activity. Thus, it can be postulated that CBS functions as a CO-sensing heme protein.

VI. Interactions of Multiple Gas-Transducing Systems

A. Multiplicity of actions: a hallmark of gas behavior

HO, NOS, and CBS are heme proteins that generate CO, NO, and H_2S , respectively. Although these enzymes have adapted ways to recognize specific substrates and cofactors

and protect themselves from being bound to nonphysiologic ligands of similar polarity and shape, interactions among gas ligands do occur. At least nine different interactions between a gas and a generating system can be considered (CO/HO, CO/NOS, CO/CBS, *etc.*), without taking into account the binding effects of O₂. Here, we mostly limit consideration to acute interactions of CO and NO at the level of their biosynthetic enzymes, NOS and HO, and sGC, a primary heme protein target/receptor for these gases.

1. Does CO inhibit NOS and does NO inhibit HO? CO has been suggested to inhibit NOS activity by coordinating to the NOS prosthetic heme group. However, such inhibition seemingly requires a high concentration of CO. For example, by using purified murine macrophage iNOS, White and Marletta (349) found that a mixture of 80%CO and 20% O₂ (a near-saturated CO solution that resulted in direct CO-binding to the NOS prosthetic heme) inhibited NOS activity by 73 to 79%. Similar results were obtained independently (196, 198, 265) by using recombinant neuronal NOS (nNOS). However, an important question is what is the actual physiologic inhibitory concentration of CO? Scheele *et al.* (265) note that the CO affinity for NOS is relatively weak; it is 300 times less than the CO affinity for human Mb, and they suggest that 1 mM CO, a near-saturated concentration, would be required to inhibit NOS. It would appear, however, that such inhibition by CO is unlikely *in vivo*, unless such a high concentration can be achieved locally. Although local CO concentration cannot be currently measured and is unknown, such a possibility should be pursued.

Whereas CO does not appear to inhibit NOS unless it is at high concentrations, based on *in vitro* experiments, NO has been reported to bind and inhibit HO (338). The ligation of NO to the Fe²⁺ (ferrous) heme of recombinant human HO-2 was demonstrated by resonance Raman and EPR spectroscopy (134), and stopped-flow studies revealed that NO binds 500-fold more tightly to Fe³⁺-human HO-1 than to the Fe³⁺-myoglobin (338). In terms of the inhibitory effect, by using the NO donor, NOC9, Wang *et al.* (338) reported the IC₅₀ for human HO-1 as 0.08 mM.

2. Does CO autoinhibit HO and does NO autoinhibit NOS? Can a gas self-inhibit the activity of its own synthesizing enzyme? When exogenous gases were applied to their respective enzymes *in vitro*, the answer was "yes" for both CO and NO. The HO reaction was substantially attenuated under a gas phase of 20% CO and 80% O₂ (366). By contrast, however, endogenously produced CO did not appear to inhibit the same reaction (191). It is therefore worth noting the mechanism by which HO can escape from CO autoinhibition (170, 299, 300). A notable feature of the HO reaction resides in the oxidation of verdoheme to biliverdin. This reaction proceeds without interference by CO, which is produced in the second step of the overall HO reaction as α -mesohydroxyheme is converted to verdoheme (Fig. 2A).

The endogenously produced CO does not seem to interfere with the third step (single-turnover reaction) of the overall HO reaction (155). The affinity of CO for verdoheme is low compared with that for heme. As CO is being generated during the second step of the HO reaction, it is temporarily trapped within a special space in the heme pocket of the enzyme and then released after the generation of biliverdin. It is through this mechanism that CO autoinhibition of HO is

avoided (299). However, excess exogenous CO does inhibit this third reaction step. Under a gas phase of 20% CO and 80% O₂ (366), the HO reaction is substantially attenuated, specifically at the verdoheme stage. These findings suggest that the active site of HO may be equipped with structural features that allow the HO to escape autoinhibition by local CO during the reaction, but not by external CO. Somewhat consistent with this concept is x-ray crystallography data, which show that the heme-HO complex has a structure that increases the affinity for O₂, but decreases the affinity for CO (300).

Similar to the inhibition of HO by exogenous CO, exogenous NO (105, 254) has been shown to inhibit NOS activity at concentrations between 0.1 and 10 μ M (1, 105, 192). Griscavage *et al.* (105) suggested that enzymatically generated NO could autoregulate NOS, with direct consequences on NOS activity and local changes in NO concentration. The mechanism of NO autoregulation may be somewhat different, however, from that of CO autoregulation, as NO binds to both Fe²⁺ and Fe³⁺ oxidation states in heme proteins, whereas CO binds solely to the Fe²⁺ oxidation state of NOS heme proteins.

Stuehr *et al.* (295) comprehensively summarized a novel catalytic model that emphasized the importance of heme oxidation states during NO biosynthesis, suggesting a possible role for NO as an intrinsic regulator. During NO synthesis, the iron of the NOS prosthetic heme alternates between the Fe²⁺ and Fe³⁺ oxidation states (192). Under an anaerobic atmosphere, the heme iron of nNOS was shown to bind NO as a sixth ligand in both the Fe²⁺ and Fe³⁺ oxidation states, generating stable NOS heme iron-NO complexes (339). During NO synthesis, NO binds to the Fe³⁺-heme before exiting the NOS, and the reduction of the Fe³⁺-heme is the rate-limiting step for the overall enzyme reaction (264).

3. CO Attenuation of NO-mediated sGC activation. As discussed previously, a principal means by which CO and NO transmit signals is through binding to the heme moiety at the active site of sGC. What happens if both CO and NO simultaneously diffuse to the sGC? To answer this question, an experiment was conducted with purified bovine sGC to determine whether CO modulates NO-dependent activation of sGC (1.7 nM in a reaction mixture) (142). At *in vitro* concentrations of 10 to 30 μ M, CO exhibited dual effects on the activation of purified bovine sGC induced by the NO donor S-nitroso-N-acetylpenicillamine (SNAP). In the presence of SNAP at <100 nM, CO elicited a modest activation of sGC. However, in the presence of SNAP at greater concentrations, the application of CO modestly but significantly attenuated sGC activation. These results suggested that CO serves as a partial antagonist for sGC, limiting the dynamic range of the NO-dependent activation of the enzyme. Many biochemical investigations have provided good evidence for the acute interactions of CO and NO at the level of the generating enzymes. To use these findings to discuss more-complicated systems *in vivo*, we must consider the following factors of gas generation: (a) concentrations of gases in tissues, cells, or even compartments in the cells; (b) spatial localization of gases; and (c) temporal regulation of gas generation.

B. Quantitative arguments

Organs and cells are specialized in their ability to produce different gases at different rates, and it is this specialization

that controls cellular function. Many studies have extrapolated from the protein expression of gas-producing enzymes to the amount of gas generated. However, such extrapolation is far from ideal because it is the availability of substrates and trace elements that controls enzyme activities and is more likely to determine the rate of gas formation in a tissue than simple protein expression.

Unlike NO, which is synthesized from L-arginine, a readily available substrate, it is generally assumed that little free heme is available to act as a substrate for the CO-generating enzyme, HO. Furthermore, production of CO appears to be controlled in a more tonic fashion, in which no acute on-off switch is required, differing from NO, which is more tightly regulated. HO-2, the constitutive isoform, contains three Cys-Pro signatures, known as heme-regulatory motifs (HRMs), which regulate processes related to iron and oxidative metabolism (124). Yi *et al.* (362, 363) showed that the C-terminal HRMs act as a thiol/disulfide redox switch, controlling the affinity of the enzyme for heme. To understand better the molecular mechanisms of gas signaling *in vivo*, more rigorous measurements of the actual levels of gas production with high spatial and temporal resolution are required. This is very difficult because gases bind to multiple entities, reducing their free levels, and currently no robust experimental approach to measure their local concentrations exists. Currently, real-time measurement of CO with high spatial resolution is not available. Here we focus on the quantitative differences in tissue between CO, NO, and H₂S and discuss the possible physiologic consequences that these differences might induce.

1. Tissue concentrations of CO. CO has attracted much interest since being implicated as a gaseous messenger for various biologic systems (230, 261, 296, 328). To understand the molecular basis and mechanisms whereby CO mediates cellular functions, it is important to determine the local concentration of CO in target tissues. Analytic procedures used to measure endogenous CO concentrations include gas chromatography–gas-reduction detection (330), gas chromatography–mass spectroscopic detection (14), laser sensor–infrared absorption (165, 208), and UV-visible spectro photometric measurement of the CO–hemoglobin or the CO–myoglobin complex (2). Although recent quantum cascade laser technology (165, 208) enabled us to perform the real-time detection of biogenic CO generation, the technology to resolve both spatial and temporal dynamics of CO is not yet available. Readers are referred to comprehensive articles by Vreman *et al.* (332) and Marks *et al.* (191).

One of the first attempts to determine the level of endogenous CO was made by using an isolated perfused liver preparation. Concentrations of CO in the effluent were determined spectrophotometrically by measuring the formation of the ferrous–CO complex of myoglobin (296, 297). The steady-state generation of CO was calculated to be 0.7 nmol/min per gram of liver. When the differences in local flow rates between *ex vivo* and *in vivo* systems are considered, it appears that local concentrations of CO in and around sinusoidal vessels are approximately 1 μ M (296).

Recently, the development of a gas chromatography/reduction gas detector (GC/RGD) system allowed measurement of CO with a sensitivity of 1 pmole and a linear range up to 120 pmoles (330). By using this technique, the CO tissue concentration in rat liver was found to be 4 pmol CO/mg FW

(fresh weight), which was similar to that measured by Sue-matsu *et al.* (296). In the rat brain, Vreman *et al.* (359) found the CO content to be 2 pmol CO/mg FW. By using GC, Ishikawa *et al.* (135) detected 1 μ M CO in rat cerebrospinal fluid (CSF). In the same CSF, the concentration of bilirubin-IX α , an end product from heme degradation through the HO reaction, was determined to be 0.8 μ M, suggesting that the stoichiometry of CO and bilirubin-IX α is close to 1 to 1. Taken together, these data suggest that CO concentrations in the liver and brain are in a micromolar range. By comparison, this value is one or two orders higher than the concentration of NO.

2. Tissue concentrations of NO. It is a difficult task to measure endogenous NO gas *in vivo* because of its low concentration and its short half-life. Analytic procedures to measure endogenous NO concentrations include electrochemical detection by using microelectrodes (16, 321) and chemical detection by using fluorescent indicators (163). NO microelectrodes can achieve a low detection limit [*e.g.*, 6 nM (16)] and fast response time with high temporal resolution, but they cannot provide information on the spatial distribution of the gas within the tissue of interest. Conversely, fluorescent probes can provide information on spatial distribution, but cannot provide real-time information on NO flux. This is because fluorescent probes irreversibly react with NO. *In vivo* studies indicate that the NO concentration in tissues is likely to be in the 0.1 to 100 nM range (21, 38, 41), whereas values of perivascular NO concentrations from the resistance arterioles have been reported to be 500 to 600 nM (29, 321).

Numerous studies have tried to answer the following question: How much NO is required to activate sGC *in vivo*? The answer depends on (a) how much NO is actually produced, and (b) how much NO is delivered and coordinated to the prosthetic heme group of sGC, as an axial ligand. In the literature, the low-end concentration of NO required for half-maximal activation of purified sGC is 1.7 nM (103). By contrast, Stone and Marletta (293) reported an NO concentration of 250 nM at 10°C *in vitro*. Theoretically, the physiologic half-maximal activation of sGC at 37–38°C should be even higher, when one considers that NO reacts with not only with sGC, but also with other molecules, such as superoxide, thiol groups, hemoglobin, and cytochrome *c* oxidase, thereby reducing the effective concentration of the gas at the site of sGC (37, 196, 234).

In vascular smooth muscle cells (VSMCs), NO binding to the heme group of sGC occurs within milliseconds to a few seconds, although subsequent release of cGMP is much slower (49). Half-maximal activation of sGC requires 23 to 250 nM NO. The deactivation of sGC, with a half-life of 1 to 2 min, is at least an order of magnitude slower than its activation (64). This might imply that, even after the NO in the local environment dissipates, the sGC remains activated. This adds another level of complexity to the question of how much NO is needed to relax the smooth muscle *in situ*.

The difficulty in measuring the tissue concentration of NO has accelerated the field of mathematical modeling of NO delivery. Many mathematical models predicted a concentration range between 100 and 250 nM (38, 56, 327). Direct enzymatic production of NO in tissue depends on the availability of substrates and cofactors and the expression of the NO synthases (nNOS, iNOS, and eNOS (207)). Until recently, most NO available for vascular walls was believed to




FIG. 11. Vasodilatory response on reducing endogenous CO generation associated with augmented NO generation under a CO-suppressed condition in the rat brain. (A) Changes in arteriolar diameter at 60 min after the superfusion of various reagents. Supplementation of CO ($10 \mu\text{M}$) significantly reduces the vasodilatory response induced by HO inhibition. Inhibition of NOS by L-NAME (1 mM) abolishes this vasodilatation. Diameters are standardized as a percentage of baseline diameters before applying the reagents. * $p < 0.05$; an increase as compared with the vehicle-treated control. # $p < 0.05$; as compared with the ZnPP-treated group. Values are expressed as mean \pm SEM. **(B)** Time-dependent elevation of NO production in the pial microcirculation. In the control group, NO-associated fluorescence is faint at 20 min. At 60 min, it becomes obvious at the vascular walls and at the cells located in extravascular space. Conversely, in the ZnPP-treated group, fluorescence is evident even at 20 min, and it increases further at 60 min. Adapted from Ishikawa *et al.*, *Circ Res* 97: e104–e114, 2005 (135).

be derived from eNOS in endothelial cells. However, Kashiwagi *et al.* (148) found that nNOS-containing nerve fibers, which innervate arterioles and nerve terminals, are major sources of arteriolar NO, indicating an additional source in the vicinity of arteriolar walls (Fig. 11). Others also reported the presence of nNOS in perivascular nerve fibers (64, 219). These findings are reinforced further by the theoretic study in which consideration of the perivascular source

of NO gives rise to a more realistic prediction of the NO-concentration profile in and around an arteriole, making it closer to the measured values (149). Although determination of tissue concentrations of NO is not easily achieved, these investigations may allow us to speculate that its concentration is in a nanomolar range, much less than that of CO. Possible consequences of the difference in CO and NO gas tissue concentrations are discussed later.

3. Tissue concentrations of H₂S. Notwithstanding the numerous reports of potent actions of H₂S in many organs, the cellular and molecular sources of this gas and the mechanisms of its release are still far from clear. To unravel these mechanisms, spatiotemporal determination of the H₂S concentration must be acquired. However, among CO, NO, and H₂S, the determination of H₂S concentration in biologic samples, let alone the spatial determination of gas generation, appears to be the most challenging case. As mentioned in Section III.D. besides existing as free H₂S, the gas is reversibly converted into different molecular entities of its related species. Processes of this conversion are sensitive not only to the natural biologic stimuli but also to the experimental conditions, making it difficult to determine actual local concentrations of H₂S. Technical uncertainties of this kind challenge unraveling the mechanisms whereby H₂S evokes biologic events.

Current methods to analyze H₂S concentrations in biologic samples fall into two categories. One is designed to measure solely the “free” H₂S, involving no derivatization process. The polarographic H₂S sensor (79) is one such method. The other is designed to measure “labile” H₂S, involving chemical treatment of samples with either acid or reducing agents to liberate H₂S from sulfur compounds of cellular-H₂S pools such as Fe–S complex (acid-labile) and bound-sulfane sulfur (dithiothreitol-labile). Colorimetric assays using methylene blue (108), gas chromatography–mass spectrometry (126), and high-performance liquid chromatography are often used to measure labile sulfur [see reviews by Tangerman (310) and Ubuka (323)].

Reported values of labile H₂S in plasma and blood varied mostly between 20 and 300 μM (351, 352). In contrast, with a polarographic H₂S sensor with the detection limit of near 10 nM (79, 160), no detectable H₂S was found in either blood or plasma without any derivatization (352). Readers are referred to comprehensive summaries by Whitfield *et al.* (352) and Whiteman and Moore (351), in which values and the analytic methods used are comprehensively surveyed.

To measure free H₂S in the rat brain homogenate, Ishigami *et al.* (133) developed a method using silver particles to trap free H₂S, with the detection limit of near 9 μM ; however, as in blood and plasma, no detectable H₂S was found. In other studies, free H₂S in the mouse brain was reported as 14 nM (96), whereas labile sulfur varied between 30 and 70 μM (323, 344). Investigators (351) interpreted these results to mean that H₂S was stored in plasma rather than as free H₂S. It is further suggested that H₂S release from labile sulfur might take place in response to physiologic stimuli (156).

By using brain tissues from rodents, Ishigami *et al.* (133) reported the intriguing result that alkalization of the homogenates caused a release of H₂S from bound sulfur. Moreover, in murine primary astrocytes, an increase in extracellular K⁺ concentration causes an alkalization of intracellular pH ([pH]_i). An increase in [pH]_i could occur in




FIG. 12. Three different routes by which CO controls sGC activities and vascular tone. (A) CO modestly stimulates sGC, thereby reducing the tonic contractile tension of vascular walls. For this action to take place, the local amount of NO must be low, as reported in the liver microcirculation, where constitutive NO appears to be cancelled by basal superoxide. (B) In contrast, when a sufficient amount of NO exists, CO partially inhibits sGC, enhancing its tonic contractile actions. (C) CO interferes with NOS activities as a first step, and it subsequently reduces NO, resulting in sGC inhibition. Here, the gas acts as a tonic vasoconstrictor.

response to neuronal activity, suggesting a neuron-originated control of H₂S release in the central nervous system. However, it is important to note that the analytic conditions used to liberate the gas (*i.e.*, the ways to alkalize the sample) may have significantly affected the amounts of labile sulfur. Whitfield *et al.* (352) showed a rapid liberation of H₂S from 5% bovine serum albumin (BSA) on mixing it with a strong alkaline buffer. The authors cautioned that using a strong alkaline solution might cause artificial generation of H₂S. Although considerable advances have occurred in the quantitative analysis of H₂S, more-rigorous approaches are needed to acquire spatial information about this gas.

C. Functional arguments

1. Anatomical proximity of gas-producing and gas-reception sites. Experimental evidence suggests that CO modulates the generation of NO, and, by so doing, regulates vascular tone. Like NO, CO has vasodilatory properties in the liver where endogenous NO production appears low (296). In the brain, which produces relatively high levels of NO, how these gaseous monoxides interact with each other to control cerebrovascular tone is unclear. Ishikawa *et al.* (135) found that CO derived from HO acted as a tonic regulator against NO-dependent vasodilation in the adult rat brain. The authors showed that suppressing endogenous CO caused an increase in arteriolar diameter that was accompanied by an increase in local NO generation, demonstrating a causal relation between CO and the rate of NO production (Fig. 11). Such an inhibitory function of CO on NO generation appeared

to be mediated by the ability of CO to bind the prosthetic heme of NOS. Additionally, immunohistochemical analyses of the rat brain showed that HO-2, the constitutively expressed form of HO, was present in neurons and arachnoid trabecular cells expressing nNOS and the vascular endothelium expressing eNOS, suggesting a colocalization between CO- and NO-generating sites. These results demonstrate the importance of spatial relations among the gas-producing enzymes and their reception systems.

Taken together with other studies, it can be argued that CO regulates vascular tone in at least three distinct ways that depend on the microanatomic arrangements of the vasoactive gas-generation and -receptor systems. These arrangements are summarized as cartoons in Fig. 12. First in the liver, CO modestly stimulates sGC in hepatic stellate cells, thereby reducing the tonic contractile tension of sinusoids. For this action to take place, the local amount of NO must be low, as found in the liver microcirculation, in which constitutive NO appears to be negated by basal superoxide (99, 169, 296, 297). Second, in resistance arterioles, where sufficient amounts of NO are found, CO could target sGC and modulate NO-mediated vasodilation. The observation that transgenic mice overexpressing cell-specific HO-1 in VSMCs exhibit systemic hypertension (130) supports this concept. Additionally, we found that endogenous CO produced by HO-2 in Müller glial cells plays a role in refining the NO-mediated activation of sGC in the retina (Fig. 13) (142). Finally, in the cerebral microcirculation, CO interferes with NOS activity and subsequently reduces NO generation, thereby limiting vasodilation. It appears that the mechanisms by which the




FIG. 13. Visualization of sGC activities with alterations in NO and CO generation. Monoclonal antibody against sGC, mAb3221, makes it possible to examine the activation state of sGC. Shown here is the immunoreactivity to mAb3221, which acquires a greater binding affinity through its recognition of a regiospecific structure determined by the two subunits of sGC. (A) Vehicle-treated control. (B) L-Arg treatment. (C) L-NAME treatment. (D) ZnPP treatment. Scale bar, 50 μm . (E) Schematic drawing of the relation between gas-producing enzymes and sGC in the rat retina. It is proposed that NO is the dominant activator of sGC, but endogenous CO produced in Muller glia cells plays a role in refining the NO-mediated regulation of sGC function. Blue, green, yellow, and orange represent increasing partial O_2

pressure ($p\text{O}_2$). OS, outer segment; ONL, outer nuclear layer; INL, inner nuclear layer; IPL, inner plexiform layer; OpFL, optic fiber layer. Adapted by permission from *The FASEB Journal*: Kajimura *et al.*, *FASEB J* 17: 506–508, 2003 (142).

gases exert their actions depend in part on the colocalization of the NOS and HO enzymes with sGC. These findings demonstrate the importance of spatial relations among the gas-producing enzymes and their reception systems in evaluating the functional roles of gases.

Several mechanisms exist by which the HO-CO system might modulate NO-dependent biologic events. First, oxidative degradation of heme by HO can downregulate catalytic activities of heme proteins, including NOS (305). A second possibility is related to substrate availability. Because both HO and NOS enzymes use NADPH as a reducing equivalent and molecular O_2 as co-substrates, competition for these substances may mediate enzyme activity under normal conditions. Because NADPH is an intracellular substance that is not transported between cells, for HO and NOS to be in competition for these substrates, they must reside in the same cell. The finding that these enzymes do colocalize in the same cell supports the possibility that substrate competition may modulate enzyme activity. A third mechanism is related to the key observation made by White *et al.* (349), in which NOS activity is directly inhibited by CO *in vitro*, suggesting that the site of CO action is on the prosthetic heme of the NOS enzyme. As mentioned earlier, this inhibition requires a high concentration of CO, as much as 1 mM (265). By contrast, however, the reported values of tissue CO concentration are only on the order of $\sim 1 \mu\text{M}$, significantly lower. One possibility to explain this discrepancy is that the *in vivo* mechanism involves local concentrations of CO, which may be much higher than global averages would suggest. If the turnover of HO-2 were fast enough, then it is possible that a large concentration of CO may exist locally. Provided that both HO-2 and NOS are expressed in the same cell, it is conceivable that NOS activity could be regulated by HO-2 in an autocrine manner. Although a gas is often thought to diffuse easily to a distant location in the tissue, the effective distance from the gas-generating site to its target could be much shorter than expected.

2. Is CO vasodilatory or vasoconstrictive? The observation that CO acts as a tonic inhibitor of NO-mediated vasodilation appears to contradict the results of other studies reporting that CO acts as a vasodilator (137, 176, 177, 297, 341). However, several possibilities exist that may help to explain this discrepancy. First, the principal target molecules for CO could be different in different experimental systems; thus, it is reasonable to expect different cellular responses based on different receptor systems. Leffler *et al.* (137, 164, 176) showed that superfusion of either CO (10^{-11} to 10^{-9} M) or heme-L-lysinate (10^{-10} to 10^{-7} M) dilates cerebral arterioles of newborn pigs (1 to 3 days old) by $\sim 25\%$. These authors concluded that CO does this by activating the Ca^{2+} -activated potassium channel ($\text{K}_{\text{Ca}^{2+}}$) through a cGMP-independent mechanism. For the detailed mechanisms of $\text{K}_{\text{Ca}^{2+}}$ channel gating by endogenous signaling molecules, readers are referred to Hou *et al.* (122). It is reasonable to speculate that in the adult rat model, the major action of CO is tonic inhibition of NOS activity, which results in attenuating cGMP-dependent vasodilatory mechanisms, whereas in the newborn pig, it is to activate $\text{K}_{\text{Ca}^{2+}}$ involving cGMP-independent relaxation of VSMCs.

Second, expression levels of CO- and NO-producing enzymes and those of target proteins could differ widely in different developmental stages within one animal model or between different species. By using cultured cerebellar granule cells of neonatal rats, Ingi *et al.* (131) demonstrated that production of CO decreased with the maturation of cells, whereas that of NO increased. More importantly, in mature cultures in which NO production reached a high level, HO inhibition potentiated the NO-mediated cGMP increase. These data were interpreted to mean that endogenous CO acted as an antagonist of NO-dependent cGMP production. Such results are consistent with previous studies from our laboratory in the rat retina (142). These investigators concluded that the role of CO varies depending on whether NO is present. Furthermore, studies revealed that the expression

levels of sGC and nNOS change dramatically during post-natal development of the rat cerebral cortex (77).

A key factor that determines whether CO acts as either a constrictor or as a dilator could lie with the bioavailability of NO in each organ. In the brain, appreciable amounts of NO are present in both the vessel wall and the perivascular space (40, 58), whereas, in the liver, NO released from the sinusoidal endothelium appears to be extremely low, in part due to reaction with superoxide produced by Kupffer cells (296, 297).

What is the physiologic implication of having differential CO effects, particularly in the brain? We postulate that the effect of CO in regulating vascular tone is multifaceted where low tissue availability of NO renders CO a vasodilator, whereas high tissue NO availability renders CO a constrictor (141). Under resting conditions in the rat brain, endogenously produced CO could keep blood vessels from unnecessary dilation by suppressing local NOS activity, which may, in turn, contribute to the maintenance of normal intracranial pressure. Under traumatic brain injuries, such as cerebral ischemia and subarachnoid hemorrhage, CO can be overproduced, at least at some time point, because of an increase in free heme on the hydrolysis of heme proteins (55) or by an induction of *HO-1* (303) or both. In addition, substantial alterations in NO and H₂S might occur in relation to a reduced supply of O₂, substrate availability, or altered redox states of gas-producing enzymes. Thus, aberrant actions of CO, together with NO, H₂S, and O₂ under these pathologic circumstances, deserve further investigation.

To summarize, although NO acts as a principal vasodilator, it may be important physiologically to have a modulating mechanism whereby NO alone does not dominate the control of cerebral vascular tone. CO generated by *HO-2* might play a role in counteracting unnecessary overproduction of NO. This would imply a critical role for endogenous CO in maintaining resting cerebrovascular tone.

3. CBS as a CO sensor *in vivo*. Several lines of evidence support the concept that CBS acts as an *in vivo* CO sensor. First, studies using recombinant CBS have shown that CO inhibits CBS with a K_i value of $\sim 5 \mu\text{M}$ (312). Second, the low-end value of endogenous CO found in the literature is 5 pmol CO per milligram FW in the mouse liver (330), suggesting that its tissue concentration is in the micromolar range. Third, murine hepatocytes express both CO-producing *HO-2* (99) and H₂S-producing CBS (our observation), with additional *HO-1* induced in both hepatocytes and Kupffer cells during stress. The close proximity of the enzyme distributions taken together with measured CO concentrations, and the kinetics of CBS activity, suggests that CBS is acting as a CO sensor *in vivo*.

Shintani *et al.* (281) demonstrated that an increase in hepatic CO content caused a global decrease in transsulfuration metabolites such as cystathionine, cysteine, and hypotaurine, suggesting that CO inhibits the transsulfuration pathway. Furthermore, CO-overproducing livers showed a decrease in labile H₂S amount, whereas the livers of heterozygous CBS-knockout mice showed no decrease, suggesting that CO inhibits the activity of CBS *in vivo*. Furthermore, an administration of a stress-inducible level of CO (as 20 $\mu\text{mol/kg}$ of CO-releasing molecule) caused a decrease in hepatic H₂S content to stimulate HCO₃⁻-dependent biliary choleresis. Such a CO-sensitive metabolic adaptation may play a role in quality control of bile excretion under disease conditions (281).

A remaining question is what is the physicochemical mechanism whereby CO interferes with the activity of CBS. Specifically, how is the iron center of the heme in this enzyme reduced to the Fe²⁺ oxidation state, and what kind of reducing agent accounts for this reduction *in vivo*. In the case of hemoglobin in the erythrocyte, methemoglobin reductase prevents the iron center of the heme from being oxidized. What might be playing the equivalent role in the case of CBS? At present, the regulation of CBS oxidative states *in vivo* is unknown and remains an important issue to be investigated.

4. *HO-2* as an O₂ sensor: a possible role in hypoxia-induced vasodilation. It was reported that *HO-2* enzyme activity was activated by phosphorylation of serine 79 (28), implying the existence of an endogenous control mechanism in the central nervous system. Because *HO-2* has been proposed to be an O₂ sensor in chemosensing tissues, such as carotid body glomus cells (244, 353), it is reasonable that *HO-2* plays a role in local hypoxia-induced vasodilation in the brain (65, 85, 175, 238, 286). In this hypoxic situation, the action of CO could be mediated in a tonic manner in which no on/off switch is required. If the rate of CO production by *HO-2* were more sensitive to a decrease in O₂ than the rate of NO production by NOS isozymes (*i.e.*, the O₂ affinity of an enzyme-intermediate-product complex at a rate-limiting step for the HO reaction is weaker than that for NOS reaction), then NOS would still be able to operate at the concentration of intracellular O₂ at which *HO-2* can no longer produce CO efficiently. It could then be argued that hypoxia-induced vasodilation is mediated by augmented NO formation because of the reduced capacity of CO to inhibit NOS activity.

Here, it is worth noting that an overall K_m value for O₂, which is usually an important determinant of enzyme function during hypoxia, does not provide a key to the HO reaction because it consists of three oxygenation steps (Fig. 2). To gain insight into the O₂ requirements of HO, one must find out which of the three oxygenation steps limits the rate of activity and the O₂ equilibrium constant for each step. *In vitro* studies demonstrated that the rate-determining step of the heme degradation is the conversion of verdoheme to the ferric biliverdin complex (184, 195). However, although the rate-determining step involves binding of O₂ to verdoheme, which is much slower than the binding of O₂ to the heme complex, we can only speculate on the nature of the mechanisms *in vivo*, as the *HO-2* kinetic parameters are extremely difficult to determine *in vivo*.

5. Cross-talk between H₂S and NO. Besides the modulation of enzymatic activity by gaseous molecules, chemical reactions should be considered. Whiteman *et al.* (350) proposed that a reaction between H₂S and NO produces S-nitrothiols (RSNO), by showing that *in vitro* incubation of sodium hydrosulfide (NaHS, H₂S donor) with NO leads to the formation of an RSNO. Conversely, H₂S was found to reduce GSNO and release NO (314). This led to the development of a novel method for measuring RSNO by using H₂S (314).

Although H₂S is generally considered to act as a vasodilator, through its action on ATP-dependent K⁺ channels located on vascular smooth cell membrane (370), studies using the aortic ring model showed a contractile response to H₂S (6, 345). This provided evidence that the opposite response to H₂S was due to the reaction of NO with H₂S. These findings

add a new mechanism to the maintenance of cellular redox states [see Whiteman and Moore (351) for a comprehensive summary of experimental evidence showing cross-talk between H₂S and NO].

D. Non-heme protein O₂ sensors/HIF/PHD

Hypoxia-inducible factor (HIF) is a heterodimeric complex consisting of α - and β -subunits, which belong to a family of helix-loop-helix Per/Arnt/Sim (bHLH-PAS)-domain proteins. At least three distinct α -subunit isoforms (HIF-1 α , HIF-2 α and HIF-3 α) and a single β -subunit (HIF-1 β) are known. Protein stability is regulated by the degradation of the α subunit. Under normoxic conditions, HIF prolyl hydroxylases (PHD1, PHD2, and PHD3) hydroxylate two proline residues (Pro-402 and Pro-564 in HIF-1 α) in the oxygen-degradation domain (ODD) of the HIF-1/2 α -subunit by using O₂ as a substrate. Modified ODDs allow binding of von Hippel-Lindau (VHL) ubiquitin ligase, leading to polyubiquitination and proteasomal degradation (150). Thus, HIF-1 α protein is barely detectable under normoxia. Under hypoxic conditions, HIF-1 α subunits can escape from hydroxylation because of decreased PHD activity (HIF-1 α stabilization) and translocate to the nucleus, where they form heterodimers with the HIF-1 β subunit and bind to the hypoxia-responsive element of target genes.

Hypoxia-inducible factors (HIF-1 and 2) are responsible for the upregulation of genes involved in hypoxic adaptation, including those of glycolysis, erythropoiesis, and angiogenesis, all of which are essential for survival under anaerobic conditions (273). In this sense, O₂ sensing is the physiologic response in which activated HIFs modulate cellular functions by regulating gene expression (HIF pathway).

Under normoxia, both exogenously administered and endogenously produced NO stabilizes HIF-1 α in a dose- and a time-dependent manner *via* distinct mechanisms from the classic cGMP-mediated pathway (36). This HIF-1 α stabilization is due to decreased ubiquitin-dependent HIF-1 α degradation. Under normoxia, NO inhibits PHD activity, most likely through direct interaction between NO and iron in ligand-like manner. The NO donor SNAP (*S*-nitroso-*N*-acetylpenicillamine) activated the HIF pathway under normoxia. However, SNAP does not inhibit hydroxylation of HIF-1 α by PHD2, but causes *S*-nitrosation of cysteine 520 in HIF-1 α ODD (236). This inhibits recruitment of VHL to hydroxylated HIF-1 α , thereby inhibiting HIF-1 α degradation.

In contrast, NO inhibits HIF-1 α stabilization and hence activation under hypoxia. Several mechanisms have been reported for this inhibition. First, physiologic levels of NO can inhibit COX under hypoxia, which reduces the O₂ consumption at mitochondria, leading to redistribution of O₂ from mitochondria to other part of the cells. This increases the O₂ availability for other O₂-consuming enzymes, such as PHDs (36). Second, under hypoxia, NO is converted to peroxynitrite on interaction with mitochondria-driven superoxide, which leads to mitochondrial damage.

VII. Physiological Significance of CO, NO, and H₂S on Mitochondrial Signaling and Their Relation to O₂ Metabolism

CO, NO, and H₂S are known to inhibit O₂ consumption by inhibiting COX, the terminal electron acceptor of the electron-transport chain (ETC). Chemical mechanisms of this inhibi-

tion by three gases are analyzed and well-compared by Cooper and Brown in their recent review (67). COX possesses four redox-active metal centers (Cu_A, heme *a*, heme *a*₃, and Cu_B) all of which can be targeted by gases. The three gases, CO, NO, and H₂S, can all bind to the iron center of the prosthetic heme in the COX enzyme complex. During electron transport, Cu_A accepts the first electron from ferrocytochrome *c*. The electron is transported to heme *a*, from which it passes to the binuclear heme *a*₃/Cu_B center, where the reduction of O₂ takes place (12). CO is a competitive inhibitor that binds only to the reduced binuclear heme *a*₃/Cu_B center of COX. NO, however, can bind to both the reduced and oxidized states of the heme *a*₃/Cu_B complex, and its inhibition can be either competitive or uncompetitive. H₂S, which binds to both the oxidized enzyme and the turnover intermediate, is a non-competitive inhibitor. COX is thus a target and central mediator of mitochondrial respiration, not only through its natural ligand, O₂, but also through the binding of CO, NO, and H₂S. Here, we review four physiological processes affected by gaseous interactions in mitochondria: (a) mitochondrial redox signaling (MRS), (b) O₂ sensing and hypoxia, (c) mitochondrial biogenesis, and (d) cytoprotection.

A. Mitochondrial redox signaling

The inhibition of COX by CO, NO, and H₂S suppresses oxidative phosphorylation (OXPHOS) and reduces ATP production. Simultaneously, this downregulation of OXPHOS changes the redox state of the ETC and produces reactive O₂ species (ROS). In some cases, ROS function as signaling molecules, thereby controlling cell functions. This process is known as "mitochondrial redox signaling (MRS)." In OXPHOS, reducing equivalents produced in TCA cycle send electrons into the ETC from complexes I and II. These electrons are passed to complex III and finally transferred to O₂ at complex IV (COX) (143). However, a small fraction of the electrons leak from the ETC, even under normal conditions. These electrons react with O₂ and produce superoxide anion (O₂⁻). It is worth noting that ~1% of the O₂ consumed in the cell is used for this reaction (31, 249).

B. Relations between CO, NO, H₂S, COX, and hypoxia

CO binds to the reduced form of COX with a *K*_i value of 0.3 μ M (67). Its binding to COX is reversible and competitive with O₂ (52). By using HEK293 cells, D'Amino *et al.* (70) reported a dose-dependent inhibition of COX by exogenous CO, which was enhanced under hypoxic conditions. They also showed that endogenously produced CO inhibited COX. CO derived from *HO-1* inhibited mitochondrial respiration by 12% under 20% O₂, but by 70% under 1% O₂. The *K*_i of CO for COX was 1.44 μ M at 20%, whereas it was only 0.35 μ M at 1% O₂. Similar results were reported previously (113, 239). Considering that tissue CO concentrations are in the micromolar range, it appears plausible that CO inhibits COX *in vivo*.

CO is known to produce antiinflammatory and anti-apoptotic effects, which are apparently regulated at the level of COX and mediated by MRS (260, 262, 369). By using RAW264.7 cells, Zuckerbraun (373) reported that CO production of ROS was derived from the ETC and caused by the inhibition of COX, thereby eliciting MRS. RAW264.2 cells produced TNF- α in response to LPS stimulation through p38

MAPK activity. The antiinflammatory effect of CO is responsible for the inhibition of this TNF- α production. Zuckerman *et al.* also showed that CO inhibits the activation of p38 MAPK though induction of MRS. Furthermore, CO up-regulates superoxide dismutase (SOD)2 expression. Because SOD converts O_2^- to the signaling molecule H_2O_2 , this characteristic may also enhance the MRS. Downstream signaling pathways of CO-elicited MRS diverge widely, and readers are referred to a review on this subject by Bilban *et al.* (25).

NO binds COX both reversibly and irreversibly (34, 61). Unlike CO, NO can bind both the reduced and oxidized forms of COX (67). Reported values of K_i of NO for COX are 60 nM at 30 μM and 20 nM at 10 μM O_2 , respectively (34, 309). A recent report showed a much lower K_i of 0.2 nM for NO at the O_2 -binding site on COX (193). Because tissue levels of NO have been reported in a range between 10 and 450 nM (190, 277), it seems possible that NO can bind to COX *in vivo*. Because the inhibitory effect of NO on COX is much more efficient under hypoxic conditions, a question remains as to the *in vivo* physiologic effect. This is because the level of NO under hypoxic conditions is suggested to be lower than that under normoxic conditions (174), because NOS also uses O_2 as substrate. It is not known, however, whether NO has enhanced inhibitory effects under hypoxia.

It has been suggested that the effect of NO inhibition of COX is the induction of MRS, which secondarily regulates many cellular responses, including ER (endoplasmic reticulum) stress (358), O_2 redistribution (109), and acceleration of glycolytic metabolism (7). NO also has a vasodilatory effect through the sGC/cGMP pathway, which can increase the blood flow to the tissue. Thus, both the classic sGC/cGMP pathway and the MRS pathway seem to cooperate to induce the maximal NO effect *in vivo*. One important consideration is the possibility that NO reacts with O_2^- to produce ONOO $^-$, a highly reactive ROS species that might cause harmful effects to the cell (36). If so, MRS elicited by NO must be more tightly regulated as compared with that by CO.

H_2S is a competitive inhibitor of COX that has ability to bind to both the oxidized and turnover intermediate of COX (67). Reported K_i values are 0.2 μM by using purified COX (239), 10 μM using isolated mitochondria (365) and 30 μM using whole cells (178). Notwithstanding the lack of a reliable method to measure the H_2S concentration in tissue, Doeller *et al.* (79) reported a range of H_2S tissue concentration between 1 to 10 μM (79), suggesting that H_2S could inhibit COX at the tissue level.

C. Interactions of CO and NO on COX

No report focuses on the interaction of CO and NO on COX, specifically. However, D'Amico *et al.* (70) reported an interesting finding. They upregulated both NO and CO production in RAW264.7 cells by LPS stimulation and observed the effect of hypoxia on COX inhibition. Although LPS had no effect on CO level, it decreased the NO level. From these results, the authors concluded that COX inhibition was associated with CO, but not with NO. Although the inhibitory effect of these gases is stronger under hypoxic conditions, hypoxia itself might not be a suitable condition for their activity. First, because both NOS and HO use O_2 as their substrate, hypoxia might limit the availability of O_2 , thereby reducing the activity of both NOS and HO. Second, NO has vasodilatory effects

through the sGC/cGMP pathway at a much smaller amount of NO, which may increase the tissue O_2 concentration beyond the level that increases the affinity of COX to bind O_2 . And third, the concentration of CO, that induces MRS, depends on the redox state in the cells (74).

HO-1 induction accelerates heme degradation and thereby affects the activity of heme-containing enzymes. *HO-1/CO* suppresses the activity of mitochondrial NOS (mtNOS) because mtNOS requires heme for its catalytic activity leading to reduced NO production and NO-induced MRS (66). Conversely, *HO-1* could reduce O_2^- production outside mitochondria by downregulating GP91^{phox}, a component of NADPH oxidase (NOX2) (305). Furthermore, ROS from mitochondria has been shown to increase NOX1 (75). All these findings suggest that ROS induced by *HO-1*-generated CO could be the net result of ROS production in the cell and not merely from COX inhibition.

D. O_2 sensing and hypoxic response: effects of CO, NO, and H_2S

Although a detailed description of O_2 -sensing mechanisms is beyond the scope of this review, we briefly discuss O_2 sensing to understand better the role of small gases on O_2 sensing. Many excellent reviews are available on tissue O_2 -sensing mechanisms (172, 272, 343). It is worth stating that, in most cases, MRS is also used as a mechanism for O_2 sensing. Previously, mechanisms for O_2 sensing were assumed to be different between acute and chronic hypoxic responses. However, a growing body of evidence suggests that they are principally the same because O_2 sensing is based on sensing the decrease in O_2 concentration through mitochondrial OXPHOS or ETC. Of course, some tissues use apparently different mechanisms, involving NADPH oxidase-related ROS detection.

Two distinct hypoxic responses exist, acute and chronic. The chronic hypoxic response requires transcription of new genes for its effect. Genes newly transcribed are those necessary for adaptation to anaerobic metabolism, such as erythropoiesis, angiogenesis, and glycolysis, most of which are regulated by the HIF pathway. Under hypoxia, stabilization and activation of HIFs depends on the canonic MRS, which results in PHD inhibition, thereby rescuing HIF-1 α subunits from proteasome degradation.

Conversely, the acute hypoxic response is executed by specialized tissue such as the carotid body, pulmonary artery smooth muscle cells, and adrenomedulla cells (347). These tissues sense reduced O_2 concentration and immediately respond by excreting hormones or contracting smooth muscle cells. The principal purpose of acute O_2 sensing is to increase ventilation and circulation to ensure adequate O_2 delivery to meet O_2 demand. The final step of the acute O_2 -sensing mechanism is widely accepted to be an increase in intracellular Ca^{2+} through the opening of the L-type Ca^{2+} channel (357). Although this opening of the Ca^{2+} channel is the result of closure of several type K^+ channels, mechanisms that close these K^+ channels have not been fully investigated. In this part of this review, we discuss the role of these small gases on the acute O_2 -sensing mechanism.

Williams *et al.* (353) reported the possibility that HO-2 is an O_2 sensor in the carotid body. In the carotid body, the activity of voltage-dependent, Ca^{2+} -sensitive, large-conductance K^+

channel (B_{KCa}) is inhibited by CO. Williams *et al.* showed that HO-2 is physically associated with the channel component, and CO derived from HO-2 is associated with the activity of this channel. It was hypothesized that the activity of the channel needed CO derived from HO-2, of which production is reduced under hypoxic conditions, thereby working as an O₂ sensor. However, this possibility has been questioned by subsequent studies using HO-2-knockout mice that showed no compromised response to hypoxia (227). However, HO-2-knockout mice show a lower O₂ concentration in the blood (hypoxemia) together with impaired ventilation response to hypoxia (3), indicating the existence of a ventilation-perfusion mismatch in these mice. Accordingly, these results suggest that HO-2 could be an O₂ sensor in hypoxic pulmonary vasoconstriction (HPV) or the neuroepithelial body in the lung or both. However, it is not clear whether CO-elicited MRS plays a role in acute O₂ sensing.

NO is an important regulatory factor of blood vessel tone, and reports showed that NO inhibits hypoxic pulmonary vasoconstriction (HPV) (104, 174, 348). Actually, NO production has been shown to decrease in hypoxic lung (174). NO has vasodilatory effects through the sGC/cGMP pathway (334). This in turn has given rise to the idea that HPV might result from an impaired vasodilatory effect due to decreased NO production under hypoxia (104, 174, 348). However, Bernarl *et al.* (24) recently proposed an interesting hypothesis about the role of NO on acute O₂ sensing (24). They reported that NO production was increased in pulmonary artery endothelium and that this increase in NO accelerated the release of zinc from metallothionein (MT) by nitrosylation. This Zn activated protein kinase C, which eventually caused HPV (NP/MT/zinc pathway). This hypothesis describes a new role of endothelium-derived NO in HPV. However, one consideration is that knocking out all types of NOS had no effect on HPV (104, 174, 348). Accordingly, further investigation is needed to clarify whether NO is the principal effector or only a modulator of HPV.

Almost all the investigations on the role of H₂S in acute O₂ sensing have been made in HPV. HPV is the contraction of middle-size pulmonary arteries in response to acute hypoxia (347). During HPV, blood flow within poorly ventilated lung is redirected to areas with higher pO₂, thereby improving ventilation-perfusion. Olson *et al.* (224) recently reported that H₂S is produced in the vessel wall. They also showed that treatment with cysteine, a precursor of H₂S, enhanced HPV, and conversely, inhibition of H₂S production impaired HPV. They also found that hypoxia and H₂S share the same downstream pathways. From these results, they proposed a novel possibility of H₂S as an O₂ sensor in HPV.

H₂S is ubiquitously produced in cytoplasm and oxidized in mitochondria. Olson *et al.* (223) hypothesized that non-oxidized H₂S has biologic activity associated with HPV. Because oxidation depends on O₂ availability, O₂ concentration is the critical factor that determines the total amount of biologically active H₂S. According to this theory, high O₂ concentration correlates with lower H₂S activity and a dilated pulmonary artery. Conversely, low O₂ concentration correlates with higher H₂S activity and artery contraction (223). Actually, H₂S has been reported to have both vasodilatory and vasoconstrictive effects, depending on its concentration (6, 345). Furthermore, O₂ concentration has another effect on H₂S-mediated O₂ sensing. O₂ has been shown to act nega-

tively on the activities of both CBS and CSE (15, 288), which may have an additive effect on the H₂S-mediated vascular response. Reduced production of H₂S under hypoxia has also been reported (352). Olson *et al.* (224) reported the possibility of H₂S as a universal O₂ sensor by showing H₂S acted as O₂ sensor in trout and zebrafish gills.

In summary, although NO, CO, and H₂S seem to be involved in acute O₂ sensing in their own way, no direct proof indicates that they use MRS for O₂ sensing. This might be due in part to the extremely high sensitivity of O₂-sensing tissue of OXPHOS for O₂ (80). This might cause decreases of ATP at much higher O₂ concentrations compared with other non-O₂-sensing cells. One possibility is that eliciting activation of AMP-dependent protein kinase (AMPK) inhibits the K⁺ channel in these specialized tissues (357). Also, we cannot rule out the possibility of MRS as an O₂-sensing mechanism, because ROS production has been shown even in acute O₂-sensing tissue under acute hypoxia.

E. Effects of CO and NO on mitochondrial biogenesis

What is mitochondrial biogenesis, and why does it occur? The principal purpose of O₂ sensing is to ensure that O₂ delivery matches O₂ demands at the cellular level. In this context, O₂ sensing functions to maintain or increase the energy supply in the tissue. Considering that cell functions depend mostly on mitochondrial OXPHOS, it is reasonable for cells to increase their number of mitochondria to meet their cellular energy demands. Because small gases are involved in O₂ sensing, as discussed previously, we next consider the roles of these gases on the mitochondrial biogenesis.

Mitochondrial biogenesis is a complex process involving the coordinated expression of mitochondrial and nuclear genes. Because discussion of the mechanism of mitochondrial biogenesis is beyond the scope of this review, readers are referred to an excellent review in this field (76). The key molecules in mitochondrial biogenesis are transcriptional activator peroxisome proliferators-activated receptor γ -coactivator-1 α (PGC-1 α) and transcriptional factor nuclear respiratory factor-1 and 2 (NRF-1 and NRF-2). NRFs are the transcriptional factors that control the majority of proteins involved in OXPHOS in mitochondria. Additionally, PGC-1 α and NRFs are responsible for the transcription of Tfam, a central molecule controlling mitochondrial DNA replication and transcription of mitochondria-encoded genes. Many physiologic signals control the biogenesis of mitochondria, including exercise (121) and hypoxia (107). Because no reports are available in the current literature concerning the role of H₂S, we briefly review the involvement of NO and CO in mitochondrial biogenesis.

Nisoli *et al.* (217) have reported that in mouse brown adipocyte precursor cells, mitochondrial biogenesis is dependent on NO, and this NO effect is mediated by sGC. The same group has shown, by using different cell systems from different species, that NO can induce mitochondrial biogenesis (218). Because mitochondrial number was reduced in eNOS-knockout mice regardless of the tissue, NO derived from eNOS has been assumed to be responsible for NO-induced mitochondrial biogenesis (217). Recently, however, involvement of nNOS in mitochondrial biogenesis also was reported in rat ischemic brain (107). One characteristic of NO-induced mitochondrial biogenesis is that newly synthesized mito-

chondria can fully produce ATP through OXPHOS (218). Furthermore, ATP synthesis in NO-induced mitochondria was not accompanied by a reduction of ATP produced by glycolysis, which resulted in an increase in total ATP. This may be a characteristic of energy production through NO.

Compared with NO, research into CO-induced mitochondrial biogenesis started only recently. However, contrary to NO, evidence suggests the involvement of MRS in CO-induced mitochondrial biogenesis. Recently, endogenously produced CO, induced by transfection of the *HO-1* gene, has been reported to induce mitochondrial biogenesis in rat myocardium (301). *HO-1*/CO-induced mitochondrial biogenesis required both H₂O₂ and sGC activity. The production of H₂O₂ was derived from mitochondria and required the activity of the AKT/PKB pathway for activation of PGC-1 α , NRFs, and Tfam. Interestingly, sGC activity was not involved in this AKT activation.

Lancel *et al.* (173) also reported myocardial mitochondrial biogenesis in septic mice injected with the CO-releasing donor, CORM-3. Additionally, with human muscle biopsy samples, Rhodes *et al.* (252) reported that inhalation of CO together with exercise induced upregulation of mRNA levels of PGC-1 α , NRF-1, Tfam, and DNA-polymerase gamma. Although this CO inhalation also increased COX subunit I and citrate synthase at protein levels, mtDNA was not increased significantly.

Both ischemia and exercise are conditions that increase cellular energy demands. However, whereas the former requires NO, the latter requires CO-induced mitochondrial biogenesis. CO-induced mitochondrial biogenesis accompanies the upregulation of *HO-1* and SOD2 (252), which suggests the involvement of mitochondrial oxidative stress. Although brain ischemia seems to be associated also with mitochondrial oxidative stress, involvement of CO was not reported. Conversely, NO-induced mitochondrial biogenesis is associated with the sGC/cGMP pathway. Although NO can elicit a strong MRS, it is not clear why this pathway is not the main pathway for mitochondrial biogenesis. This may suggest the existence of unknown regulatory mechanisms downstream of MRS elicited by different stimuli.

F. Cytoprotective effects of CO, NO, and H₂S

CO, NO, and H₂S were considered poisonous gases previously. A growing body of evidence now suggests that at physiologic concentrations, these gases have cytoprotective roles against many pathologic conditions. However, the mechanisms whereby these gases exert cytoprotective and pharmacologic effects are not simple and are still largely unknown. In this part, we discuss the protective role of these gases, focusing on the mitochondria. Principally, MRS is derived from the ETC of mitochondria under compromised energy-supply conditions, such as hypoxia. Accordingly, it is probable that most of the signals elicited by MRS are necessary for the protection and survival of the cell.

In this context, stabilization and activation of the HIF system is no doubt the most important downstream pathway under hypoxia. However, MRS elicited by small gases does not necessarily accelerate the HIF pathway. We discuss the characteristic downstream of MRS that is elicited by these gases. Activation of AMPK is the most characteristic downstream of NO-induced MRS. Quintero *et al.* (248) reported the

interesting characteristic of NO-induced AMPK activation in HUVECs. AMPK is usually activated by a decreased ATP level (263). However, in HUVECs, NO-induced AMPK activation was associated with neither the ATP level nor the sGC activity, suggesting that NO-induced mitochondrial redox signaling activates AMPK. This activation was elicited by mitochondrial ROS, although observed independence from the ATP level may be due to the difference of AMPK subunits. AMPK comprises three subunits, and the activity depends on the catalytic α -subunit. Most cells use the α 2-subunit, which is sensitive to the ATP level, whereas HUVECs used the α 1-subunit. AMPK accelerates glycolysis by upregulating GLUT4, hexokinase II, and 6-phosphofructo-2 kinase. Glycolysis is usually upregulated by HIFs. However, interestingly, NO-induced MRS causes O₂ redistribution, thereby increasing O₂ concentration in the cell, which in turn inhibits the stabilization of HIF-1 α -subunits (109).

Why does NO-induced MRS inhibit HIF-induced glycolysis while enhancing AMPK-induced glycolysis? One possibility is the rapidity of the AMPK pathway to activate the glycolytic system. AMPK is fully activated 15 to 30 min after the hypoxic exposure (171), whereas activation of HIF-1 takes much longer. NO-induced AMPK activation might be an energy stress. One interesting and important finding is the early reduction of the ETC by NO. NO can bind to both reduced and oxidized COX (68). By doing so, NO can control the redox state of the ETC. Interestingly Clementi *et al.* (62) reported that NO controls COX activity at a basal level (62). Thus, NO may be able to control COX activity to elicit MRS. Considering that mild to moderate inhibition of COX activity does not compromise OXPHOS capacity, NO may use ETC to generate a signal through the regulation of COX. Other downstream targets are translocation of redox-sensitive transcriptional factors and Ca²⁺ efflux from cells. The former is related to induction of genes necessary for survival. Efflux of Ca²⁺ may enhance the activity of AMPK and may also inhibit MPT by reducing the sensitivity to oxidative stress (111). The current understanding of the cytotoxic *versus* cytoprotective effects of NO in the mammalian central nervous system, emphasizing multiple properties of NO, has been well reviewed by others (45).

The role of CO-induced MRS has not been extensively studied, as compared with NO (25, 240). One characteristic is involvement in anti-inflammatory reactions. This may be due in part to the preferential use of macrophage-derived cell lines. Because CO binds only to reduced COX, is it not known whether CO also uses ETC to generate signals that are specific for CO, and not for other gases. CO can stabilize the HIF-1 α -subunit, thereby modulating the HIF pathway. However, by CO alone, this activation does not seem to be practical because a large amount of H₂O₂ is necessary to maintain activation of the HIF pathway.

Currently, no report exists of H₂S using classic MRS. Like NO, H₂S can bind to both reduced and oxidized COX. It might be possible that H₂S can also control COX at a physiologic level. However, despite the similarity to NO at COX binding, no proof is known that H₂S elicits MRS.

G. The roles of H₂S, NO, and CO in "suspended animation"

Suspended animation is a conserved physiologic response to anoxia in which all life processes reversibly arrest, including

movement and development (91, 231, 232). Surprisingly, this characteristic phenomenon completely returns to normal without any damage when animals are released from stress. This characteristic phenomenon is an adaptation to reduced energy demand and is similar to conditions like hibernation and daily torpor. From studies using *Caenorhabditis elegans*, suspended animation appeared not to be a mere passive response to a compromised state of energy supply, but rather a highly controlled active phenomenon (201, 220). Although suspended animation was originally reported in severe hypoxia, conditions other than hypoxia also can induce this phenomenon. Of particular interest is that gases including H₂S can induce this phenomenon.

Blackstone *et al.* (26) reported that inhalation of a nontoxic level (80 ppm) of H₂S in awake self-breathing mice could reversibly reduce the metabolic rate to as low as 10% of the normal state and the body core temperature down to ~2°C above (15°C) ambient temperature. A subsequent study showed that decreased metabolism and cardiac function were not associated with the reduction of core body temperature (329). The same group further reported that this suspended animation-like condition protects the animals from lethal hypoxia (5 to 3% O₂) (27). Similar results were reported in large animals by injecting sulfide into anesthetized pigs (282).

Suspended animation induced by CO was reported in the embryo of *Caenorhabditis elegans* (221). *Caenorhabditis elegans* entered suspended animation under anoxia below 0.01 kPa. At modest hypoxia (0.5 kPa), an embryo can survive and continue development by an adaptive response through HIF-1-pathway induction. However, over an O₂ range between 0.1 to 0.01 kPa, although the embryo showed development, it eventually died. CO could induce suspended animation in this O₂ environment and rescue the embryo from otherwise lethal hypoxia.

Suspended animation induced by NO was reported by using the *Drosophila* embryo (315). The embryo entered suspended animation under hypoxia. An NO donor also induced suspended animation in the embryo, even under normoxia. This NO-induced suspended animation was inhibited by a scavenger. Interestingly, blocking of respiration by cyanide also induced suspended animation. However, changes in RNA and protein regulation that are observed under hypoxia and NO treatment were not observed in cyanide-induced suspended animation. Currently, no study is using large animals.

In summary, suspended animation including hibernation is a highly controlled adaptive response to hypoxia and related conditions. Recent studies have revealed molecular mechanisms of this interesting and important phenomenon (8). It is not known what signals are involved between O₂ sensing at the COX and rapid metabolic downregulation. Although these three gases may have different pathways to induce suspended animation, COX inhibition is the common characteristic. Accordingly, it is highly probable that suspended animation is located downstream of COX inhibition. If so, several questions remain. Is inhibition of COX enough to induce suspended animation? Is MRS necessary for this induction? Do all these gases have their own signals to induce suspended animation? Studies with gases seem to give an important hint, particularly in the *Caenorhabditis elegans* experiment. Death of an embryo at the O₂ concentration of between 0.1 to 0.01 kPa seems to result from energy exhaustion,

because the embryos did not stop their embryogenesis and development, although they require a high energy supply. The embryo seems to escape lethal hypoxia by reducing energy expenditure with CO treatment. These situations resemble the septic condition, in which animals are in an exhausted energy condition (179). Moreover, gases with an inhibiting effect on COX improve the survival rate of septic animals (19). Inhibition of respiration is no doubt associated with a reduced energy supply. However, mere blockade of the COX activity does not seem to induce suspended animation. Inhibition of respiration through COX inhibition can be a trigger for suspended animation. However, some additional signals seem to be necessary for complete induction of this interesting condition.

To summarize, NO, CO, and H₂S can inhibit COX. Through this inhibition, all three gases elicit MRS, which is necessary for an adaptive response to hypoxia. In addition, these gases display protective roles on mitochondria by inhibiting MPT. Finally, these gases have therapeutic potentials by inducing suspended animation. In this section, we focused on MRS as a gas-mediated signaling mechanism. However, these gases may also regulate cellular signaling without affecting ETC or OXPHOS capacity. COX activity seems to exceed the ETC capacity as seen in muscle tissue (168). Hence, mild COX-inhibition does not necessarily imply a limitation of the ETC. This may allow cellular pathways to be regulated through COX activity without affecting mitochondrial respiration. This may explain how these toxic gases can be fundamental components of complex cellular signaling. Further studies are needed to understand the complex mechanism of COX regulation by these gases.

VIII. Altered Gas Balance in CNS Diseases

What might happen if the gas balance were significantly altered in disorders such as strokes? When and how might we manipulate gas levels to treat disease? Although the majority of studies have suggested both cytoprotective and cytotoxic roles for CO, NO, and H₂S gases under pathologic conditions, these suggestions were often made based on either exogenous application of a gas, expression levels of a producing enzyme, or the phenotypes obtained by using knockout mice, but not on actual gas amounts. What is important to study is the direct cause-and-effect relation between gases and their clinical manifestation. Here we consider some of the governing factors controlling local gas amounts, including (a) substrate availability, (b) enzyme control resulting from allosteric control and covalent modification, and (c) genetic control of enzyme expression. With these in mind, we describe the relevance of gas biology in neurodegenerative diseases of the central nervous system (CNS).

A. CO in CNS diseases

CO has been implicated in pathologic processes of the brain. Two isoforms of HO have been identified, the inducible HO-1 and the constitutively expressed HO-2. For HO-2, several mechanisms have been proposed for regulation of its activity. One is through phosphorylation by casein kinase 2 during neuronal stimulation (28). More recently, Yi *et al.* (362, 363) showed that the C-terminal heme regulatory motifs (HRMs; Cys-Pro signature) act as a thiol/disulfide redox switch controlling the affinity of the HO-2 for heme. Here,

HRMs known to control processes related to iron and oxidative metabolism can integrate heme homeostasis with CO signaling. Such regulatory mechanisms are under active investigation.

Substrate availability is an important determinant of CO production. Unlike NO production, which uses readily available L-arginine as a substrate, free heme availability under normal conditions is thought to be limited (48). However, free heme levels are thought to increase with ischemic insults due to the hydrolysis of heme proteins (54), but whether such an increase in free heme leads to CO overproduction remains speculative. Notwithstanding the uncertainties about CO overproduction, HO-CO systems themselves have been implicated in diseases in the brain, including stroke, Alzheimer disease, and Parkinson disease.

Neural injury can be either ameliorated or exacerbated (336) by the HO-CO system. However, many studies using stroke models suggested cytoprotective effects of *HO-1* and *HO-2*. Overexpression of *HO-1* in the mouse brain caused a reduction in infarct volumes induced by middle cerebral artery occlusion. Cell viability of primary neuronal cells of *HO-1*-knockout mice was decreased when challenged with acute excitotoxicity compared with that of the wild type (4). Moreover, *HO-2* appeared to protect against lipid peroxidation-mediated cell loss and impaired motor recovery after traumatic brain injury (54, 55), whereas its deletion exacerbated intracerebral hemorrhage-induced brain edema (337).

HO-1 is induced in response to various prooxidants and stressors. Intense *HO-1* immunostaining in the parkinsonian brain has been demonstrated, indicating that *HO-1* may be involved in the pathogenesis of Parkinson disease (267). Overexpression of *HO-1* in the rat substantia nigra significantly increased the survival rate of dopaminergic neurons against 1-methyl-4-phenylpyridinium-induced neurotoxicity. Furthermore, inhibition of HO activity exacerbated rotatory behavior of the rat, suggesting a role of endogenous CO (125).

Like Parkinson's disease, oxidative stress appears to be involved in the pathogenesis of Alzheimer disease (268). *HO-1* immunoreactivity is greatly enhanced in the neurons and astrocytes of the hippocampus and cerebral cortex of Alzheimer disease patients and coexpressed in senile plaques and neurofibrillary tangles (268). Amyloid precursor protein (APP) generates the β -amyloid peptide that has been postulated to participate in the neurotoxicity of Alzheimer disease. APP has been found to bind HO and inhibit its activity (307). However the mechanisms whereby *HO-1* or CO or both control these age-related neurodegenerative disorders are not clear at present.

The involvement of the HO-CO system has received considerable attention as a target for the development of effective therapeutic interventions against degenerative and inflammatory diseases in the CNS [see review by Schipper *et al.* (269)]. It has been proposed that the cytoprotective roles of the HO-CO system are initiated by a series of molecular reactions or interactions or both in response to changes in redox states of the cell, which in turn elicit "homeostatic" responses, as opposed to "chaotic" ones (25). *HO-1* has been described as a therapeutic funnel (13, 25, 162, 229) because of the multiple effects mediated by this molecule. Calabrese *et al.* (43, 46) view the adaptive mechanisms linked to the HO pathways as being crucial for both survival and the physical

quality of life. They termed this complex network of adaptive processes, composed of several protective genes, the "vitagene system". "Vitagenes" encode for heat-shock proteins (Hsps), Hsp32, Hsp70, thioredoxin, and the sirtuin protein systems. Because the system may provide a point at which CO, O₂, NO, and H₂S interact with one another, the neuroprotective potential of the "vitagene system" as a target for new approaches to neural antidegeneration deserve further investigation.

B. NO in CNS diseases

Unlike the situation for CO and H₂S, it has been proven that control of NO synthesis is coordinated with neuronal activity. During neurotransmission, neurons transiently synthesize NO in response to stimulation of the glutamate-mediated NMDA receptor, in which the activity of nNOS is tightly regulated by the intracellular Ca²⁺ level (32, 159).

NO has been suggested to mediate neurotoxicity in response to the extracellular accumulation of glutamate. With pathologic stimulation, NO derived from iNOS in microglia and astrocytes is associated with neuronal cell death (116). In addition, NO can trigger the activation of transcription factors through its binding to COX (235), leading to gene regulation. NO and other reactive nitrogen species can act as pathologic agents in processes such as neuroinflammation and neurodegeneration (90, 120). These deleterious effects are thought to be attributable to targeted modifications of critical cysteine residues in proteins, including S-nitrosylation and S-oxidation, as well as by lipid nitration (44, 45, 205, 215). Studies support this scenario for neurologic disorders such as Alzheimer disease (71), amyotrophic lateral sclerosis, Parkinson disease (59, 311), and ischemic brain damage (30, 205).

C. H₂S in CNS diseases

One possible function of H₂S in the brain is to act as a neuromodulator. Currently, however, no definitive mechanism has been reported to link the control of H₂S synthesis with neuronal activity. In the brain, CBS is the predominant enzyme responsible for H₂S generation. Besides CO, which can inhibit CBS activity, both S-adenosyl-methionine (SAM) (89) and peroxynitrite (ONOO⁻) (50) can modulate its activity. The human full-length CBS is a homotetramer of 63-kDa subunits, the activity of which is increased by SAM (89). A truncated CBS dimer with a 45-kDa subunit, which is more active, but unresponsive to SAM (153), has been found in HepG2 cells exposed to tumor necrosis factor (372). Unlike NOS, regulation of CBS by Ca²⁺/calmodulin is most unlikely, as Chen *et al.* (57) failed to report any stimulation of CBS activity in the presence of Ca²⁺/calmodulin. Interestingly, Celano *et al.* (50) showed inactivation of the Fe³⁺ CBS dimer with ONOO⁻ (50), which could provide a control mechanism for H₂S synthesis under pathologic conditions.

One of the suggested targets for H₂S is the NMDA receptor in the neuron. Although H₂S alone does not induce long-term potentiation, it does so by potentiating glutamatergic transmission through the function of NMDA receptors in neurons (214). Qu *et al.* (247) raised the interesting possibility that this potentiation by H₂S is redox dependent. Given that the neuronal NMDA-receptor possesses thiol groups in the

extracellular domain (302), these authors speculate that H₂S modulates NMDA activity by its ability to reduce the Cys744 and Cys798 (247). GAPDH is another target for H₂S. Mustafa *et al.* (212) reported the interesting finding that sulfhydration, the formation of SSH in cysteines, of GAPDH augments the enzyme activity by sevenfold (212), implicating a novel H₂S-dependent control of cellular energy metabolism in the CNS.

CBS is encoded by a gene on chromosome 21 (21q22-3). One of the manifestations of CBS deficiency is mental retardation. Qu *et al.* (246) explained this by the inability of H₂S to induce long-term potentiation *via* the potentiation of the NMDA receptor in the hippocampus, leading to the compromised memory function. They also speculate that the memory deficit seen in Alzheimer disease may be related to reduced H₂S. By contrast, CBS activity in fibroblasts from Down syndrome patients is ~150% higher than that in those from normal individuals (51), and H₂S is overproduced, based on the amount of excreted thiosulfate in the urine (145). However, the role of H₂S overproduction in mental retardation is not well understood.

In stroke, H₂S appears to exacerbate ischemic injuries, and thus, its inhibition has been suggested as a potential treatment in stroke therapy (304). Evidence is accumulating to demonstrate that inhibitors of H₂S production or therapeutic H₂S donor compounds exert significant effects in various animal models of inflammation, reperfusion injury, and circulatory shock (304). However, H₂S can also induce a reversible state of hyperthermia and a suspended animation-like state in rodents, as discussed in Section VII.G.

IX. Challenges and Perspectives

Although recent advances in gaseous signaling have unraveled uncertainties about their actions in our body, we are still left to understand the biologic potentials of newly emerging gases, such as sulfur dioxide (SO₂) (182) and hydrogen cyanide (HCN) (106) and to elucidate mechanisms whereby well-known gases, such as ammonia (NH₃) and carbon dioxide (CO₂), exert biologic effects. In the last section, we described challenges to make breakthrough in the field of gas biology. We provide some detailed mechanisms of gaseous transductions and their interactions. However, many unknown features are lacking. O₂ is by far most well-studied gas as to its reception systems and functions. Looking back at the history of the O₂-sensing research, Otto Warburg received the Nobel Prize in Physiology and Medicine in 1931 for "his discovery of nature and mode of action of the respiratory enzymes." It took more than two and a half centuries to prove the vital mechanism of O₂ use in intracellular combustion of energy substances after John Mayow conducted the experiment suggesting the existence of "O₂" in the air. Since then, technical advances to measure O₂ continuously, accurately, and directly within living tissue (60, 325) were made. These tools that stimulated the field of O₂-sensing research and brought about important discoveries.

Many technical advances are needed to detect physiologic levels of O₂, CO, NO, and H₂S *in vivo* in a real-time manner with reasonable spatial information. However, a relative lack of technical breakthroughs for detecting gas behavior *in vivo* appears to be a limit for transforming good speculative ideas

into natural philosophical thoughts. Therefore, one of the awaiting challenges to move gas biology forward is development and implementation of reliable methods for continuous, noninvasive, and sensitive measurements of gaseous mediators.

Among CO, NO, and H₂S, the field of NO is better established than the others. Since NO was first identified as the endothelium-derived relaxing factor in the late 1980s (95, 129), many approaches have attempted to provide an adequate means for measuring physiologic levels of NO. Several techniques, including the electrochemical sensors (42, 276) and fluorescence-visualization methods (163), have been successful in achieving this aim. With these advanced technologies, the field of NO research has made substantial advances. Conversely, equivalent tools are yet to be made available for CO and H₂S. Gas-releasing molecules, however, such as NOC (278) and NOR for NO and CORM (210) for CO, have added great insight into the mechanisms whereby NO and CO exerts their biologic effects.

Although we are still waiting for new tools for visualizing and measuring gaseous molecules *in situ*, the field of gas biology has added several cutting-edge technologies. We believe that a series of these advanced technologies can help us to make breakthroughs and to unravel mechanisms of gas generation and gas reception. One such technology is metabolome analysis using advanced mass spectrometry to explore systematically gas-responsive regulator enzymes *in vivo*. We have applied capillary electrophoresis mass-based metabolome analysis to profile small molecular metabolites in pathogenic bacteria or in mouse livers. A comparison of transcriptional expression profiles with metabolome data led us to hypothesize the existence of novel metabolic pathways and their regulatory mechanisms, and eventually to succeed in the discovery of variant TCA cycles in *Mycobacterium tuberculosis* (317). Furthermore, we found novel pathways to synthesize "pseudo-GSH metabolites" in mammals, which could account for compensatory mechanisms against oxidative stress in the liver (285). This technology has proven to be powerful because simple application of a gas to cultured cells and data collection through differential metabolomic display between disease and control conditions allowed us to hypothesize gas-responsive rate-limiting steps for metabolic pathways of interest.

When combined with metabolome analysis, large-scale computational biosimulation of metabolism is a useful strategy to develop hypotheses on regulatory mechanisms for metabolic systems, as demonstrated by our recent study to predict novel roles of hemoglobin to trigger hypoxia-induced glycolytic activation through multiple enzymes (157). Infrared laser Raman spectrophotometry and related bioimaging devices (IR-RS imaging) are technologies that allow us to examine gas-sensitive structural changes of metal-containing prosthetic groups of enzymes in living cells in culture. Furthermore, two-dimensional mass spectrometry analysis of biologic tissues by means of mass spectrometry imaging (MSI) will make it possible to detect, with high spatial resolution, the abundance of hundreds of molecules that control cell behavior (114, 290, 306). It is our hope that, with the help of these cutting-edge technologies, we will be able to gain new insights into the complexities of gas interactions and to translate experimental work into new therapies to treat human diseases.

Acknowledgments

We thank Mr. Takuya Iwabuchi for preparation of figures and Dr. Yoshinori Yukutake for useful discussion. This work was supported by a Grant-in-Aid for Scientific Research 21500353 (to M. K.) from the Japan Society for the Promotion of Science (JSPS), by a Grant-in-Aid for Creative Scientific Research 17GS0419 (to M.S.) from JSPS, and by Global COE Program for Metabolomics Systems Biology from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) (to M.S.). M.S. is the leader of ERATO (Exploratory Research for Advanced Technology) Gas Biology Project from the Japan Science and Technology Agency. R.F. is an Assistant Professor supported by Research and Development of the Next-Generation Integrated Simulation of Living Matter, a part of the Development and Use of the Next-Generation Supercomputer Project of MEXT (to M.S.). R.M. B. is an Assistant Professor supported by Global COE Program for Metabolomics Systems Biology from MEXT.

References

1. Abu-Soud HM, Wang J, Rousseau DL, Fukuto JM, Ignarro LJ, and Stuehr DJ. Neuronal nitric oxide synthase self-inactivates by forming a ferrous-nitrosyl complex during aerobic catalysis. *J Biol Chem* 270: 22997–23006, 1995.
2. Acevedo CH and Ahmed A. Hemeoxygenase-1 inhibits human myometrial contractility via carbon monoxide and is upregulated by progesterone during pregnancy. *J Clin Invest* 101: 949–955, 1998.
3. Adachi T, Ishikawa K, Hida W, Matsumoto H, Masuda T, Date F, Ogawa K, Takeda K, Furuyama K, Zhang Y, Kitamura T, Ogawa H, Maruyama Y, and Shibahara S. Hypoxemia and blunted hypoxic ventilatory responses in mice lacking heme oxygenase-2. *Biochem Biophys Res Commun* 320: 514–522, 2004.
4. Ahmad AS, Zhuang H, and Dore S. Heme oxygenase-1 protects brain from acute excitotoxicity. *Neuroscience* 141: 1703–1708, 2006.
5. Alderton WK, Cooper CE, and Knowles RG. Nitric oxide synthases: structure, function and inhibition. *Biochem J* 357: 593–615, 2001.
6. Ali MY, Ping CY, Mok YY, Ling L, Whiteman M, Bhatia M, and Moore PK. Regulation of vascular nitric oxide *in vitro* and *in vivo*; a new role for endogenous hydrogen sulphide? *Br J Pharmacol* 149: 625–634, 2006.
7. Almeida A, Almeida J, Bolanos JP, and Moncada S. Different responses of astrocytes and neurons to nitric oxide: the role of glycolytically generated ATP in astrocyte protection. *Proc Natl Acad Sci U S A* 98: 15294–15299, 2001.
8. Andrews MT. Advances in molecular biology of hibernation in mammals. *Bioessays* 29: 431–440, 2007.
9. Antonini E and Brunori M. North-Holland Research Monographs: frontiers of biology. In: *The Derivatives of Ferrous Hemoglobin and Myoglobin: Hemoglobin and Myoglobin in Their Reactions with Ligands*, edited by Neuberger A and Tatum EL. Amsterdam: North-Holland Publishing, 1971, pp. 13–39.
10. Aono S. Biochemical and biophysical properties of the CO-sensing transcriptional activator CoxA. *Acc Chem Res* 36: 825–831, 2003.
11. Aono S, Honma Y, Ohkubo K, Tawara T, Kamiya T, and Nakajima H. CO sensing and regulation of gene expression by the transcriptional activator CoxA. *J Inorg Biochem* 82: 51–56, 2000.
12. Babcock GT and Wikstrom M. Oxygen activation and the conservation of energy in cell respiration. *Nature* 356: 301–309, 1992.
13. Bach FH. Heme oxygenase-1 and transplantation tolerance. *Hum Immunol* 67: 430–432, 2006.
14. Balazy M and Jiang H. Analysis of carbon monoxide in biological fluids by isotopic dilution GC/MS. *Acta Haematol* 103(suppl 1): 78, 2000.
15. Banerjee R and Zou CG. Redox regulation and reaction mechanism of human cystathionine β -synthase: a PLP-dependent hemesensor protein. *Arch Biochem Biophys* 433: 144–156, 2005.
16. Barbosa RM, Lourenco CF, Santos RM, Pomerleau F, Huettl P, Gerhardt GA, and Laranjinha J. In vivo real-time measurement of nitric oxide in anesthetized rat brain. *Methods Enzymol* 441: 351–367, 2008.
17. Basolo F and Johnson RC. *Coordination Chemistry*. London: Science Reviews Limited, 1986.
18. Battino R. *IUPAC Solubility Data Series*. Oxford: Pergamon Press, 1981.
19. Baumgart K, Radermacher P, and Wagner F. Applying gases for microcirculatory and cellular oxygenation in sepsis: effects of nitric oxide, carbon monoxide, and hydrogen sulfide. *Curr Opin Anaesthesiol* 22: 168–176, 2009.
20. Beauchamp RO Jr, Bus JS, Popp JA, Boreiko CJ, and Andjelkovich DA. A critical review of the literature on hydrogen sulfide toxicity. *Crit Rev Toxicol* 13: 25–97, 1984.
21. Bellamy TC, Griffiths C, and Garthwaite J. Differential sensitivity of guanylyl cyclase and mitochondrial respiration to nitric oxide measured using clamped concentrations. *J Biol Chem* 277: 31801–31807, 2002.
22. Benavides GA, Squadrito GL, Mills RW, Patel HD, Isbell TS, Patel RP, Darley-Usmar VM, Doeller JE, and Kraus DW. Hydrogen sulfide mediates the vasoactivity of garlic. *Proc Natl Acad Sci U S A* 104: 17977–17982, 2007.
23. Berk PD, Rodkey FL, Blaschke TF, Collison HA, and Waggoner JG. Comparison of plasma bilirubin turnover and carbon monoxide production in man. *J Lab Clin Med* 83: 29–37, 1974.
24. Bernal PJ, Leelavanichkul K, Bauer E, Cao R, Wilson A, Wasserloos KJ, Watkins SC, Pitt BR, and St Croix CM. Nitric-oxide-mediated zinc release contributes to hypoxic regulation of pulmonary vascular tone. *Circ Res* 102: 1575–1583, 2008.
25. Bilban M, Haschemi A, Wegiel B, Chin BY, Wagner O, and Otterbein LE. Heme oxygenase and carbon monoxide initiate homeostatic signaling. *J Mol Med* 86: 267–279, 2008.
26. Blackstone E, Morrison M, and Roth MB. H₂S induces a suspended animation-like state in mice. *Science* 308: 518, 2005.
27. Blackstone E and Roth MB. Suspended animation-like state protects mice from lethal hypoxia. *Shock* 27: 370–372, 2007.
28. Boehning D, Moon C, Sharma S, Hurt KJ, Hester LD, Ronnett GV, Shugar D, and Snyder SH. Carbon monoxide neurotransmission activated by CK2 phosphorylation of heme oxygenase-2. *Neuron* 40: 129–137, 2003.
29. Bohlen HG and Nase GP. Dependence of intestinal arteriolar regulation on flow-mediated nitric oxide formation. *Am J Physiol Heart Circ Physiol* 279: H2249–H2258, 2000.
30. Bolanos JP and Almeida A. Roles of nitric oxide in brain hypoxia-ischemia. *Biochim Biophys Acta* 1411: 415–436, 1999.

31. Boveris A and Chance B. The mitochondrial generation of hydrogen peroxide: general properties and effect of hyperbaric oxygen. *Biochem J* 134: 707–716, 1973.
32. Bredt DS and Snyder SH. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. *Proc Natl Acad Sci U S A* 87: 682–685, 1990.
33. Brown GC. Nitric oxide and mitochondria. *Front Biosci* 12: 1024–1033, 2007.
34. Brown GC and Cooper CE. Nanomolar concentrations of nitric oxide reversibly inhibit synaptosomal respiration by competing with oxygen at cytochrome oxidase. *FEBS Lett* 356: 295–298, 1994.
35. Brucker EA, Olson JS, Ikeda-Saito M, and Phillips GN Jr. Nitric oxide myoglobin: crystal structure and analysis of ligand geometry. *Proteins* 30: 352–356, 1998.
36. Brune B and Zhou J. Hypoxia-inducible factor-1 α under the control of nitric oxide. *Methods Enzymol* 435: 463–478, 2007.
37. Brunori M. Nitric oxide, cytochrome-c oxidase and myoglobin. *Trends Biochem Sci* 26: 21–23, 2001.
38. Buerk DG. Can we model nitric oxide biotransport? a survey of mathematical models for a simple diatomic molecule with surprisingly complex biological activities. *Annu Rev Biomed Eng* 3: 109–143, 2001.
39. Buerk DG. Nitric oxide regulation of microvascular oxygen. *Antioxid Redox Signal* 9: 829–843, 2007.
40. Buerk DG, Ances BM, Greenberg JH, and Detre JA. Temporal dynamics of brain tissue nitric oxide during functional forepaw stimulation in rats. *Neuroimage* 18: 1–9, 2003.
41. Buerk DG, Lamkin-Kennard K, and Jaron D. Modeling the influence of superoxide dismutase on superoxide and nitric oxide interactions, including reversible inhibition of oxygen consumption. *Free Radic Biol Med* 34: 1488–1503, 2003.
42. Buerk DG, Shonat RD, Riva CE, and Cranstoun SD. O₂ gradients and countercurrent exchange in the cat vitreous humor near retinal arterioles and venules. *Microvasc Res* 45: 134–148, 1993.
43. Calabrese V, Cornelius C, Mancuso C, Barone E, Calafato S, Bates T, Rizzarelli E, and Kostova AT. Vitagenes, dietary antioxidants and neuroprotection in neurodegenerative diseases. *Front Biosci* 14: 376–397, 2009.
44. Calabrese V, Cornelius C, Rizzarelli E, Owen JB, Dinkova-Kostova AT, and Butterfield DA. Nitric oxide in cell survival: a janus molecule. *Antioxid Redox Signal* 11: 2717–2739, 2009.
45. Calabrese V, Mancuso C, Calvani M, Rizzarelli E, Butterfield DA, and Stella AM. Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. *Nat Rev Neurosci* 8: 766–775, 2007.
46. Calabrese V, Stella AM, Butterfield DA, and Scapagnini G. Redox regulation in neurodegeneration and longevity: role of the heme oxygenase and HSP70 systems in brain stress tolerance. *Antioxid Redox Signal* 6: 895–913, 2004.
47. Cargil RW. *IUPAC Solubility Data Series*. Oxford: Pergamon Press, 1990.
48. Cary SP and Marletta MA. The case of CO signaling: why the jury is still out. *J Clin Invest* 107: 1071–1073, 2001.
49. Cary SP, Winger JA, Derbyshire ER, and Marletta MA. Nitric oxide signaling: no longer simply on or off. *Trends Biochem Sci* 31: 231–239, 2006.
50. Celano L, Gil M, Carballal S, Duran R, Denicola A, Banerjee R, and Alvarez B. Inactivation of cystathionine β -synthase with peroxynitrite. *Arch Biochem Biophys* 491: 96–105, 2009.
51. Chadefaux B, Rethore MO, Raoul O, Ceballos I, Poissonnier M, Gilgenkranz S, and Allard D. Cystathionine β -synthase: gene dosage effect in trisomy 21. *Biochem Biophys Res Commun* 128: 40–44, 1985.
52. Chance B, Erecinska M, and Wagner M. Mitochondrial responses to carbon monoxide toxicity. *Ann N Y Acad Sci* 174: 193–204, 1970.
53. Chang AL, Tuckerman JR, Gonzalez G, Mayer R, Weinhouse H, Volman G, Amikam D, Benziman M, and Gilles-Gonzalez MA. Phosphodiesterase A1, a regulator of cellulose synthesis in *Acetobacter xylinum*, is a heme-based sensor. *Biochemistry* 40: 3420–3426, 2001.
54. Chang EF, Claus CP, Vreman HJ, Wong RJ, and Noble-Haesslein LJ. Heme regulation in traumatic brain injury: relevance to the adult and developing brain. *J Cereb Blood Flow Metab* 25: 1401–1417, 2005.
55. Chang EF, Wong RJ, Vreman HJ, Igarashi T, Galo E, Sharp FR, Stevenson DK, and Noble-Haesslein LJ. Heme oxygenase-2 protects against lipid peroxidation-mediated cell loss and impaired motor recovery after traumatic brain injury. *J Neurosci* 23: 3689–3696, 2003.
56. Chen K, Pittman RN, and Popel AS. Nitric oxide in the vasculature: where does it come from and where does it go? A quantitative perspective. *Antioxid Redox Signal* 10: 1185–1198, 2008.
57. Chen X, Jhee KH, and Kruger WD. Production of the neuromodulator H₂S by cystathionine β -synthase via the condensation of cysteine and homocysteine. *J Biol Chem* 279: 52082–52086, 2004.
58. Cherian L and Robertson CS. L-Arginine and free radical scavengers increase cerebral blood flow and brain tissue nitric oxide concentrations after controlled cortical impact injury in rats. *J Neurotrauma* 20: 77–85, 2003.
59. Chung KK, Thomas B, Li X, Pletnikova O, Troncoso JC, Marsh L, Dawson VL, and Dawson TM. S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. *Science* 304: 1328–1331, 2004.
60. Clark LC Jr, Wolf R, Granger D, and Taylor Z. Continuous recording of blood oxygen tensions by polarography. *J Appl Physiol* 6: 189–193, 1953.
61. Cleeter MW, Cooper JM, Darley-Usmar VM, Moncada S, and Schapira AH. Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide: implications for neurodegenerative diseases. *FEBS Lett* 345: 50–54, 1994.
62. Clementi E, Brown GC, Foxwell N, and Moncada S. On the mechanism by which vascular endothelial cells regulate their oxygen consumption. *Proc Natl Acad Sci USA* 96: 1559–1562, 1999.
63. Cole DE, Evrovski J, and Pirone R. Urinary thiosulfate determined by suppressed ion chromatography with conductimetric detection. *J Chromatogr B Biomed Appl* 672: 149–154, 1995.
64. Condorelli P and George SC. In vivo control of soluble guanylate cyclase activation by nitric oxide: a kinetic analysis. *Biophys J* 80: 2110–2119, 2001.
65. Coney AM and Marshall JM. Role of adenosine and its receptors in the vasodilatation induced in the cerebral cortex of the rat by systemic hypoxia. *J Physiol (London)* 509: 507–518, 1998.
66. Converso DP, Taille C, Carreras MC, Jaitovich A, Poderoso JJ, and Boczkowski J. HO-1 is located in liver mitochondria and modulates mitochondrial heme content and metabolism. *FASEB J* 20: 1236–1238, 2006.
67. Cooper CE and Brown GC. The inhibition of mitochondrial cytochrome oxidase by the gases carbon monoxide, nitric

- oxide, hydrogen cyanide and hydrogen sulfide: chemical mechanism and physiological significance. *J Bioenerg Biomembr* 40: 533–539, 2008.
68. Cooper CE, Torres J, Sharpe MA, and Wilson MT. Nitric oxide ejects electrons from the binuclear centre of cytochrome *c* oxidase by reacting with oxidised copper: a general mechanism for the interaction of copper proteins with nitric oxide? *FEBS Lett* 414: 281–284, 1997.
 69. Cooper GJ, Zhou Y, Bouyer P, Grichtchenko, II, and Boron WF. Transport of volatile solutes through AQP1. *J Physiol* 542: 17–29, 2002.
 70. D'Amico G, Lam F, Hagen T, and Moncada S. Inhibition of cellular respiration by endogenously produced carbon monoxide. *J Cell Sci* 119: 2291–2298, 2006.
 71. Davis RE, Miller S, Herrnstadt C, Ghosh SS, Fahy E, Shinobu LA, Galasko D, Thal LJ, Beal MF, Howell N, and Parker WD Jr. Mutations in mitochondrial cytochrome *c* oxidase genes segregate with late-onset Alzheimer disease. *Proc Natl Acad Sci U S A* 94: 4526–4531, 1997.
 72. Denninger JW and Marletta MA. Guanylate cyclase and the NO/cGMP signaling pathway. *Biochim Biophys Acta* 1411: 334–350, 1999.
 73. Derbyshire ER and Marletta MA. Biochemistry of soluble guanylate cyclase. *Handb Exp Pharmacol* 191: 17–31, 2009.
 74. Desmard M, Boczkowski J, Poderoso J, and Motterlini R. Mitochondrial and cellular heme-dependent proteins as targets for the bioactive function of the heme oxygenase/carbon monoxide system. *Antioxid Redox Signal* 9: 2139–2155, 2007.
 75. Desouki MM, Kulawiec M, Bansal S, Das GM, and Singh KK. Cross talk between mitochondria and superoxide generating NADPH oxidase in breast and ovarian tumors. *Cancer Biol Ther* 4: 1367–1373, 2005.
 76. Diaz F and Moraes CT. Mitochondrial biogenesis and turnover. *Cell Calcium* 44: 24–35, 2008.
 77. Ding JD, Burette A, and Weinberg RJ. Expression of soluble guanylyl cyclase in rat cerebral cortex during postnatal development. *J Comp Neurol* 485: 255–265, 2005.
 78. Dioum EM, Rutter J, Tuckerman JR, Gonzalez G, Gilles-Gonzalez MA, and McKnight SL. NPAS2: a gas-responsive transcription factor. *Science* 298: 2385–2387, 2002.
 79. Doeller JE, Isbell TS, Benavides G, Koenitzer J, Patel H, Patel RP, Lancaster JR Jr, Darley-Usmar VM, and Kraus DW. Polarographic measurement of hydrogen sulfide production and consumption by mammalian tissues. *Anal Biochem* 341: 40–51, 2005.
 80. Duchen MR and Biscoe TJ. Mitochondrial function in type I cells isolated from rabbit arterial chemoreceptors. *J Physiol* 450: 13–31, 1992.
 81. Endeward V, Cartron JP, Ripoche P, and Gros G. RhAG protein of the Rhesus complex is a CO₂ channel in the human red cell membrane. *FASEB J* 22: 64–73, 2008.
 82. Engel RR, Matsen JM, Chapman SS, and Schwartz S. Carbon monoxide production from heme compounds by bacteria. *J Bacteriol* 112: 1310–1315, 1972.
 83. Evans CL. The toxicity of hydrogen sulphide and other sulphides. *Q J Exp Physiol Cogn Med Sci* 52: 231–248, 1967.
 84. Fang X, Yang B, Matthay MA, and Verkman AS. Evidence against aquaporin-1-dependent CO₂ permeability in lung and kidney. *J Physiol* 542: 63–69, 2002.
 85. Faraci FM and Heistad DD. Regulation of the cerebral circulation: role of endothelium and potassium channels. *Physiol Rev* 78: 53–97, 1998.
 86. Fernandez-Alberti S, Bacelo DE, Binning RC Jr, Echave J, Chergui M, and Lopez-Garriga J. Sulfide-binding hemoglobins: effects of mutations on active-site flexibility. *Bioophys J* 91: 1698–1709, 2006.
 87. Fink MP. Cytopathic hypoxia: mitochondrial dysfunction as mechanism contributing to organ dysfunction in sepsis. *Crit Care Clin* 17: 219–237, 2001.
 88. Finkelstein A. Water and nonelectrolyte permeability of lipid bilayer membranes. *J Gen Physiol* 68: 127–135, 1976.
 89. Finkelstein JD, Kyle WE, Martin JL, and Pick AM. Activation of cystathionine synthase by adenosylmethionine and adenosylethionine. *Biochem Biophys Res Commun* 66: 81–87, 1975.
 90. Floyd RA. Neuroinflammatory processes are important in neurodegenerative diseases: an hypothesis to explain the increased formation of reactive oxygen and nitrogen species as major factors involved in neurodegenerative disease development. *Free Radic Biol Med* 26: 1346–1355, 1999.
 91. Foe VE and Alberts BM. Reversible chromosome condensation induced in *Drosophila* embryos by anoxia: visualization of interphase nuclear organization. *J Cell Biol* 100: 1623–1636, 1985.
 92. Fogg PGT and Young CL. *IUPAC Solubility Data Series*. Oxford: Pergamon Press, 1981.
 93. Forster RE, Gros G, Lin L, Ono Y, and Wunder M. The effect of 4,4'-diisothiocyanato-stilbene-2,2'-disulfonate on CO₂ permeability of the red blood cell membrane. *Proc Natl Acad Sci U S A* 95: 15815–15820, 1998.
 94. Fukuto JM and Collins MD. Interactive endogenous small molecule (gaseous) signaling: implications for teratogenesis. *Curr Pharm Des* 13: 2952–2978, 2007.
 95. Furchgott RF. Studies on relaxation of rabbit aorta by sodium nitrite: the basis for the proposal that the acid-activatable inhibitory factor from retractor penis is inorganic nitrite and the endothelium-derived relaxing factor is nitric oxide. In: *Vasodilation: Vascular Smooth Muscle, Peptides, and Endothelium*, edited by Vanhoutte PM. New York: Raven Press, 1988, pp. 401–414.
 96. Furne J, Saeed A, and Levitt MD. Whole tissue hydrogen sulfide concentrations are orders of magnitude lower than presently accepted values. *Am J Physiol Regul Integr Comp Physiol* 295: R1479–R1485, 2008.
 97. Furne J, Springfield J, Koenig T, DeMaster E, and Levitt MD. Oxidation of hydrogen sulfide and methanethiol to thiosulfate by rat tissues: a specialized function of the colonic mucosa. *Biochem Pharmacol* 62: 255–259, 2001.
 98. Gilles-Gonzalez MA, Ditta GS, and Helinski DR. A haemoprotein with kinase activity encoded by the oxygen sensor of *Rhizobium meliloti*. *Nature* 350: 170–172, 1991.
 99. Goda N, Suzuki K, Naito M, Takeoka S, Tsuchida E, Ishimura Y, Tamatani T, and Suematsu M. Distribution of heme oxygenase isoforms in rat liver: topographic basis for carbon monoxide-mediated microvascular relaxation. *J Clin Invest* 101: 604–612, 1998.
 100. Granatier J, Urban M, and Sadlej AJ. Van der Waals complexes of Cu, Ag, and Au with hydrogen sulfide: the bonding character. *J Phys Chem A* 111: 13238–13244, 2007.
 101. Gray RD and Gibson QH. The effect of inositol hexaphosphate on the kinetics of CO and O₂ binding by human hemoglobin. *J Biol Chem* 246: 7168–7174, 1971.
 102. Greenwood NN and Earnshaw A. *Chemistry of the Elements*. Oxford: Pergamon Press, 1984.
 103. Griffiths C, Wykes V, Bellamy TC, and Garthwaite J. A new and simple method for delivering clamped nitric oxide

- concentrations in the physiological range: application to activation of guanylyl cyclase-coupled nitric oxide receptors. *Mol Pharmacol* 64: 1349–1356, 2003.
104. Grimminger F, Spriestersbach R, Weissmann N, Walmrath D, and Seeger W. Nitric oxide generation and hypoxic vasoconstriction in buffer-perfused rabbit lungs. *J Appl Physiol* 78: 1509–1155, 1995.
 105. Griscavage JM, Fukuto JM, Komori Y, and Ignarro LJ. Nitric oxide inhibits neuronal nitric oxide synthase by interacting with the heme prosthetic group: role of tetrahydrobiopterin in modulating the inhibitory action of nitric oxide. *J Biol Chem* 269: 21644–21649, 1994.
 106. Gunasekar PG, Prabhakaran K, Li L, Zhang L, Isom GE, and Borowitz JL. Receptor mechanisms mediating cyanide generation in PC12 cells and rat brain. *Neurosci Res* 49: 13–18, 2004.
 107. Gutsaeva DR, Carraway MS, Suliman HB, Demchenko IT, Shitara H, Yonekawa H, and Piantadosi CA. Transient hypoxia stimulates mitochondrial biogenesis in brain subcortex by a neuronal nitric oxide synthase-dependent mechanism. *J Neurosci* 28: 2015–2024, 2008.
 108. Haddad PR and Heckenberg AL. Trace determination of sulfide by reversed-phase ion-interaction chromatography using pre-column derivatization. *J Chromatogr* 447: 415–420, 1988.
 109. Hagen T, Taylor CT, Lam F, and Moncada S. Redistribution of intracellular oxygen in hypoxia by nitric oxide: effect on HIF1 α . *Science* 302: 1975–1978, 2003.
 110. Haggard HW. The fate of sulfides in the blood. *J Biol Chem* 49: 519–529, 1921.
 111. Halestrap AP. What is the mitochondrial permeability transition pore? *J Mol Cell Cardiol* 46: 821–831, 2009.
 112. Hankeln T, Ebner B, Fuchs C, Gerlach F, Haberkamp M, Laufs TL, Roesner A, Schmidt M, Weich B, Wystub S, Saaler-Reinhardt S, Reuss S, Bolognesi M, De Sanctis D, Marden MC, Kiger L, Moens L, Dewilde S, Nevo E, Avivi A, Weber RE, Fago A, and Burmester T. Neuroglobin and cytoglobin in search of their role in the vertebrate globin family. *J Inorg Biochem* 99: 110–119, 2005.
 113. Hansen FB and Nicholls P. Control of respiration in proteoliposomes containing cytochrome *aa*₃. II. Inhibition by carbon monoxide and azide. *Biochim Biophys Acta* 502: 400–408, 1978.
 114. Harada T, Yuba-Kubo A, Sugiura Y, Zaima N, Hayasaka T, Goto-Inoue N, Wakui M, Suematsu M, Takeshita K, Ogawa K, Yoshida Y, and Setou M. Visualization of volatile substances in different organelles with an atmospheric-pressure mass microscope. *Anal Chem* 81: 9153–9157, 2009.
 115. Herrera M, Hong NJ, and Garvin JL. Aquaporin-1 transports NO across cell membranes. *Hypertension* 48: 157–164, 2006.
 116. Hewett SJ, Csernansky CA, and Choi DW. Selective potentiation of NMDA-induced neuronal injury following induction of astrocytic iNOS. *Neuron* 13: 487–494, 1994.
 117. Hill AV. The diffusion of oxygen and lactic acid through tissues. *Proc Roy Soc B* 104: 39–96, 1928.
 118. Hill M, Pereira V, Chauveau C, Zagani R, Remy S, Tesson L, Mazal D, Ubillos L, Brion R, Asghar K, Mashreghi MF, Kotsch K, Moffett J, Doebis C, Seifert M, Boczkowski J, Osinaga E, and Anegon I. Heme oxygenase-1 inhibits rat and human breast cancer cell proliferation: mutual cross inhibition with indoleamine 2,3-dioxygenase. *FASEB J* 19: 1957–1968, 2005.
 119. Hill WG, Rivers RL, and Zeidel ML. Role of leaflet asymmetry in the permeability of model biological membranes to protons, solutes, and gases. *J Gen Physiol* 114: 405–414, 1999.
 120. Hirsch EC and Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? *Lancet Neurol* 8: 382–397, 2009.
 121. Holloszy JO and Booth FW. Biochemical adaptations to endurance exercise in muscle. *Annu Rev Physiol* 38: 273–291, 1976.
 122. Hou S, Heinemann SH, and Hoshi T. Modulation of BKCa channel gating by endogenous signaling molecules. *Physiology (Bethesda)* 24: 26–35, 2009.
 123. Hou S, Larsen RW, Boudko D, Riley CW, Karatan E, Zimmer M, Ordal GW, and Alam M. Myoglobin-like aerotaxis transducers in Archaea and bacteria. *Nature* 403: 540–544, 2000.
 124. Huang TJ, McCoubrey WK Jr, and Maines MD. Heme oxygenase-2 interaction with metalloporphyrins: function of heme regulatory motifs. *Antioxid Redox Signal* 3: 685–696, 2001.
 125. Hung SY, Liou HC, Kang KH, Wu RM, Wen CC, and Fu WM. Overexpression of heme oxygenase-1 protects dopaminergic neurons against 1-methyl-4-phenylpyridinium-induced neurotoxicity. *Mol Pharmacol* 74: 1564–1575, 2008.
 126. Hyspler R, Ticha A, Indrova M, Zadac Z, Hysplerova L, Gasparic J, and Churacek J. A simple, optimized method for the determination of sulphide in whole blood by GC-MS as a marker of bowel fermentation processes. *J Chromatogr B Analyt Technol Biomed Life Sci* 770: 255–259, 2002.
 127. Ibrahim M, Kuchinskas M, Youn H, Kerby RL, Roberts GP, Poulos TL, and Spiro TG. Mechanism of the CO-sensing heme protein CoxA: new insights from the truncated heme domain and UVRR spectroscopy. *J Inorg Biochem* 101: 1776–1785, 2007.
 128. Ignarro LJ. Nitric oxide as a unique signaling molecule in the vascular system: a historical overview. *J Physiol Pharmacol* 53: 503–514, 2002.
 129. Ignarro LJ, Byrns RE, and Wood KS. Biochemical and pharmacological properties of EDRF and its similarity to nitric oxide radical. In: *Vasodilation: Vascular Smooth Muscle, Peptides, and Endothelium*, edited by Vanhoutte PM. New York: Raven Press, 1988, pp. 427–435.
 130. Imai T, Morita T, Shindo T, Nagai R, Yazaki Y, Kurihara H, Suematsu M, and Katayama S. Vascular smooth muscle cell-directed overexpression of heme oxygenase-1 elevates blood pressure through attenuation of nitric oxide-induced vasodilation in mice. *Circ Res* 89: 55–62, 2001.
 131. Ingi T, Cheng J, and Ronnett GV. Carbon monoxide: an endogenous modulator of the nitric oxide-cyclic GMP signaling system. *Neuron* 16: 835–842, 1996.
 132. Insko MA, Deckwerth TL, Hill P, Toombs CF, and Szabo C. Detection of exhaled hydrogen sulphide gas in rats exposed to intravenous sodium sulphide. *Br J Pharmacol* 157: 944–951, 2009.
 133. Ishigami M, Hiraki K, Umemura K, Ogasawara Y, Ishii K, and Kimura H. A source of hydrogen sulfide and a mechanism of its release in the brain. *Antioxid Redox Signal* 11: 205–214, 2009.
 134. Ishikawa K, Takeuchi N, Takahashi S, Matera KM, Sato M, Shibahara S, Rousseau DL, Ikeda-Saito M, and Yoshida T. Heme oxygenase-2. Properties of the heme complex of the

- purified tryptic fragment of recombinant human heme oxygenase-2. *J Biol Chem* 270: 6345–6350, 1995.
135. Ishikawa M, Kajimura M, Adachi T, Maruyama K, Makino N, Goda N, Yamaguchi T, Sekizuka E, and Suematsu M. Carbon monoxide from heme oxygenase-2 is a tonic regulator against NO-dependent vasodilatation in the adult rat cerebral microcirculation. *Circ Res* 97: e104–e114, 2005.
 136. Iyer LM, Anantharaman V, and Aravind L. Ancient conserved domains shared by animal soluble guanylyl cyclases and bacterial signaling proteins. *BMC Genomics* 4: 5, 2003.
 137. Jaggar JH, Leffler CW, Cheranov SY, Tcheranova D, Shuyu E, and Cheng X. Carbon monoxide dilates cerebral arterioles by enhancing the coupling of Ca²⁺ sparks to Ca²⁺-activated K⁺ channels. *Circ Res* 91: 610–617, 2002.
 138. Johnson EA. The reversion to haemoglobin of sulphhaemoglobin and its coordination derivatives. *Biochim Biophys Acta* 207: 30–40, 1970.
 139. Julian D, Statile JL, Wohlgemuth SE, and Arp AJ. Enzymatic hydrogen sulfide production in marine invertebrate tissues. *Comp Biochem Physiol A Mol Integr Physiol* 133: 105–115, 2002.
 140. Kaczorowski DJ and Zuckerbraun BS. Carbon monoxide: medicinal chemistry and biological effects. *Curr Med Chem* 14: 2720–2725, 2007.
 141. Kajimura M, Goda N, and Suematsu M. Organ design for generation and reception of CO: lessons from the liver. *Antioxid Redox Signal* 4: 633–637, 2002.
 142. Kajimura M, Shimoyama M, Tsuyama S, Suzuki T, Kozaki S, Takenaka S, Tsubota K, Oguchi Y, and Suematsu M. Visualization of gaseous monoxide reception by soluble guanylate cyclase in the rat retina. *FASEB J* 17: 506–508, 2003.
 143. Kakkar P and Singh BK. Mitochondria: a hub of redox activities and cellular distress control. *Mol Cell Biochem* 305: 235–253, 2007.
 144. Kamoun P. Endogenous production of hydrogen sulfide in mammals. *Amino Acids* 26: 243–254, 2004.
 145. Kamoun P, Belardinelli MC, Chabli A, Lallouchi K, and Chadeaux-Vekemans B. Endogenous hydrogen sulfide overproduction in Down syndrome. *Am J Med Genet A* 116A: 310–311, 2003.
 146. Karow DS, Pan D, Davis JH, Behrends S, Mathies RA, and Marletta MA. Characterization of functional heme domains from soluble guanylate cyclase. *Biochemistry* 44: 16266–16274, 2005.
 147. Kashiba M, Kajimura M, Goda N, and Suematsu M. From O₂ to H₂S: a landscape view of gas biology. *Keio J Med* 51: 1–10, 2002.
 148. Kashiwagi S, Kajimura M, Yoshimura Y, and Suematsu M. Nonendothelial source of nitric oxide in arterioles but not in venules: alternative source revealed *in vivo* by diamino-fluorescein microfluorography. *Circ Res* 91: e55–e64, 2002.
 149. Kavdia M and Popel AS. Contribution of nNOS- and eNOS-derived NO to microvascular smooth muscle NO exposure. *J Appl Physiol* 97: 293–301, 2004.
 150. Ke Q and Costa M. Hypoxia-inducible factor-1 (HIF-1). *Mol Pharmacol* 70: 1469–1480, 2006.
 151. Keilin D and Slater EC. Cytochrome. *Br Med Bull* 9: 89–97, 1953.
 152. Kery V, Bukovska G, and Kraus JP. Transsulfuration depends on heme in addition to pyridoxal 5'-phosphate: cystathionine β -synthase is a heme protein. *J Biol Chem* 269: 25283–25288, 1994.
 153. Kery V, Poneleit L, and Kraus JP. Trypsin cleavage of human cystathionine β -synthase into an evolutionarily conserved active core: structural and functional consequences. *Arch Biochem Biophys* 355: 222–232, 1998.
 154. Kharitonov VG, Sharma VS, Pilz RB, Magde D, and Koesling D. Basis of guanylate cyclase activation by carbon monoxide. *Proc Natl Acad Sci U S A* 92: 2568–2571, 1995.
 155. Kikuchi G, Yoshida T, and Noguchi M. Heme oxygenase and heme degradation. *Biochem Biophys Res Commun* 338: 558–567, 2005.
 156. Kimura H. Hydrogen sulfide: from brain to gut. *Antioxid Redox Signal* 12: 1–13, 2010.
 157. Kinoshita A, Tsukada K, Soga T, Hishiki T, Ueno Y, Nakayama Y, Tomita M, and Suematsu M. Roles of hemoglobin allostery in hypoxia-induced metabolic alterations in erythrocytes: simulation and its verification by metabolome analysis. *J Biol Chem* 282: 10731–10741, 2007.
 158. Kleinzeller A. Charles Ernest Overton's concept of a cell membrane. In: *Membrane Permeability: 100 Years since Ernest Overton*. London: Academic Press, 1999, pp. 1–18.
 159. Knowles RG, Palacios M, Palmer RM, and Moncada S. Formation of nitric oxide from L-arginine in the central nervous system: a transduction mechanism for stimulation of the soluble guanylate cyclase. *Proc Natl Acad Sci USA* 86: 5159–5162, 1989.
 160. Koenitzer JR, Isbell TS, Patel HD, Benavides GA, Dickinson DA, Patel RP, Darley-Usmar VM, Lancaster JR Jr, Doeller JE, and Kraus DW. Hydrogen sulfide mediates vasoactivity in an O₂-dependent manner. *Am J Physiol Heart Circ Physiol* 292: H1953–H1960, 2007.
 161. Koesling D and Friebe A. Soluble guanylyl cyclase: structure and regulation. *Rev Physiol Biochem Pharmacol* 135: 41–65, 1999.
 162. Koizumi S. Human heme oxygenase-1 deficiency: a lesson on serendipity in the discovery of the novel disease. *Pediatr Int* 49: 125–132, 2007.
 163. Kojima H, Nakatsubo N, Kikuchi K, Kawahara S, Kirino Y, Nagoshi H, Hirata Y, and Nagano T. Detection and imaging of nitric oxide with novel fluorescent indicators: diamino-fluoresceins. *Anal Chem* 70: 2446–2453, 1998.
 164. Koneru P and Leffler CW. Role of cGMP in carbon monoxide-induced cerebral vasodilation in piglets. *Am J Physiol Heart Circ Physiol* 286: H304–H309, 2004.
 165. Kosterev AA, Tittel FK, Durante W, Allen M, Kohler R, Gmachl C, Capasso F, Sivco DL, and Cho AY. Detection of biogenic CO production above vascular cell cultures using a near-room-temperature QC-DFB laser. *Appl Physiol B* 74: 95–99, 2002.
 166. Kraus DW and Wittenberg JB. Hemoglobins of the *Lucina pectinata*/bacteria symbiosis, I: molecular properties, kinetics and equilibria of reactions with ligands. *J Biol Chem* 265: 16043–16053, 1990.
 167. Krogh A. The rate of diffusion of gases through animal tissues, with some remarks on the coefficient of invasion. *J Physiol* 52: 391–408, 1919.
 168. Kunz WS, Kudin A, Vielhaber S, Elger CE, Attardi G, and Villani G. Flux control of cytochrome c oxidase in human skeletal muscle. *J Biol Chem* 275: 27741–27745, 2000.
 169. Kyokane T, Norimizu S, Tanihara H, Yamaguchi T, Takeoka S, Tsuchida E, Naito M, Nimura Y, Ishimura Y, and Suematsu M. Carbon monoxide from heme catabolism

- protects against hepatobiliary dysfunction in endotoxin-treated rat liver. *Gastroenterology* 120: 1227–1240, 2001.
170. Lad L, Schuller DJ, Shimizu H, Friedman J, Li H, Ortiz de Montellano PR, and Poulos TL. Comparison of the heme-free and -bound crystal structures of human heme oxygenase-1. *J Biol Chem* 278: 7834–7843, 2003.
 171. Laderoute KR, Amin K, Calaoagan JM, Knapp M, Le T, Orduna J, Foretz M, and Viollet B. 5'-AMP-activated protein kinase (AMPK) is induced by low-oxygen and glucose deprivation conditions found in solid-tumor microenvironments. *Mol Cell Biol* 26: 5336–5347, 2006.
 172. Lahiri S, Roy A, Baby SM, Hoshi T, Semenza GL, and Prabhakar NR. Oxygen sensing in the body. *Prog Biophys Mol Biol* 91: 249–286, 2006.
 173. Lancel S, Hassoun SM, Favory R, Decoster B, Motterlini R, and Neviere R. Carbon monoxide rescues mice from lethal sepsis by supporting mitochondrial energetic metabolism and activating mitochondrial biogenesis. *J Pharmacol Exp Ther* 329: 641–648, 2009.
 174. Le Cras TD and McMurtry IF. Nitric oxide production in the hypoxic lung. *Am J Physiol Lung Cell Mol Physiol* 280: L575–L582, 2001.
 175. Lee PJ, Jiang BH, Chin BY, Iyer NV, Alam J, Semenza GL, and Choi AM. Hypoxia-inducible factor-1 mediates transcriptional activation of the heme oxygenase-1 gene in response to hypoxia. *J Biol Chem* 272: 5375–5381, 1997.
 176. Leffler CW, Nasjletti A, Yu C, Johnson RA, Fedinec AL, and Walker N. Carbon monoxide and cerebral microvascular tone in newborn pigs. *Am J Physiol Heart Circ Physiol* 276: H1641–H1646, 1999.
 177. Leffler CW, Parfenova H, Jaggar JH, and Wang R. Carbon monoxide and hydrogen sulfide: gaseous messengers in cerebrovascular circulation. *J Appl Physiol* 100: 1065–1076, 2006.
 178. Leschelle X, Gubern M, Andriamihaja M, Blottiere HM, Couplan E, Gonzalez-Barroso MD, Petit C, Pagniez A, Chaumontet C, Mignotte B, Bouillaud F, and Blachier F. Adaptive metabolic response of human colonic epithelial cells to the adverse effects of the luminal compound sulfide. *Biochim Biophys Acta* 1725: 201–212, 2005.
 179. Levy RJ. Mitochondrial dysfunction, bioenergetic impairment, and metabolic down-regulation in sepsis. *Shock* 28: 24–28, 2007.
 180. Li L, Hsu A, and Moore PK. Actions and interactions of nitric oxide, carbon monoxide and hydrogen sulphide in the cardiovascular system and in inflammation: a tale of three gases! *Pharmacol Ther* 123: 386–400, 2009.
 181. Li L and Moore PK. Putative biological roles of hydrogen sulfide in health and disease: a breath of not so fresh air? *Trends Pharmacol Sci* 29: 84–90, 2008.
 182. Li X, Bazer FW, Gao H, Jobgen W, Johnson GA, Li P, McKnight JR, Satterfield MC, Spencer TE, and Wu G. Amino acids and gaseous signaling. *Amino Acids* 37: 65–78, 2009.
 183. Lide DR. *Handbook of Chemistry and Physics*. Cleveland, Ohio: CRC Press, 1999.
 184. Liu Y and Ortiz de Montellano PR. Reaction intermediates and single turnover rate constants for the oxidation of heme by human heme oxygenase-1. *J Biol Chem* 275: 5297–5307, 2000.
 185. Lloyd D. Hydrogen sulfide: clandestine microbial messenger? *Trends Microbiol* 14: 456–462, 2006.
 186. Longmuir IS and Roughton FJ. The diffusion coefficients of carbon monoxide and nitrogen in haemoglobin solutions. *J Physiol* 118: 264–275, 1952.
 187. Lowicka E and Beltowski J. Hydrogen sulfide (H₂S): the third gas of interest for pharmacologists. *Pharmacol Rep* 59: 4–24, 2007.
 188. Makino R, Matsuda H, Obayashi E, Shiro Y, Iizuka T, and Hori H. EPR characterization of axial bond in metal center of native and cobalt-substituted guanylate cyclase. *J Biol Chem* 274: 7714–7723, 1999.
 189. Makino R, Obayashi E, Homma N, Shiro Y, and Hori H. YC-1 facilitates release of the proximal His residue in the NO and CO complexes of soluble guanylate cyclase. *J Biol Chem* 278: 11130–11307, 2003.
 190. Malinski T, Taha Z, Grunfeld S, Patton S, Kapturczak M, and Tomboulian P. Diffusion of nitric oxide in the aorta wall monitored in situ by porphyrinic microsensors. *Biochem Biophys Res Commun* 193: 1076–1082, 1993.
 191. Marks GS, Vreman HJ, McLaughlin BE, Brien JF, and Nakatsu K. Measurement of endogenous carbon monoxide formation in biological systems. *Antioxid Redox Signal* 4: 271–277, 2002.
 192. Marletta MA. Nitric oxide synthase structure and mechanism. *J Biol Chem* 268: 12231–12234, 1993.
 193. Mason MG, Nicholls P, Wilson MT, and Cooper CE. Nitric oxide inhibition of respiration involves both competitive (heme) and noncompetitive (copper) binding to cytochrome c oxidase. *Proc Natl Acad Sci U S A* 103: 708–713, 2006.
 194. Masuda H and Fukuzumi S. *Bioinorganic Chemistry*. Tokyo: Sankyoshuppan, 2006, pp. 64–67.
 195. Matsui T, Nakajima A, Fujii H, Matera KM, Migita CT, Yoshida T, and Ikeda-Saito M. O₂- and H₂O₂-dependent verdoheme degradation by heme oxygenase: reaction mechanisms and potential physiological roles of the dual pathway degradation. *J Biol Chem* 280: 36833–36840, 2005.
 196. Matsuoaka A, Stuehr DJ, Olson JS, Clark P, and Ikeda-Saito M. L-arginine and calmodulin regulation of the heme iron reactivity in neuronal nitric oxide synthase. *J Biol Chem* 269: 20335–20339, 1994.
 197. McCleverty JA. Chemistry of nitric oxide relevant to biology. *Chem Rev* 104: 403–418, 2004.
 198. McMillan K, Bredt DS, Hirsch DJ, Snyder SH, Clark JE, and Masters BS. Cloned, expressed rat cerebellar nitric oxide synthase contains stoichiometric amounts of heme, which binds carbon monoxide. *Proc Natl Acad Sci U S A* 89: 11141–11145, 1992.
 199. Meier M, Janosik M, Kery V, Kraus JP, and Burkhard P. Structure of human cystathionine β-synthase: a unique pyridoxal 5'-phosphate-dependent heme protein. *EMBO J* 20: 3910–3916, 2001.
 200. Miles EW. Pyridoxal phosphate enzymes catalyzing β-elimination and β-replacement reactions. In: *Vitamin B6, Pyridoxal Phosphate: Chemical, Biochemical and Medical Aspects*, edited by Dolphin D, Poulson D, and Avramovic O. New York: John Wiley and Sons, 1986, pp. 235–310.
 201. Miller DL and Roth MB. *C. elegans* are protected from lethal hypoxia by an embryonic diapause. *Curr Biol* 19: 1233–1237, 2009.
 202. Miller TW, Isenberg JS, and Roberts DD. Molecular regulation of tumor angiogenesis and perfusion via redox signaling. *Chem Rev* 109: 3099–3124, 2009.
 203. Millero FJ. The thermodynamics and kinetics of the hydrogen sulfide system in natural waters. *Marine Chem* 18: 121–147, 1986.
 204. Missner A, Kugler P, Saparov SM, Sommer K, Mathai JC, Zeidel ML, and Pohl P. Carbon dioxide transport through membranes. *J Biol Chem* 283: 25340–25347, 2008.

205. Moncada S and Bolanos JP. Nitric oxide, cell bioenergetics and neurodegeneration. *J Neurochem* 97: 1676–1689, 2006.
206. Moncada S and Higgs EA. Nitric oxide and the vascular endothelium. *Handb Exp Pharmacol* 176: 213–254, 2006.
207. Moncada S, Palmer RM, and Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. *Pharmacol Rev* 43: 109–142, 1991.
208. Morimoto Y, Durante W, Lancaster DG, Klattenhoff J, and Tittel FK. Real-time measurements of endogenous CO production from vascular cells using an ultrasensitive laser sensor. *Am J Physiol Heart Circ Physiol* 280: H483–H488, 2001.
209. Morselli-Labate AM, Fantini L, and Pezzilli R. Hydrogen sulfide, nitric oxide and a molecular mass 66 u substance in the exhaled breath of chronic pancreatitis patients. *Pancreatol* 7: 497–504, 2007.
210. Motterlini R, Clark JE, Foresti R, Sarathchandra P, Mann BE, and Green CJ. Carbon monoxide-releasing molecules: characterization of biochemical and vascular activities. *Circ Res* 90: E17–E24, 2002.
211. Mullershausen F, Koesling D, and Friebe A. NO-sensitive guanylyl cyclase and NO-induced feedback inhibition in cGMP signaling. *Front Biosci* 10: 1269–1278, 2005.
212. Mustafa AK, Gadalla MM, and Snyder SH. Signaling by gasotransmitters. *Sci Signal* 2: re2, doi:10.1126, 2009.
213. Nagahara N, Ito T, Kitamura H, and Nishino T. Tissue and subcellular distribution of mercaptopyruvate sulfurtransferase in the rat: confocal laser fluorescence and immunoelectron microscopic studies combined with biochemical analysis. *Histochem Cell Biol* 110: 243–250, 1998.
214. Nagai Y, Tsugane M, Oka J, and Kimura H. Hydrogen sulfide induces calcium waves in astrocytes. *FASEB J* 18: 557–559, 2004.
215. Nakamura T and Lipton SA. Emerging roles of S-nitrosylation in protein misfolding and neurodegenerative diseases. *Antioxid Redox Signal* 10: 87–101, 2008.
216. Nieto-Draghi C, Mackie AD, and Bonet Avalos J. Transport coefficients and dynamic properties of hydrogen sulfide from molecular simulation. *J Chem Phys* 123: 014505, 2005.
217. Nisoli E, Clementi E, Paolucci C, Cozzi V, Tonello C, Sciorati C, Bracale R, Valerio A, Francolini M, Moncada S, and Carruba MO. Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. *Science* 299: 896–899, 2003.
218. Nisoli E, Falcone S, Tonello C, Cozzi V, Palomba L, Fiorani M, Pisconti A, Brunelli S, Cardile A, Francolini M, Cantoni O, Carruba MO, Moncada S, and Clementi E. Mitochondrial biogenesis by NO yields functionally active mitochondria in mammals. *Proc Natl Acad Sci U S A* 101: 16507–16512, 2004.
219. Nozaki K, Moskowitz MA, Maynard KI, Koketsu N, Dawson TM, Bredt DS, and Snyder SH. Possible origins and distribution of immunoreactive nitric oxide synthase-containing nerve fibers in cerebral arteries. *J Cereb Blood Flow Metab* 13: 70–79, 1993.
220. Nystul TG, Goldmark JP, Padilla PA, and Roth MB. Suspended animation in *C. elegans* requires the spindle checkpoint. *Science* 302: 1038–1041, 2003.
221. Nystul TG and Roth MB. Carbon monoxide-induced suspended animation protects against hypoxic damage in *Caenorhabditis elegans*. *Proc Natl Acad Sci U S A* 101: 9133–9136, 2004.
222. Ogasawara Y, Isoda S, and Tanabe S. Tissue and subcellular distribution of bound and acid-labile sulfur, and the enzymic capacity for sulfide production in the rat. *Biol Pharm Bull* 17: 1535–1542, 1994.
223. Olson KR. Hydrogen sulfide and oxygen sensing: implications in cardiorespiratory control. *J Exp Biol* 211: 2727–2734, 2008.
224. Olson KR, Dombkowski RA, Russell MJ, Doellman MM, Head SK, Whitfield NL, and Madden JA. Hydrogen sulfide as an oxygen sensor/transducer in vertebrate hypoxic vasoconstriction and hypoxic vasodilation. *J Exp Biol* 209: 4011–4023, 2006.
225. Olson KR and Donald JA. Nervous control of circulation: the role of gasotransmitters, NO, CO, and H₂S. *Acta Histochem* 111: 244–256, 2009.
226. Omura T, Sadano H, Hasegawa T, Yoshida Y, and Komiyama S. Hemoprotein H-450 identified as a form of cytochrome P-450 having an endogenous ligand at the 6th coordination position of the heme. *J Biochem* 96: 1491–1500, 1984.
227. Ortega-Saenz P, Pascual A, Gomez-Diaz R, and Lopez-Barneo J. Acute oxygen sensing in heme oxygenase-2 null mice. *J Gen Physiol* 128: 405–411, 2006.
228. Osipov AN, Borisenko GG, and Vladimirov YA. Biological activity of hemoprotein nitrosyl complexes. *Biochemistry (Mosc)* 72: 1491–1504, 2007.
229. Otterbein LE, Soares MP, Yamashita K, and Bach FH. Heme oxygenase-1: unleashing the protective properties of heme. *Trends Immunol* 24: 449–455, 2003.
230. Ozawa N, Goda N, Makino N, Yamaguchi T, Yoshimura Y, and Suematsu M. Leydig cell-derived heme oxygenase-1 regulates apoptosis of premeiotic germ cells in response to stress. *J Clin Invest* 109: 457–467, 2002.
231. Padilla PA, Nystul TG, Zager RA, Johnson AC, and Roth MB. Dephosphorylation of cell cycle-regulated proteins correlates with anoxia-induced suspended animation in *Caenorhabditis elegans*. *Mol Biol Cell* 13: 1473–1483, 2002.
232. Padilla PA and Roth MB. Oxygen deprivation causes suspended animation in the zebrafish embryo. *Proc Natl Acad Sci USA* 98: 7331–7335, 2001.
233. Pal B and Kitagawa T. Interactions of soluble guanylate cyclase with diatomics as probed by resonance Raman spectroscopy. *J Inorg Biochem* 99: 267–279, 2005.
234. Palacios-Callender M, Hollis V, Mitchison M, Frakich N, Unitt D, and Moncada S. Cytochrome c oxidase regulates endogenous nitric oxide availability in respiring cells: a possible explanation for hypoxic vasodilation. *Proc Natl Acad Sci U S A* 104: 18508–18513, 2007.
235. Palacios-Callender M, Quintero M, Hollis VS, Springett RJ, and Moncada S. Endogenous NO regulates superoxide production at low oxygen concentrations by modifying the redox state of cytochrome c oxidase. *Proc Natl Acad Sci USA* 101: 7630–7635, 2004.
236. Park YK, Ahn DR, Oh M, Lee T, Yang EG, Son M, and Park H. Nitric oxide donor, (+/-)-S-nitroso-N-acetylpenicillamine, stabilizes transactive hypoxia-inducible factor-1 α by inhibiting von Hippel-Lindau recruitment and asparagine hydroxylation. *Mol Pharmacol* 74: 236–245, 2008.
237. Pearson RJ, Wilson T, and Wang R. Endogenous hydrogen sulfide and the cardiovascular system: what's the smell all about? *Clin Invest Med* 29: 146–150, 2006.
238. Pelligrino DA, Wang Q, Koenig HM, and Albrecht RF. Role of nitric oxide, adenosine, N-methyl-D-aspartate receptors,

- and neuronal activation in hypoxia-induced pial arteriolar dilation in rats. *Brain Res* 704: 61–70, 1995.
239. Petersen LC. The effect of inhibitors on the oxygen kinetics of cytochrome *c* oxidase. *Biochim Biophys Acta* 460: 299–3207, 1977.
 240. Piantadosi CA. Biological chemistry of carbon monoxide. *Antioxid Redox Signal* 4: 259–270, 2002.
 241. Picton R, Eggo MC, Merrill GA, Langman MJ, and Singh S. Mucosal protection against sulphide: importance of the enzyme rhodanese. *Gut* 50: 201–205, 2002.
 242. Pietri R, Lewis A, Leon RG, Casabona G, Kiger L, Yeh SR, Fernandez-Alberti S, Marden MC, Cadilla CL, and Lopez-Garriga J. Factors controlling the reactivity of hydrogen sulfide with heme proteins. *Biochemistry* 48: 4881–4894, 2009.
 243. Poulos TL. Soluble guanylate cyclase. *Curr Opin Struct Biol* 16: 736–743, 2006.
 244. Prabhakar NR, Dinerman JL, Agani FH, and Snyder SH. Carbon monoxide: a role in carotid body chemoreception. *Proc Natl Acad Sci U S A* 92: 1994–1997, 1995.
 245. Prasad GV, Coury LA, Finn F, and Zeidel ML. Reconstituted aquaporin 1 water channels transport CO₂ across membranes. *J Biol Chem* 273: 33123–33126, 1998.
 246. Qu K, Chen CP, Halliwell B, Moore PK, and Wong PT. Hydrogen sulfide is a mediator of cerebral ischemic damage. *Stroke* 37: 889–893, 2006.
 247. Qu K, Lee SW, Bian JS, Low CM, and Wong PT. Hydrogen sulfide: neurochemistry and neurobiology. *Neurochem Int* 52: 155–165, 2008.
 248. Quintero M, Colombo SL, Godfrey A, and Moncada S. Mitochondria as signaling organelles in the vascular endothelium. *Proc Natl Acad Sci U S A* 103: 5379–5384, 2006.
 249. Raha S and Robinson BH. Mitochondria, oxygen free radicals, and apoptosis. *Am J Med Genet* 106: 62–70, 2001.
 250. Raman CS. Endothelial nitric oxide synthase. In: *Handbook of Metalloproteins*, edited by Messerschmidt A, Huber R, Poulos TL and Wieghardt K. Amsterdam: John Wiley & Sons, 2001, pp. 300–316.
 251. Reick M, Garcia JA, Dudley C, and McKnight SL. NPAS2: an analog of clock operative in the mammalian forebrain. *Science* 293: 506–509, 2001.
 252. Rhodes MA, Carraway MS, Piantadosi CA, Reynolds CM, Cherry AD, Wester TE, Natoli MJ, Massey EW, Moon RE, and Suliman HB. Carbon monoxide, skeletal muscle oxidative stress, and mitochondrial biogenesis in humans. *Am J Physiol Heart Circ Physiol* 297: H392–H329, 2009.
 253. Ripoche P, Goossens D, Devuyt O, Gane P, Colin Y, Verkman AS, and Cartron JP. Role of RhAG and AQP1 in NH₃ and CO₂ gas transport in red cell ghosts: a stopped-flow analysis. *Transfus Clin Biol* 13: 117–122, 2006.
 254. Rogers NE and Ignarro LJ. Constitutive nitric oxide synthase from cerebellum is reversibly inhibited by nitric oxide formed from L-arginine. *Biochem Biophys Res Commun* 189: 242–249, 1992.
 255. Romberg RW and Kassner RJ. Nitric oxide and carbon monoxide equilibria of horse myoglobin and (*N*-methylimidazole)protoheme: evidence for steric interaction with the distal residues. *Biochemistry* 18: 5387–5392, 1979.
 256. Rose EJ and Hoffman BM. Nitric oxide ferrohemes: kinetics of formation and photodissociation quantum yields. *J Am Chem Soc* 105: 2866–2873, 1983.
 257. Rosenfeld RJ, Tainer JA, and Getzoff ED. Inducible nitric oxide synthase. In: *Handbook of Metalloproteins*, edited by Messerschmidt A, Huber R, Poulos TL and Wieghardt K. Amsterdam: John Wiley & Sons, 2001, pp. 285–299.
 258. Roughton FJ. Diffusion and chemical reaction velocity as joint factors in determining the rate of uptake of oxygen and carbon monoxide by the red blood corpuscle. *Proc Roy Soc B* 111: 1–36, 1932.
 259. Russwurm M and Koesling D. NO activation of guanylyl cyclase. *EMBO J* 23: 4443–4450, 2004.
 260. Ryter SW, Alam J, and Choi AM. Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. *Physiol Rev* 86: 583–650, 2006.
 261. Ryter SW, Morse D, and Choi AM. Carbon monoxide: to boldly go where NO has gone before. *Sci STKE* 2004: RE6, 2004.
 262. Ryter SW and Otterbein LE. Carbon monoxide in biology and medicine. *Bioessays* 26: 270–280, 2004.
 263. Sanz P. AMP-activated protein kinase: structure and regulation. *Curr Protein Pept Sci* 9: 478–492, 2008.
 264. Scheele JS, Bruner E, Kharitonov VG, Martasek P, Roman LJ, Masters BS, Sharma VS, and Magde D. Kinetics of NO ligation with nitric-oxide synthase by flash photolysis and stopped-flow spectrophotometry. *J Biol Chem* 274: 13105–13110, 1999.
 265. Scheele JS, Kharitonov VG, Martasek P, Roman LJ, Sharma VS, Masters BS, and Magde D. Kinetics of CO ligation with nitric-oxide synthase by flash photolysis and stopped-flow spectrophotometry. *J Biol Chem* 272: 12523–12528, 1997.
 266. Scheidt WR and Frisse ME. Nitrosylmetalloporphyrins, II: synthesis and molecular stereochemistry of nitrosyl- $\alpha,\beta,\gamma,\delta$ -tetraphenylporphyrinatoiron(II). *J Am Chem Soc* 97: 17–21, 1975.
 267. Schipper HM. Glial HO-1 expression, iron deposition and oxidative stress in neurodegenerative diseases. *Neurotox Res* 1: 57–70, 1999.
 268. Schipper HM. Heme oxygenase-1: role in brain aging and neurodegeneration. *Exp Gerontol* 35: 821–830, 2000.
 269. Schipper HM, Song W, Zukor H, Hascalovici JR, and Zeligman D. Heme oxygenase-1 and neurodegeneration: expanding frontiers of engagement. *J Neurochem* 110: 469–485, 2009.
 270. Schuller DJ, Wilks A, Ortiz de Montellano PR, and Poulos TL. Crystal structure of human heme oxygenase-1. *Nat Struct Biol* 6: 860–867, 1999.
 271. Searcy DG and Lee SH. Sulfur reduction by human erythrocytes. *J Exp Zool* 282: 310–322, 1998.
 272. Semenza GL. Perspectives on oxygen sensing. *Cell* 98: 281–284, 1999.
 273. Semenza GL. Targeting HIF-1 for cancer therapy. *Nat Rev Cancer* 3: 721–732, 2003.
 274. Sharma VS and Magde D. Activation of soluble guanylate cyclase by carbon monoxide and nitric oxide: a mechanistic model. *Methods* 19: 494–505, 1999.
 275. Shelper D, Kerby RL, He Y, and Roberts GP. CooA, a CO-sensing transcription factor from *Rhodospirillum rubrum*, is a CO-binding heme protein. *Proc Natl Acad Sci USA* 94: 11216–11220, 1997.
 276. Shibuki K. An electrochemical microprobe for detecting nitric oxide release in brain tissue. *Neurosci Res* 9: 69–76, 1990.
 277. Shibuki K and Okada D. Endogenous nitric oxide release required for long-term synaptic depression in the cerebellum. *Nature* 349: 326–328, 1991.

278. Shibuta S, Mashimo T, Zhang P, Ohara A, and Yoshiya I. A new nitric oxide donor, NOC-18, exhibits a nociceptive effect in the rat formalin model. *J Neurol Sci* 141: 1–5, 1996.
279. Shibuya N, Tanaka M, Yoshida M, Ogasawara Y, Togawa T, Ishii K, and Kimura H. 3-Mercaptopyruvate sulfurtransferase produces hydrogen sulfide and bound sulfane sulfur in the brain. *Antioxid Redox Signal* 11: 703–714, 2009.
280. Shimazu T, Ikeuchi H, Sugimoto H, Goodwin CW, Mason AD Jr, and Pruitt BA Jr. Half-life of blood carboxyhemoglobin after short-term and long-term exposure to carbon monoxide. *J Trauma* 49: 126–131, 2000.
281. Shintani T, Iwabuchi T, Soga T, Kato Y, Yamamoto T, Takano N, Hishiki T, Ueno Y, Ikeda S, Sakuragawa T, Ishikawa K, Goda N, Kitagawa Y, Kajimura M, Matsumoto K, and Suematsu M. Cystathionine β -synthase as a carbon monoxide-sensitive regulator of bile excretion. *Hepatology* 49: 141–150, 2009.
282. Simon F, Giudici R, Duy CN, Schelzig H, Oter S, Groger M, Wachter U, Vogt J, Speit G, Szabo C, Radermacher P, and Calzia E. Hemodynamic and metabolic effects of hydrogen sulfide during porcine ischemia/reperfusion injury. *Shock* 30: 359–364, 2008.
283. Singh S, Madzellan P, and Banerjee R. Properties of an unusual heme cofactor in PLP-dependent cystathionine β -synthase. *Nat Prod Rep* 24: 631–639, 2007.
284. Singh S, Padovani D, Leslie RA, Chiku T, and Banerjee R. Relative contributions of cystathionine β -synthase and γ -cystathionase to H₂S biogenesis via alternative transsulfuration reactions. *J Biol Chem* 284: 22457–22466, 2009.
285. Soga T, Baran R, Suematsu M, Ueno Y, Ikeda S, Sakurakawa T, Kakazu Y, Ishikawa T, Robert M, Nishioka T, and Tomita M. Differential metabolomics reveals ophthalmic acid as an oxidative stress biomarker indicating hepatic glutathione consumption. *J Biol Chem* 281: 16768–16776, 2006.
286. Staunton M, Dulitz MG, Fang C, Schmelting WT, Kampine JP, and Farber NE. The effects of graded hypoxia on intraparenchymal arterioles in rat brain slices. *Neuroreport* 9: 1419–1423, 1998.
287. Stewart RD. The effect of carbon monoxide on humans. *Annu Rev Pharmacol* 15: 409–423, 1975.
288. Stipanuk MH. Sulfur amino acid metabolism: pathways for production and removal of homocysteine and cysteine. *Annu Rev Nutr* 24: 539–577, 2004.
289. Stipanuk MH and Beck PW. Characterization of the enzymic capacity for cysteine desulphhydration in liver and kidney of the rat. *Biochem J* 206: 267–277, 1982.
290. Stoeckli M, Chaurand P, Hallahan DE, and Caprioli RM. Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. *Nat Med* 7: 493–496, 2001.
291. Stone JR and Marletta MA. The ferrous heme of soluble guanylate cyclase: formation of hexacoordinate complexes with carbon monoxide and nitrosomethane. *Biochemistry* 34: 16397–16403, 1995.
292. Stone JR and Marletta MA. Soluble guanylate cyclase from bovine lung: activation with nitric oxide and carbon monoxide and spectral characterization of the ferrous and ferric states. *Biochemistry* 33: 5636–5640, 1994.
293. Stone JR and Marletta MA. Spectral and kinetic studies on the activation of soluble guanylate cyclase by nitric oxide. *Biochemistry* 35: 1093–1099, 1996.
294. Stone JR and Marletta MA. Synergistic activation of soluble guanylate cyclase by YC-1 and carbon monoxide: implications for the role of cleavage of the iron-histidine bond during activation by nitric oxide. *Chem Biol* 5: 255–261, 1998.
295. Stuehr DJ, Santolini J, Wang ZQ, Wei CC, and Adak S. Update on mechanism and catalytic regulation in the NO synthases. *J Biol Chem* 279: 36167–36170, 2004.
296. Suematsu M, Goda N, Sano T, Kashiwagi S, Egawa T, Shinoda Y, and Ishimura Y. Carbon monoxide: an endogenous modulator of sinusoidal tone in the perfused rat liver. *J Clin Invest* 96: 2431–2437, 1995.
297. Suematsu M, Kashiwagi S, Sano T, Goda N, Shinoda Y, and Ishimura Y. Carbon monoxide as an endogenous modulator of hepatic vascular perfusion. *Biochem Biophys Res Commun* 205: 1333–1337, 1994.
298. Suganuma K, Tsukada K, Kashiba M, Tsuneshige A, Furukawa T, Kubota T, Goda N, Kitajima M, Yonetani T, and Suematsu M. Erythrocytes with T-state-stabilized hemoglobin as a therapeutic tool for postischemic liver dysfunction. *Antioxid Redox Signal* 8: 1847–1855, 2006.
299. Sugishima M, Sakamoto H, Noguchi M, and Fukuyama K. CO-trapping site in heme oxygenase revealed by photolysis of its co-bound heme complex: mechanism of escaping from product inhibition. *J Mol Biol* 341: 7–13, 2004.
300. Sugishima M, Sakamoto H, Noguchi M, and Fukuyama K. Crystal structures of ferrous and CO-, CN⁻, and NO-bound forms of rat heme oxygenase-1 (HO-1) in complex with heme: structural implications for discrimination between CO and O₂ in HO-1. *Biochemistry* 42: 9898–9905, 2003.
301. Suliman HB, Carraway MS, Tatro LG, and Piantadosi CA. A new activating role for CO in cardiac mitochondrial biogenesis. *J Cell Sci* 120: 299–308, 2007.
302. Sullivan JM, Traynelis SF, Chen HS, Escobar W, Heinemann SF, and Lipton SA. Identification of two cysteine residues that are required for redox modulation of the NMDA subtype of glutamate receptor. *Neuron* 13: 929–936, 1994.
303. Suzuki H, Kanamaru K, Tsunoda H, Inada H, Kuroki M, Sun H, Waga S, and Tanaka T. Heme oxygenase-1 gene induction as an intrinsic regulation against delayed cerebral vasospasm in rats. *J Clin Invest* 104: 59–66, 1999.
304. Szabo C. Hydrogen sulphide and its therapeutic potential. *Nat Rev Drug Discov* 6: 917–935, 2007.
305. Taille C, El-Benna J, Lanone S, Dang MC, Ogier-Denis E, Aubier M, and Boczkowski J. Induction of heme oxygenase-1 inhibits NAD(P)H oxidase activity by down-regulating cytochrome b558 expression via the reduction of heme availability. *J Biol Chem* 279: 28681–28688, 2004.
306. Taira S, Sugiura Y, Moritake S, Shimma S, Ichiyanagi Y, and Setou M. Nanoparticle-assisted laser desorption/ionization based mass imaging with cellular resolution. *Anal Chem* 80: 4761–4766, 2008.
307. Takahashi M, Dore S, Ferris CD, Tomita T, Sawa A, Wolosker H, Borchelt DR, Iwatsubo T, Kim SH, Thinakaran G, Sisodia SS, and Snyder SH. Amyloid precursor proteins inhibit heme oxygenase activity and augment neurotoxicity in Alzheimer's disease. *Neuron* 28: 461–473, 2000.
308. Tamimi A, Edward BR, and Sandall OC. Diffusion coefficients for hydrogen sulfide, carbon dioxide, and nitrous oxide in water over the temperature range 293–368K. *J Chem Eng Data* 39: 330–332, 1994.
309. Tamura M, Hazeki O, Nioka S, and Chance B. In vivo study of tissue oxygen metabolism using optical and nuclear magnetic resonance spectroscopies. *Annu Rev Physiol* 51: 813–834, 1989.

310. Tangerman A. Measurement and biological significance of the volatile sulfur compounds hydrogen sulfide, methanethiol and dimethyl sulfide in various biological matrices. *J Chromatogr B Analyt Technol Biomed Life Sci* 877: 3366–3377, 2009.
311. Tansey MG, Frank-Cannon TC, McCoy MK, Lee JK, Martinez TN, McAlpine FE, Ruhn KA, and Tran TA. Neuroinflammation in Parkinson's disease: is there sufficient evidence for mechanism-based interventional therapy? *Front Biosci* 13: 709–717, 2008.
312. Taoka S and Banerjee R. Characterization of NO binding to human cystathionine β -synthase: possible implications of the effects of CO and NO binding to the human enzyme. *J Inorg Biochem* 87: 245–251, 2001.
313. Taoka S, West M, and Banerjee R. Characterization of the heme and pyridoxal phosphate cofactors of human cystathionine β -synthase reveals nonequivalent active sites. *Biochemistry* 38: 2738–2744, 1999.
314. Teng X, Isbell TS, Crawford JH, Bosworth CA, Giles GI, Koenitzer J, Lancaster JR Jr, Doeller JE, Kraus DW, and Patel RP. Novel method for measuring S-nitrosothiols using hydrogen sulfide. *Methods Enzymol* 441: 161–172, 2008.
315. Teodoro RO and O'Farrell PH. Nitric oxide-induced suspended animation promotes survival during hypoxia. *EMBO J* 22: 580–587, 2003.
316. Thomas DD, Liu X, Kantrow SP, and Lancaster JR Jr. The biological lifetime of nitric oxide: implications for the perivascular dynamics of NO and O₂. *Proc Natl Acad Sci U S A* 98: 355–360, 2001.
317. Tian J, Bryk R, Itoh M, Suematsu M, and Nathan C. Variant tricarboxylic acid cycle in *Mycobacterium tuberculosis*: identification of α -ketoglutarate decarboxylase. *Proc Natl Acad Sci U S A* 102: 10670–10675, 2005.
318. Tomita T, Gonzalez G, Chang AL, Ikeda-Saito M, and Gilles-Gonzalez MA. A comparative resonance Raman analysis of heme-binding PAS domains: heme iron coordination structures of the BjFixL, AxPDEA1, EcDos, and MtDos proteins. *Biochemistry* 41: 4819–4826, 2002.
319. Tomita T, Ogura T, Tsuyama S, Imai Y, and Kitagawa T. Effects of GTP on bound nitric oxide of soluble guanylate cyclase probed by resonance Raman spectroscopy. *Biochemistry* 36: 10155–10160, 1997.
320. Traylor TG and Sharma VS. Why NO? *Biochemistry* 31: 2847–2849, 1992.
321. Tsai AG, Acero C, Nance PR, Cabrales P, Frangos JA, Buerk DG, and Intaglietta M. Elevated plasma viscosity in extreme hemodilution increases perivascular nitric oxide concentration and microvascular perfusion. *Am J Physiol Heart Circ Physiol* 288: H1730–H1739, 2005.
322. Tsuneshige A and Yonetani T. Oxygenation properties of human erythrocytes containing exclusively α -nitrosyl hemoglobin: a promising blood transfusant candidate. *Artif Cells Blood Substitut Immobil Biotechnol* 29: 347–357, 2001.
323. Ubuka T. Assay methods and biological roles of labile sulfur in animal tissues. *J Chromatogr B Analyt Technol Biomed Life Sci* 781: 227–249, 2002.
324. Unno M, Matsui T, Chu GC, Couture M, Yoshida T, Rousseau DL, Olson JS, and Ikeda-Saito M. Crystal structure of the dioxygen-bound heme oxygenase from *Corynebacterium diphtheriae*: implications for heme oxygenase function. *J Biol Chem* 279: 21055–21061, 2004.
325. Vanderkooi JM, Maniara G, Green TJ, and Wilson DF. An optical method for measurement of dioxygen concentration based upon quenching of phosphorescence. *J Biol Chem* 262: 5476–5482, 1987.
326. Vanin AF, Mordvintcev PI, Hauschildt S, and Mulsch A. The relationship between L-arginine-dependent nitric oxide synthesis, nitrite release and dinitrosyl-iron complex formation by activated macrophages. *Biochim Biophys Acta* 1177: 37–42, 1993.
327. Vaughn MW, Huang KT, Kuo L, and Liao JC. Erythrocyte consumption of nitric oxide: competition experiment and model analysis. *Nitric Oxide* 5: 18–31, 2001.
328. Verma A, Hirsch DJ, Glatt CE, Ronnett GV, and Snyder SH. Carbon monoxide: a putative neural messenger. *Science* 259: 381–384, 1993.
329. Volpato GP, Searles R, Yu B, Scherrer-Crosbie M, Bloch KD, Ichinose F, and Zapol WM. Inhaled hydrogen sulfide: a rapidly reversible inhibitor of cardiac and metabolic function in the mouse. *Anesthesiology* 108: 659–668, 2008.
330. Vreman HJ, Wong RJ, Kadotani T, and Stevenson DK. Determination of carbon monoxide (CO) in rodent tissue: effect of heme administration and environmental CO exposure. *Anal Biochem* 341: 280–289, 2005.
331. Vreman HJ, Wong RJ, Sanesi CA, Dennery PA, and Stevenson DK. Simultaneous production of carbon monoxide and thiobarbituric acid reactive substances in rat tissue preparations by an iron-ascorbate system. *Can J Physiol Pharmacol* 76: 1057–1065, 1998.
332. Vreman HJ, Wong RJ, and Stevenson DK. Sources, sinks, and measurement of carbon monoxide. In: *Carbon Monoxide and Cardiovascular Functions*, edited by Wang R. Boca Raton: CRC Press, 2002, pp. 273–307.
333. Waisbren SJ, Geibel JP, Modlin IM, and Boron WF. Unusual permeability properties of gastric gland cells. *Nature* 368: 332–335, 1994.
334. Walford G and Loscalzo J. Nitric oxide in vascular biology. *J Thromb Haemost* 1: 2112–2118, 2003.
335. Walker FA. Nitric oxide interaction with insect nitrophorins and thoughts on the electron configuration of the {FeNO}₆ complex. *J Inorg Biochem* 99: 216–236, 2005.
336. Wang J and Dore S. Heme oxygenase-1 exacerbates early brain injury after intracerebral hemorrhage. *Brain* 130: 1643–1652, 2007.
337. Wang J and Dore S. Heme oxygenase 2 deficiency increases brain swelling and inflammation after intracerebral hemorrhage. *Neuroscience* 155: 1133–1141, 2008.
338. Wang J, Lu S, Moenne-Loccoz P, and Ortiz de Montellano PR. Interaction of nitric oxide with human heme oxygenase-1. *J Biol Chem* 278: 2341–2347, 2003.
339. Wang J, Rousseau DL, Abu-Soud HM, and Stuehr DJ. Heme coordination of NO in NO synthase. *Proc Natl Acad Sci U S A* 91: 10512–10516, 1994.
340. Wang R. The gasotransmitter role of hydrogen sulfide. *Antioxid Redox Signal* 5: 493–501, 2003.
341. Wang R, Wu L, and Wang Z. The direct effect of carbon monoxide on K_{Ca} channels in vascular smooth muscle cells. *Pflugers Arch* 434: 285–291, 1997.
342. Wang Y, Cohen J, Boron WF, Schulten K, and Tajkhorshid E. Exploring gas permeability of cellular membranes and membrane channels with molecular dynamics. *J Struct Biol* 157: 534–544, 2007.
343. Ward JP. Oxygen sensors in context. *Biochim Biophys Acta* 1777: 1–14, 2008.
344. Warenycia MW, Goodwin LR, Benishin CG, Reiffenstein RJ, Francom DM, Taylor JD, and Dieken FP. Acute hydrogen sulfide poisoning: demonstration of selective

- uptake of sulfide by the brainstem by measurement of brain sulfide levels. *Biochem Pharmacol* 38: 973–981, 1989.
345. Webb GD, Lim LH, Oh VM, Yeo SB, Cheong YP, Ali MY, El Oakley R, Lee CN, Wong PS, Caleb MG, Salto-Tellez M, Bhatia M, Chan ES, Taylor EA, and Moore PK. Contractile and vasorelaxant effects of hydrogen sulfide and its biosynthesis in the human internal mammary artery. *J Pharmacol Exp Ther* 324: 876–882, 2008.
 346. Weibel ER. *The Pathway for Oxygen: Structure and Function in the Mammalian Respiratory System*. Cambridge: Harvard University Press, 1984.
 347. Weir EK, Lopez-Barneo J, Buckler KJ, and Archer SL. Acute oxygen-sensing mechanisms. *N Engl J Med* 353: 2042–2055, 2005.
 348. Weissmann N, Voswinckel R, Tadic A, Hardebusch T, Ghofrani HA, Schermuly RT, Seeger W, and Grimminger F. Nitric oxide (NO)-dependent but not NO-independent guanylate cyclase activation attenuates hypoxic vasoconstriction in rabbit lungs. *Am J Respir Cell Mol Biol* 23: 222–227, 2000.
 349. White KA and Marletta MA. Nitric oxide synthase is a cytochrome P-450 type hemoprotein. *Biochemistry* 31: 6627–6631, 1992.
 350. Whiteman M, Li L, Kostetski I, Chu SH, Siau JL, Bhatia M, and Moore PK. Evidence for the formation of a novel nitrosothiol from the gaseous mediators nitric oxide and hydrogen sulphide. *Biochem Biophys Res Commun* 343: 303–310, 2006.
 351. Whiteman M and Moore PK. Hydrogen sulfide and the vasculature: a novel vasculoprotective entity and regulator of nitric oxide bioavailability? *J Cell Mol Med* 13: 488–507, 2009.
 352. Whitfield NL, Kreimier EL, Verdial FC, Skovgaard N, and Olson KR. Reappraisal of H₂S/sulfide concentration in vertebrate blood and its potential significance in ischemic preconditioning and vascular signaling. *Am J Physiol Regul Integr Comp Physiol* 294: R1930–R1937, 2008.
 353. Williams SE, Wootton P, Mason HS, Bould J, Iles DE, Riccardi D, Peers C, and Kemp PJ. Hemoxygenase-2 is an oxygen sensor for a calcium-sensitive potassium channel. *Science* 306: 2093–2097, 2004.
 354. Winger JA, Derbyshire ER, and Marletta MA. Dissociation of nitric oxide from soluble guanylate cyclase and heme-nitric oxide/oxygen binding domain constructs. *J Biol Chem* 282: 897–907, 2007.
 355. Wise DL and Houghton G. Diffusion coefficients of neon, krypton, xenon, carbon monoxide and nitric oxide in water at 10–60°C. *Chem Eng Sci* 23: 1211–1216, 1968.
 356. Wise DL and Houghton G. The diffusion coefficients of ten slightly soluble gases in water at 10–60°C. *Chem Eng Sci* 21: 999–1010, 1966.
 357. Wyatt CN and Evans AM. AMP-activated protein kinase and chemotransduction in the carotid body. *Respir Physiol Neurobiol* 157: 22–29, 2007.
 358. Xu W, Liu L, Charles IG, and Moncada S. Nitric oxide induces coupling of mitochondrial signalling with the endoplasmic reticulum stress response. *Nat Cell Biol* 6: 1129–1134, 2004.
 359. Yamaguchi T, Shioji I, Sugimoto A, Komoda Y, and Nakajima H. Epitope of 24G7 anti-bilirubin monoclonal antibody. *Biochim Biophys Acta* 1289: 110–114, 1996.
 360. Yang B, Fukuda N, van Hoek A, Matthay MA, Ma T, and Verkman AS. Carbon dioxide permeability of aquaporin-1 measured in erythrocytes and lung of aquaporin-1 null mice and in reconstituted proteoliposomes. *J Biol Chem* 275: 2686–2692, 2000.
 361. Yang G, Wu L, Jiang B, Yang W, Qi J, Cao K, Meng Q, Mustafa AK, Mu W, Zhang S, Snyder SH, and Wang R. H₂S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine γ -lyase. *Science* 322: 587–590, 2008.
 362. Yi L, Jenkins PM, Leichert LI, Jakob U, Martens JR, and Ragsdale SW. Heme regulatory motifs in heme oxygenase-2 form a thiol/disulfide redox switch that responds to the cellular redox state. *J Biol Chem* 284: 20556–20561, 2009.
 363. Yi L and Ragsdale SW. Evidence that the heme regulatory motifs in heme oxygenase-2 serve as a thiol/disulfide redox switch regulating heme binding. *J Biol Chem* 282: 21056–21067, 2007.
 364. Yonetani T, Tsuneshige A, Zhou Y, and Chen X. Electron paramagnetic resonance and oxygen binding studies of α -nitrosyl hemoglobin: a novel oxygen carrier having NO-assisted allosteric functions. *J Biol Chem* 273: 20323–20333, 1998.
 365. Yong R and Searcy DG. Sulfide oxidation coupled to ATP synthesis in chicken liver mitochondria. *Comp Biochem Physiol B Biochem Mol Biol* 129: 129–137, 2001.
 366. Yoshida T, Noguchi M, and Kikuchi G. A new intermediate of heme degradation catalyzed by the heme oxygenase system. *J Biochem* 88: 557–563, 1980.
 367. Yoshimura T. Endogenous nitric oxide, its chemical characterization and the high affinity for metal ions and metalloproteins. *CVD Grand Round Series* 3: 1–26, 1996.
 368. Young CL. *IUPAC Solubility Data Series*. Oxford: Pergamon Press, 1981.
 369. Zhang X, Shan P, Jiang G, Zhang SS, Otterbein LE, Fu XY, and Lee PJ. Endothelial STAT3 is essential for the protective effects of HO-1 in oxidant-induced lung injury. *FASEB J* 20: 2156–2158, 2006.
 370. Zhao W, Zhang J, Lu Y, and Wang R. The vasorelaxant effect of H₂S as a novel endogenous gaseous K_{ATP} channel opener. *EMBO J* 20: 6008–6016, 2001.
 371. Zhao Y, Brandish PE, Ballou DP, and Marletta MA. A molecular basis for nitric oxide sensing by soluble guanylate cyclase. *Proc Natl Acad Sci U S A* 96: 14753–14758, 1999.
 372. Zou CG and Banerjee R. Tumor necrosis factor- α -induced targeted proteolysis of cystathionine β -synthase modulates redox homeostasis. *J Biol Chem* 278: 16802–16808, 2003.
 373. Zuckerbraun BS, Chin BY, Bilban M, d'Avila JC, Rao J, Billiar TR, and Otterbein LE. Carbon monoxide signals via inhibition of cytochrome *c* oxidase and generation of mitochondrial reactive oxygen species. *FASEB J* 21: 1099–1106, 2007.

Address correspondence to:

Mayumi Kajimura, Ph.D.

Makoto Suematsu, M.D., Ph.D.

Department of Biochemistry and Integrative Medical Biology

School of Medicine, Keio University

35 Shinanomachi, Shinjuku-ku

Tokyo 160-8582

Japan

E-mail: myk30@sc.itc.keio.ac.jp

gasbiology@z6.keio.jp

Date of first submission to ARS Central, May 12, 2009; date of final revised submission, October 21, 2009; date of acceptance, November 2, 2009.

Abbreviations Used

AMPK	= AMP-dependent protein kinase
CBS	= cystathionine β -synthase
CO	= carbon monoxide
CO ₂	= carbon dioxide
CORM	= CO-releasing molecule
COX	= cytochrome <i>c</i> oxidase
CSE	= cystathionine γ -lyase
ETC	= electron-transport chain
Hcy	= homocysteine
HIF	= hypoxia-inducible factor
H ₂ O ₂	= hydrogen peroxide
HPV	= hypoxic pulmonary vasoconstriction
H ₂ S	= hydrogen sulfide
MAPK	= mitogen-activated protein kinase
MPST	= 3-mercaptopyruvate sulfurtransferase
MPT	= mitochondrial permeability transition
MRS	= mitochondrial redox signaling
NO	= nitric oxide
NOS	= nitric oxide synthase
NPAS2	= neural PER-ARNT-SIM
ODD	= oxygen-degradation domain
OXPHOS	= oxidative phosphorylation
PHD	= prolyl hydroxylase
PLP	= pyridoxal phosphate
ROS	= reactive oxygen species
sGC	= soluble guanylate cyclase
SOD	= superoxide dismutase
VHL	= von Hippel-Lindau
VSMC	= vascular smooth muscle cell
ZnPP	= zinc protoporphyrin